

Quality of Tuberculosis Services Assessment

in Ethiopia

Tools

May 2020







Quality of Tuberculosis Services Assessment

in Ethiopia

Tools

May 2020

MEASURE Evaluation
University of North Carolina at Chapel Hill
123 West Franklin Street, Suite 330
Chapel Hill, NC 27516 USA
Phone: +1 919-445-9350
measure@unc.edu

www.measureevaluation.org

This publication was produced with the support of the United States Agency for International Development (USAID) under the terms of the MEASURE Evaluation cooperative agreement AID-OAA-L-14-00004. MEASURE Evaluation is implemented by the Carolina Population Center, University of North Carolina at Chapel Hill in partnership with ICF International; John Snow, Inc.; Management Sciences for Health; Palladium; and Tulane University. Views expressed are not necessarily those of USAID or the United States government. TL-20-87

ISBN: 978-1-64232-245-3







ACKNOWLEDGMENTS

MEASURE Evaluation, which is funded by the United States Agency for International Development (USAID), thanks those who contributed to the quality of tuberculosis services assessment (QTSA) in Ethiopia.

We would like to acknowledge USAID for its support. Particular thanks go to our advisors, Charlotte Colvin, Kenneth Castro, and William Wells at USAID/Washington. We also thank Yewulsew Kassie, Anteneh Kassa, and Yared Kebede Haile at USAID/Ethiopia.

We thank Taye Letta and Eyerusalem Negussie and other staff from the Ethiopia National Tuberculosis and Leprosy Control Program, for their support and guidance.

We extend our appreciation to the Sub-Saharan Africa Research and Training Institute team, especially Yehenew Demmelash, Tseganeh Demissie, Michael Tirfe, Amsalu Binegdie, and Andualem Oumer.

We recognize the core QTSA team for its contributions. Special thanks go to Upama Khatri, Nikki Davis, Gultineh Esubalew, Stephanie Mullen, Suzanne Cloutier, and Jeanne Chauffour of MEASURE Evaluation, John Snow, Inc. ([SI), as well as and Welelaw Necho of JSI Ethiopia.

We thank the knowledge management team of MEASURE Evaluation, University of North Carolina at Chapel Hill, for editorial, design, and production services.

Suggested citation:

MEASURE Evaluation. (2020). Quality of Tuberculosis Services Assessment in Ethiopia: Tools. Chapel Hill, NC, USA: MEASURE Evaluation, University of North Carolina.

CONTENTS

Abbreviations	
Introduction	8
Ethiopia Quality of TB Services Assessment: Facility Audit	9
Ethiopia Quality of TB Services Assessment: Provider Interview	41
Ethiopia Quality of TB Services Assessment: Patient Interview	59
Ethiopia Quality of TB Services Assessment: Register Review	79

ABBREVIATIONS

aDSM active drug safety monitoring

AFB acid-fast bacillus

ART antiretroviral therapy

ARV antiretroviral

CPT co-trimoxazole preventive therapy

DK don't know

DOT directly observed treatment

DOTS directly observed treatment, short-course

DR-TB drug-resistant tuberculosis

DS-TB drug-susceptible tuberculosis

DST drug susceptibility testing

ECG electrocardiogram

EFDA Ethiopian Food and Drug Administration

FDC fixed-dose combinations
FM fluorescence microscope
FMOH Federal Ministry of Health

FQ fluoroquinolones

GPS global positioning system
HEW health extension worker

IRIS immune reconstitution inflammatory syndrome

iDOTS integrated directly observed treatment, short-course

INH isonicotinic acid hydrazide

IRIS immune reconstitution inflammatory syndrome

LPA line probe assay

MDR-TB multidrug-resistant tuberculosis

MTB mycobacterium tuberculosis

NR no response

OPD outpatient department

PBC pulmonary tuberculosis patients

PLHIV people living with HIV/AIDS

Pre-XDR-TB pre-extensively drug-resistant tuberculosis

QA quality assurance

QC quality control

QTSA Quality of TB Services Assessment

RIF rifampicin

RR-TB rifampicin-resistant tuberculosis

SL-LPA second-line anti-tuberculosis drugs

SMS short-message service

TB tuberculosis

TPT tuberculosis preventive treatment

USAID United States Agency for International Development

XDR-TB extremely drug-resistant tuberculosis

INTRODUCTION

The Quality of Tuberculosis Services Assessment (QTSA) is conducted with the support of four tools: the Facility Audit, the Provider Interview, the Patient Interview, and the Register Review. MEASURE Evaluation—a project funded by the United States Agency for International Development (USAID)—developed these four tools with the assistance of colleagues at USAID.

The tools exist in a generic format that is adaptable to any country wishing to conduct a QTSA. For instance, some countries may have different names for their health administrative units (e.g., district, province, ward, or woreda) or the name of their TB registers (e.g., TB patient logbook or TB confirmed cases register). They are customized to fit the country priorities and context in which they will be used.

The generic QTSA tools are available at the following link: https://www.measureevaluation.org/resources/publications/tl-19-41/

For Ethiopia, we added to the Provider Interview three custom modules on stigma and discrimination, pediatric TB, and contact investigation, and to the Patient Interview we added two custom modules on stigma and discrimination and contact investigation.

This document presents only the QTSA tools adapted for use in Ethiopia. It provides detailed information about the structure and content of the tools. More information on the QTSA purpose, methods, or results can be found in the individual QTSA reports. Ethiopia's QTSA report is available at the following link: https://www.measureevaluation.org/resources/publications/tr-20-415/

QTSA documents for other countries are available here: https://www.measureevaluation.org/ourwork/tuberculosis/quality-of-tb-services-assessments

Note about the Ethiopian Calendar

The dates of the Gregorian and Ethiopian calendars do not align. When questions ask about activity within the "last 12 months," this refers to the period of November 1, 2018–November 1, 2019 (equivalent to Hamle 1, 2010–Sene 30, 2011). In the Register Review, the standard review period for DS-TB was December 30, 2017–June 27, 2018 (equivalent to Tahasass 21, 2010–Sene 20, 2010) and the DR-TB review period was June 28, 2016–May 28, 2017 (equivalent to Sene 21, 2008–Ginbot 20, 2009).

ETHIOPIA QUALITY OF TB SERVICES ASSESSMENT: FACILITY AUDIT

Before the site visit to the facility, ensure that the staff members that are best able to answer the questions are available. Some of the staff that may be required include manager or in charge for clinical services, TB designated staff, pharmacist, laboratory scientist, etc.

FILL IN THE NEXT THREE SECTIONS (START OF FACILITY VISIT, FACILITY IDENTIFICATION, AND FACILITY STRUCTURE) BEFORE STARTING THE ACTUAL INTERVIEW WITH A RESPONDENT.

Start of Facility Visit									
		Visit Date [dd/mm/yyyy]	(b) Visit Start Time [Use the 24-hour clock system, e.g., 14:30]	(c) Interviewer ID	(d) Interviewer Name				
001	Visit 1		Hours Minutes						
002	Visit 2 (if needed)		Hours Minutes						

Facilit	y Identification		
		(a) Code	(b) Name
010	Region		
011	Zone/Sub-city		
012	Woreda		
013	Kebele		
014	Facility		
015	GPS Location		

Facili	Facility Structure									
	[OBSERVE THE FACILITY OR WHERE TB SERVICES ARE DELIVERED AND INDICATE WHETHER THERE ARE SIGNS (E.G., TB CLINIC, CHEST CLINIC, PULMONARY SERVICES, ETC.) ANNOUNCING AVAILABILITY OF TB SERVICES AT EACH OF THE FOLLOWING LOCATIONS]	Yes	No	DK						
020	Outside the building	1	0	88						
021	Inside the building	1	0	88						
022	On the door of the TB unit	1	0	88						

The staff member who is best able to answer the questions in the following sections is either the $\underline{\text{TB}}$ focal person or the in-charge for clinical services.

1. Facilit	ty Characteristics			
1.1	Facility Classification			
1.1.1	What type of facility is this?	Referral Hospital General Hospital Primary Hospital Health Center Medical Centre Specialty clinic Medium clinic Other (specify)		
1.1.2	Who is the managing authority of the TB clinic?	Government/Public		
1.1.3	Is this location considered urb		Urban	1 2
1.1.4	Does this facility provide outposervices, or both?	atient or inpatient	Outpatient only Inpatient only Both inpatient and outpatient	1 2 3
1.2	Facility Capacity			
1.2.1	On average, how many clients during a typical month? [ENTER 30 – 50,000]	are seen at this facility	Number of patients Don't know	888
1.2.2	Out of these clients, how man [PROBE: How many patients a for TB during a typical month? [MUST BE LESS OR EQUAL TO	re evaluated or treated '] 1.2.1]	Number of patients Don't know	888
1.2.3.1	On average, how many full-tin non-clinical) were working in t fiscal year (Hamle 1, 2010-Sen [ENTER 1 – 3000]	his facility in the last e 30, 2011)?	Number of staff Don't know	888
1.2.3.2	On average, how many full-tin working in this facility in the la 2010-Sene 30, 2011)? [MUST BE LESS OR EQUAL TO	ast fiscal year (Hamle 1,	Number of staff Don't know	888
1.2.4	[ASK ONLY IF 1.2.3.2 > 0] On average, out of these full-t many usually work in the TB u patients? [MUST BE LESS OR EQUAL TO	ime clinical staff, how nit or interact with TB	Number of staff Don't know	888

1. Facili	ty Characteristics		
1.2.5.1	On average, how many part-time staff (both clinical and non-clinical) were working in this facility in the last fiscal year (Hamle 1, 2010-Sene 30, 2011)? [ENTER 1 – 3000]	Number of staff Don't know	888
1.2.5.2	On average, how many part-time clinical staff were working in this facility as of July 8, 2019 (Hamle 1, 2011)? [MUST BE LESS OR EQUAL TO 1.2.5.1]	Number of staff Don't know	888
1.2.6	[ASK ONLY IF 1.2.5.2 > 0] On average, out of these part-time clinical staff, how many usually work in the TB unit or interact with TB patients? [MUST BE LESS OR EQUAL TO 1.2.5.2]	Number of staff Don't know	888
1.2.7	Typically, how many days per week are TB-related services offered?	Days Don't know	88
1.2.8	Approximately, how many years have TB-related services been available at this facility?	Less than 1 year 1–5 years More than 5 years Don't know	1 2 3 88

2. Availability of TB Services								
	I would like to ask about TB services that are currently available at this facility.							
2.1	Does this facility provide any form of screening for TB? Yes			1				
				No	0			
2.1.1	[ASK ONLY IF 2.1=YES]			Yes	1			
	Does this facility provide screening for TB b signs?	y clinical sympto	ms and	No	0			
2.1.2	ASK ONLY IF 2.1=YES]			Yes	1			
	Does this facility provide screening for TB for symptoms and signs?	or children by cli	nical	No	0			
2.2	Does this facility provide TB diagnosis servi	ces (either clinica	al or	Yes	1			
	laboratory)?			No	0			
	[ASK THE NEXT 3 QUESTIONS ONLY IF 2.2=	YES (diagnostic	acility)]					
2.2.1	Does this facility provide TB diagnosis servi	ces (either	Yes		1			
	clinical or laboratory) for children (less than	n 15 years old)?	No		0			
2.2.2	Has this facility provided TB diagnosis	Yes, onsite lab	only		1			
	services via onsite or offsite laboratory in	Yes, offsite lab	only		2			
	the last 12 months?			S	3			
		No lab diagnos			0			
2.2.3	Does this facility request a sputum sample	from new	Yes		1			
	presumptive TB clients?		No		0			
2.3	Has this facility provide any HIV-related ser				1			
	counselling, testing, care, or treatment in t months?	he last 12	No		0			

2. Availa	bility of TB Services						
2.4	Has this facility-initiated treatment for DS-TB or manage patients who are on DS-TB treatment in the last 12 months? No		ent only nts on treatment only	0 1 2 3			
	[ASK THE NEXT 2 QUESTIONS	ONLY IF 2.4=	1 or 2 or 3				
2.4.1	Are patients charged a fee for	TB medicine	s?		Yes		1
			I				0
2.4.2	Has this facility provided TB tre services to children (less than 1 old) in the last 12 months?		Yes, mana Yes, both	iges tre initiate	eatm es an	ent onlyd manages treatment	1 2 3 0
2.4.3	Does this facility initiate treatm drug-resistant TB (DR-TB) or m patients who are on DR-TB trea the last 12 months?	anage	Yes, mana Yes, initia	ige only te and	y man	age	1 2 3 0
2.4.3.1	(a) Has this facility referred pa second-line treatment for DR-1			•	N	es O	1
				Don't know		88	
	[ASK ONLY IF 2.4.3.1 (a)=YES]	nt	Yes, digital only			2	
	(b) Is there a record or register referrals for second-line treatn			3			
	Telefrais for second-line treating	TETIL TOT DIX-	10:				0
		Don't know				88	
	[ASK ONLY IF 2.4.3.1 (b)=YES (1 or 2 or 3)]			Observed, recorded			2
	(c) Are the results recorded? [C					, not recorded	1
		_		Not o	bser	ved	0
2.5	Does this facility work with HEWs or treatment supporters who support TB patients?	Yes, Treatr etc.) only Both HEWs	nent suppo s & treatme	rters (e	e.g., t	family members, friends,	2 3
2.6	December facility, manage at her					Vaa	0
2.6	Does this facility manage other diabetes and other comorbidit TB patients?				or	Yes	0
2.6a-c	(a) Has this facility referred TB management of other medical other comorbidities etc. in the	conditions,	e.g., diabet	•	•	Yes No Don't know	1 0 88
	[ASK ONLY IF 2.6 (a)=YES]				Yes,	digital	2
	(b) Is there a record or register of the TB patient ref for the management of other medical conditions?						1 3 0 88
	[ASK ONLY IF 2.6 (b)=YES (1 or (c) Are the results recorded? [Obs	erved, recorded erved, not recorded observed	2 1 0
2.7a.1	[ASK IF 2.4=YES (1 or 2 or 3)] Does this facility provide transpatients receiving treatment in			В	Yes No .	't know	1 0 88

2.7a.2 [ASK IF 2.4.3=YES (1 or 2 or 3)]			Yes	1
	Does this facility provide transport assistance for D	R-TB	No	0
	patients receiving treatment in the facility?		Don't know	88
2.7b.1	[ASK IF 2.4=YES (1 or 2 or 3)]	Yes	Yes	
	Does this facility provide transport assistance for	No transport assistance provided		2
	DS-TB patients referred to other health facilities?	No pa	atient referral	3
		Don't know		88
2.7b.2	[ASK IF 2.4.3=YES (1 or 2 or 3)]	Yes		1
	Does this facility provide transport assistance for	No transport assistance No patient referral		2
	DR-TB patients referred to other health facilities?			3
		Don't	know	88

3. TB Dia	agnosis [ASK ONLY IF 2.2= 1 (diagnostic facility)]						
3.1	TB Diagnosis Methods						
	Now, I will ask if this facility provides specific TB diagnosis services. For each service, I would like to know whether this facility offered the service at	Offer	ed last	: 12	Is the te or offsite	onsite	
	any time in the last 12 months.	Yes	No	DK	Onsite	Offsite	DK
3.1.1	Diagnosis of TB by clinical symptoms and signs	1	0	88			
3.1.2	Diagnosis of TB by X-ray	1	0	88	1	0	88
	[ASK THE NEXT 4 QUESTIONS ONLY IF 3.1.2 (b)=YES	5]					
3.1.2.1	Diagnosis of TB by conventional X-ray	1	0	88			
3.1.2.2	Diagnosis of TB by digital X-ray	1	0	88			
3.1.2.3	Diagnosis of TB by computer assisted digital X-ray (CAD4TB)	1	0	88			
3.1.2.4	Are patients charged a fee for diagnostic X-rays?	1	0	88			
3.1.3	Diagnosis of TB by smear microscopy	1	0	88	1	0	88
3.1.4	Diagnosis of TB by culture	1	0	88	1	0	88
3.1.5	Diagnosis of TB by GeneXpert	1	0	88	1	0	88
3.1.6	Diagnosis of TB by Fine needle Aspiration (FNA)	1	0	88	1	0	88
3.1.7	Diagnosis of TB by Biopsy	1	0	88	1	0	88
3.1.8	Diagnosis of TB by Cytology	1	0	88	1	0	88
3.1.9	Diagnosis of TB by another method (specify)	1	0	88	1	0	88
3.1.10	[ASK ONLY IF 3.1.3 (b) =NO/DK OR 3.1.5 (b) =NO/DK] (a) Has this facility referred patients to another facility for DS- TB diagnosis, either for smear microscopy or GeneXpert, in the last 12 months? Yes			1 0 88			
İ	[ASK ONLY IF 3.1.10 (a)=YES] Yes, digital only					2	
	(b) Is there a record or register of the patient		_	•			1
	referrals for DS-TB diagnosis?		-	-	per		3
					·		0
		Don'	t know				88

3. TB Dia	agnosis [ASK ONLY IF 2.2= 1 (diagnostic facility)]					
	(c) Are the results recorded? [OBSERVE]	Observed, recorded Observed, not recorded Not observed			. 0	
		Don't know				. 88
3.2	Drug Susceptibility Testing (DST) [ASK ONLY IF 2.2.2=	= 1 or 2.2.2	=3 (facility	uses ons	ite lab)]	
				Yes	No	DK
3.2.1	Was first-line drug susceptibility testing available at the 12 months?	nis facility	in the last	1	0	88
	[ASK THE NEXT 5 QUESTIONS ONLY IF 3.2.1=YES] What methods are used to detect resistance to first-li	ne drugs?		Yes	No	DK
3.2.1.1	GeneXpert			1	0	88
3.2.1.2	First line probe assays (e.g., MTBDRplus)			1	0	88
3.2.1.3	Solid culture			1	0	88
3.2.1.4	Liquid culture			1	0	88
3.2.1.5	Any other method used to detect resistance to first-lin	ne drugs? -	(specify)	1	0	88
3.2.2	[ASK ONLY IF 2.4.3=1 or 3 (facility initiates DR-TB] Is second-line drug susceptibility testing available at this facility in the last 12 months?				0	88
	[ASK THE NEXT 4 QUESTIONS ONLY IF 3.2.2=YES] What methods are used to detect resistance to second-line drugs?			Yes	No	DK
3.2.2.1	Second line probe assays (e.g., MTBDRsI)			1	0	88
3.2.2.2	Solid culture			1	0	88
3.2.2.3	Liquid culture			1	0	88
3.2.2.4	Any other method used to detect resistance to second (specify)	d-line druยู	gs?	1	0	88
3.2.3	[ASK ONLY IF 3.2.1=NO/DK OR 3.2.2=NO/DK]		Yes			1
	(a) Has this facility referred patients to another facility	-				0
	TB diagnosis, e.g., drug sensitivity testing, in the last 1 months?			ow		88
	[ASK ONLY IF 3.2.3 (a)=YES]		digital only			2
	(b) Is there a record or register of the patient referrals		paper only			1
	for DR-TB diagnosis?		both digita			3
		_				0
			't know			88
	[ASK ONLY IF 3.2.3 (b)=YES (1 or 2 or 3)]		erved, reco			2
	(c) Are the results recorded?		erved, not			1
	[OBSERVE]		observed 't know			0 88
		D01	I L KIIOW			00
3.3	TB Case Notification					
3.3.1	How many times has this facility submitted a TB repor	rt to the				
	Woreda/Regional Health Office or FMOH in the last b		r?			
	[LIMIT THE NUMBER TO 4]			Enter 8	8 if don't	know
				Yes	No	DK
3.3.2	Does this facility keep a record of TB case notification	s?		1	0	88

3. TB Dia	agnosis [ASK ONLY IF 2.2= 1 (diagnos	stic facility)]	
3.3.2.1	[ASK ONLY IF 3.3.2=YES]	HMIS/ DHIS 2 electronic only	1
	How are TB case notifications	HMIS/ DHIS 2 Paper based only	2
	recorded?	Both electronic & Paper based HMIS/ DHIS 2.	3
		Other (specify)	96

4. Conta	t Investigation and Management				
	The next couple of questions are about contact investigation and management. I would like to know whether this facility offered the following services at any time in the last 12 months.	Yes, all	Yes, partially	No	DK
4.1	Contact investigation and management according to TB program guidelines	2	1	0	88
	[ASK THE NEXT 2 QUESTIONS ONLY IF 4.1=YES]				
4.1.1	For all adult contacts (who are symptomatic or HIV-positive adults)	2	1	0	88
4.1.2	For all under 5 years child contacts	2	1	0	88
4.1.3	For all 5-14 years old child contacts	2	1	0	88

5. TB/H	IV Services [ASK ONLY IF 2.3=YES (facility provides TB/HI	V services)]			
	Now, I will ask if the facility provides specific TB/HIV ser	vices. For each	Offered	l last 12 ı	months?
	service, I would like to know whether this facility offered any time in the last 12 months.	d the service at	Yes	No	DK
5.1	HIV testing and counselling for presumptive TB patients		1	0	88
5.2	HIV testing and counselling for confirmed TB patients		1	0	88
5.3	(a) Has this facility referred patients to another facility	Yes			1
	for HIV testing and counselling in the last 12 months?	No			0
		Don't know			88
	[ASK ONLY IF 5.3 (a)=YES]	Yes, digital only			2
	(b) Is there a record or register of the patient referrals	Yes, paper only			1
	for HIV testing and counselling?	Yes, digital & pape	er		3
		No			0
		Don't know			88
	[ASK ONLY IF 5.3 (b)=YES (1 or 2 or 3)]	Observed, recorde			2
	(c) Are the results recorded?	Observed, not rec			1
	[OBSERVE]	Not observed			0
	For each service, I would like to know whether this facili service at any time in the last 12 months.	ty offered the	Yes	No	DK
5.4a	TB preventive therapy (TPT) for HIV-positive adults		1	0	88
5.4b	TB preventive therapy (TPT) for children under 5 years		1	0	88
5.4c	TB preventive therapy (TPT) for children 5-15 years		1	0	88
	[ASK THE NEXT 5 QUESTIONS ONLY IF 5.4a or 5.4b or 5.	4c =YES]			
5.5	What type of TB preventive therapy (TPT) is available at	this site?	Yes	No	DK
5.5.1	INH (6 months)		1	0	88
5.5.2	3HP (12 weeks rifapentine and INH)		1	0	88
5.5.3	3RH		1	0	88

5. TB/H	IV Services [ASK ONLY IF 2.3=YES	(facility pro	ovides TB	HIV s	ervice	s)]					
								Yes	No)	DK
5.5.4	Is TPT available through a difference community support group/healt			-	odel (e	e.g.,		1	0		88
5.5.5	[ASK ONLY IF ANY OF 5.4a – 5.4 (a) Has this facility referred patie for TB preventive therapy in the	c = NO] ents to ano	ther facili		No						1 0 88
	[ASK ONLY IF 5.5.5 (a)=YES] (b) Is there a record or register of referrals for TB preventive there [ASK ONLY IF 5.5.5 (b)=YES (1 or	ipy?	nt Ye Ye N D	es, pap es, digit oon't kn bserve	er only tal & p ow d, reco	y pape orde	ed				2 1 3 0 88 2
	(c) Are the results recorded?		N	ot obse	erved		orded				1 0 88
5.6	Does the facility provide HIV car coinfected patients?	e and treat	ment ser	vices to	о ТВ/Н	IIV		Yes 1	No 0		DK 88
	[ASK THE NEXT 3 QUESTIONS O	NLY IF 5.6=	YES]				•				
5.6.1	CPT (Co-trimoxazole preventive	therapy) fo	r TB/HIV	coinfe	cted p	atie	nts	1	0		88
5.6.2	Viral load testing for TB/HIV coin	nfected pati	ients					1	0		88
5.6.3	ART for TB/HIV coinfected patie	nts						1	0		88
5.6.3.1	[ASK ONLY IF 5.6.3=YES]										00
	Screening for symptoms of anti-	TB and ARV	/ drug int	eractio	ns			1	0		88
5.7	Do staff members provide the following information to TB/HIV coinfected patients on	(a) Provid	le inform	ation?	•		(b) How	-	-	_	ovided?
	ART and if so, is the information provided verbally and/or by written patient literacy materials?	For all patients	For some patient	No s	D D	К	Verbally	/ Wri	tten	Bot	h DK
5.7.1	What to do if patients experience anti-TB and ARV drug interactions	2	1	0	88	8	1	2	2	3	88
5.7.2	What to do if signs and symptoms of immune reconstitution inflammatory syndrome (IRIS) become evident	2	1	0	88	8	1	:	2	3	88

	reatment Services [ASK ONLY IF 2.4=1 or 2 or 3 (DS-TB treatment facility) OR ent facility)]	2.4.3 = 1 or 2 or 3 (DR-TB
6.1	Available Services	
	Now, I will ask if the facility provides specific TB treatment services.	
	For each service, I would like to know whether this facility offered the service at any time in the last 12 months.	Offered last 12 months?

	atment Services [ASK ONLY IF 2.4=1 or 2 or 3 (DS-TB tre t facility)]	eatment facilit	y) OR 2.	.4.3 = 1 or	2 or 3	(DR-TB
treatmen	c racincy)]			Yes	No	DK
6.1.1	Dispensing of drugs for TB treatment			1	0	88
6.1.2	TB treatment and follow-up during the intensive phas	е		1	0	88
6.1.3	TB treatment and follow-up during the continuation p			1	0	88
	[ASK NEXT 4 QUESTIONS ONLY IF 2.4=1 or 2 or 3 (DS-	TB treatment	facility)]	•	
6.1.4	Facility-based directly observed treatment (DOT)			1	0	88
6.1.5	[ASK ONLY IF 2.5 = 1 or 3 (facility works with HEWs)] Community-based DOT (HEW)			1	0	88
6.1.6	Home-based treatment (self-managed without the su treatment supporters)	pport of family	or	1	0	88
6.1.7	Home-based treatment (family or treatment supported	ers)		1	0	88
6.1.8	Reminder phone calls or SMS texts to support patient treatment	s' adherence to	0	1	0	88
6.1.9	Psychosocial or other adherence support			1	0	88
	[ASK THE NEXT 3 QUESTIONS ONLY IF 6.1.9=YES]			•	·L	
6.1.9.1	Counselling with a psychologist or social worker			1	0	88
6.1.9.2	One-on-one counselling (face to face) by medical staff nurse)	f (doctor, HO, o	or	1	0	88
6.1.9.3	One-on-one peer counselling (face to face) by lay cou	nsellor		1	0	88
6.1.10	Nutritional support or food baskets)			1	0	88
6.1.11	Support group for TB patients (e.g., peer support, civil TB)	c society worki	ng on	1	0	88
6.1.12	Patient tracking of those who miss an appointment			1	0	88
	[ASK THE NEXT 2 QUESTIONS ONLY IF 6.1.12=YES]					
6.1.12.1	Follow-up phone calls or SMS texts to TB patients if the appointment	iey miss an		1	0	88
6.1.12.2	Home visits to TB patients if they miss an appointmen	t		1	0	88
6.1.12.3	[ASK ONLY IF 2.5 = 1 or 3 (facility works with HEWs)] Family health team (health professionals + HEWs)			1	0	88
6.2	Treatment Practices					
	Now, I will ask you about TB treatment practices at this facility.	Yes, for all patients		or some tients	No	DK
6.2.1	Does this facility review the progress of each TB patient registered for TB treatment at the facility at least once a month during the treatment period?	2		1	0	88
6.2.2	Do you ask/observe patients regarding symptoms of drug side effects when they visit the facility for treatment?	2		1	0	88
6.2.2.1	[ASK ONLY IF 6.2.2=YES] Do you record all side effects observed and/or reported by patients?	2		1	0	88

6.2.2.1.1	t facility)]	CD Linit Dog	ictor						1
6.2.2.1.1		TB Unit Reg							2
	-	TB Patient (HIV patient							3
		harmacov		_					4
		Don't know	_		-				88
	_	Other (spec							96
6.2.2.2	[ASK ONLY IF 6.2.2=YES]	other (spec	211 y /			w-up visit			1
0.2.2.2	How often are patients screene	ed for side			•	ne initiatio		•	2
	effects?	54 101 514C		-	_		-		88
					r specify				96
							'es	No	DK
6.2.2.3	[ASK ONLY IF 6.2.2=YES]								
	Do you report Adverse Drug Ev	ents to the	EFDA (E	thiopia	n Food		1	0	88
	and Drug Administration) as th			•					
6.2.3	Do you have ancillary medication			effects	?		1	0	88
	,						_		
5.3	Patient Counselling and Educat	ion on TB	Treatme	nt					
	Do staff members provide the					[ASK ONI	Y IF (a)=Y	ES]	
	following information to TB	Provide	informat	ion?		II -	formation	_	ed?
	patients and if so, is the	Y	es						
	information provided verbally		Г	N.a	DV	Madhalli	\	Dath	
	and/or by written patient	For all	For	No	DK	Verbally	Written	Both	Dk
	literacy materials?		some						
6.3.1	What test results mean	2	1	0	88	1	2	3	88
6.3.2	How TB is spread to others	2	1	0	88	1	2	3	88
6.3.3	The need for a treatment	2	1	0	88	1	2	3	88
	supporter		1	U	00	1	2	3	00
6.3.4	How TB medication should be								
	taken, e.g., dosage, frequency,	2	1	0	88	1	2	3	88
	etc.								
6.3.5	The importance of treatment	2	1	0	88	1	2	3	88
	adherence		1	U	00	1	2	3	00
6.3.6	Options available for treatment								
	support, e.g., DOT, HEWs,	2	1	0	88	1	2	3	88
	family, family health team								_
6.3.7	What to do when experiencing	2	1	0	88	1	2	3	88
	side effects						-		
6.3.8	What to do if they run out of	2	1	0	88	1	2	3	88
	medicines		-				-		+
6.3.9	What to do if they need to leave	е							
	for more than a month to an	2	1	0	88	1	2	3	88
	area beyond the facility								
C 2 40	catchment area		<u> </u>	!!!		Vas			1
5.3.10	Is there a private room available		dual coui	nselling	wnere				_
	no one can hear or see what is a	going on?							0
						וטon't knd	ow		88
	1								

	atment Services [ASK ONLY IF 2.4=	:1 or 2 or 3 (DS-1	TB treatment facilit	y) OR 2.4.3 = 1 or 2 or 3 (D	R-TB
treatme	nt facility)] The next couple of questions ask health professional from the facilitheir family).	•	-	•	
6.4.1	Do DS-TB patients take treatments support of a family member (i.e., supervision of a health profession facility including HEWs)?	, without the	Yes, for continual Yes, both	phase onlytion phase only	1 2 3 0 88
6.4.2	[ASK ONLY IF 6.4.1=1 or 3] (A) How often do these TB patient treatment typically collect their induring intensive phase? [ASK ONLY IF 6.4.1=2 or 3] (B) How often do these TB patient treatment typically collect their induring continuation phase?	medications nts taking	Weekly Twice a month Other (specify) Don't know Daily Weekly Twice a month Monthly Other (specify)		1 2 3 96 88 1 2 3 4 96 88
6.4.3	[ASK ONLY IF 6.4.1=YES] Does the facility monitor the intercollect treatment?	ervals at which t	he patient should	Yes No Don't know	1 0 88
6.4.3.1	[ASK ONLY IF 6.4.3=YES] How does the facility monitor the intervals at which the patient should collect treatment?	Unit TB Regis Both the TB R Don't know	try Registry and the TB	treatment support card	1 2 3 88 96

7. DR-TB	Treatment Services [ASK ONLY IF 2.4.3=1 or 3 (facility initiates DR-TB tr	eatment)]	
The next	set of questions asks about the RR/DR-TB treatment services used at this	s facility in	the last 6	months.
7.1	Which RR/DR-TB treatment regimens are available at this facility?	Yes	No	DK
7.1.1	Short standard treatment Regimen (9-12 month), (4-6 Am-Mfx-Pto-Cfz-Z-HH-E/5 Mfx-Cfz-Z-E)	1	0	88
7.1.2	Individualized longer regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs-Dlm-Pto-Z)	1	0	88
7.1.3	Short standard treatment Regimen (9-12 month), (4-6 Km-Mfx-Pto-Cfz-Z-HH-E/5 Mfx-Cfz-Z-E)	1	0	88
7.1.4	Longer Standardized Regimen (20 Bdq-Mfx-Lzd-Cfz)	1	0	88
7.1.3	Other (specify)	1	0	88

What is the most used RR/MDR-TB treatment Regimen (9-12 month), (4-6 Am-Mfx-Pto-Cfz-2-HH-F/5 Mfx-Cfz-2-E)	7. DR-TB	Treatment Services [ASK ONLY IF 2.4.3=1 or 3 (facility initia	tes DR-TB ti	reatment)]	
regimen at this facility? Short standard treatment Regimen (9-12 month), (4-6 Km-Mfx-Pto-Cfz-Z-HiH-E/5 Mfx-Cfz-Z-E)	7.2	used RR/MDR-TB	Cfz-Z-HH-E/5 Mfx-Cfz-Z-E)				1
Cf.z-HH-E/S Mfx-Cfz-z-E)		regimen at this	Dlm-Pto-Z)				2
Longer Standardized Regimen (20 Bdq-Mfx-Lzd-Cfz)		facility?				Mfx-Pto-	
Other (specify) Don't know 96 88							
Don't know Short Standard Treatment Regimen (9–12 month), (4-6 Am-Mfx-Pto-Cfz-Z-HH-E/S Mfx-Cfz-Z-E)			1	•	•		-
Short Standard Treatment Regimen (9–12 month), (4-6 Am-Mfx-Pto-Cfz-Z-HH-E/5 Mfx-Cfz-Z-E) [ASK ONLY IF 7.1.1=YES] Which medications are used in this regimen (Short standard treatment Regimen)?			1				
Task ONLY IF 7.1.1=YES Which medications are used in this regimen (Short standard treatment Regimen)? Yes No DK			Don't know		•••••		88
Task ONLY IF 7.1.1=YES Which medications are used in this regimen (Short standard treatment Regimen)? Yes No DK				14C DI	or =	-/= > 45 . 6	C = =\
7.3.1 Which medications are used in this regimen (Short standard treatment Regimen)? Yes No DK 7.3.1.1 Amikacine 500 mg/2 m solution for injection 1 0 88 7.3.1.2 Clofazimine 100 mg capsule 1 0 88 7.3.1.3 Ethambutol 400 mg tablet 1 0 88 7.3.1.4 Isoniazid 300 mg tablet 1 0 88 7.3.1.5 Moxifloxacin 400 mg tablet 1 0 88 7.3.1.6 Protionamide 250 mg tablet 1 0 88 7.3.1.7 Pyrazinamide 400 mg tablet 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.1.9 Vrazinamide 400 mg tablet 1 0 88 7.3.1.1 Vrazinamide 400 mg tablet 1 0 88 7.3.1.1 Vrazinamide 400 mg tablet 1 0 88 7.3.2.1 Newly diagnosed Re-/MDR-1B patients that are confirmed or co	7.3			m-Mfx-Pto-	Ctz-Z-HH-I	=/5 Mfx-C	tz-Z-E)
Treatment Regimen ?	7.3.1	_		rd	Vas	N	DV
7.3.1.2 Clofazimine 100 mg capsule 1 0 88 7.3.1.3 Ethambutol 400 mg tablet 1 0 88 7.3.1.4 Isoniazid 300 mg tablet 1 0 88 7.3.1.5 Moxifloxacin 400 mg tablet 1 0 88 7.3.1.6 Protionamide 250 mg tablet 1 0 88 7.3.1.7 Pyrazinamide 400 mg tablet 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.2.1 IASK ONLY IF 7.1.1=YES) Which patients are eligible for this regimen (Short standard treatment regimen)? Yes No DK 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI as evidenced by: Laboratory evidence of susceptibilit		treatment Regimen)?		Yes	NO	DK
7.3.1.3 Ethambutol 400 mg tablet 1 0 88 7.3.1.4 Isoniazid 300 mg tablet 1 0 88 7.3.1.5 Moxifloxacin 400 mg tablet 1 0 88 7.3.1.6 Protionamide 250 mg tablet 1 0 88 7.3.1.7 Pyrazinamide 400 mg tablet 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.2.1 (ASK ONLY IF 7.1.1=YES) Which patients are eligible for this regimen (Short standard treatment regimen)? Yes No DK 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-PA test. 1 0 88 7.3.2.1 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB 1 0 88 7.3.2.4 </td <td>7.3.1.1</td> <td>Amikacine 500 mg/</td> <td>2 ml solution for injection</td> <td></td> <td>1</td> <td>0</td> <td>88</td>	7.3.1.1	Amikacine 500 mg/	2 ml solution for injection		1	0	88
7.3.1.4 Isoniazid 300 mg tablet 1 0 88 7.3.1.5 Moxifloxacin 400 mg tablet 1 0 88 7.3.1.6 Protionamide 250 mg tablet 1 0 88 7.3.1.7 Pyrazinamide 400 mg tablet 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.2.1 IASK ONLY IF 7.1.1=YES] Which patients are eligible for this regimen (Short standard treatment regimen)? Yes No DK 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-IPA test. 1 0 88 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB 1 0 88 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens.<	7.3.1.2	Clofazimine 100 mg	capsule		1	0	88
7.3.1.5 Moxifloxacin 400 mg tablet 1 0 88 7.3.1.6 Protionamide 250 mg tablet 1 0 88 7.3.1.7 Pyrazinamide 400 mg tablet 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.2.1 [ASK ONLY IF 7.1.1=YES] Which patients are eligible for this regimen (Short standard treatment regimen)? Yes No DK 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 1 0 88 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB 1 0 88 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 1 0 88 7.3.2.6 Other (specify) 1 0 88 7.3.3	7.3.1.3	Ethambutol 400 mg	tablet		1	0	88
7.3.1.6 Protionamide 250 mg tablet 7.3.1.7 Pyrazinamide 400 mg tablet 7.3.1.7 Pyrazinamide 400 mg tablet 7.3.1.8 Other (specify) 1 0 88 7.3.1.8 [ASK ONLY IF 7.1.1=YES] Which patients are eligible for this regimen (Short standard treatment regimen)? 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] No Months Don't know Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? P4.1.2 Bedaquiline 600 mg tablet 1 0 88	7.3.1.4	Isoniazid 300 mg ta	blet		1	0	88
7.3.1.7 Pyrazinamide 400 mg tablet 1 0 88 7.3.1.8 Other (specify) 1 0 88 7.3.2.1 [ASK ONLY IF 7.1.1=YES] Yes No DK Which patients are eligible for this regimen (Short standard treatment regimen)? Yes No DK 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 1 0 88 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB 1 0 88 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 1 0 88 7.3.2.6 Other (specify) 1 0 88 7.3.3.3 [ASK ONLY IF 7.1.1=YES] Months	7.3.1.5	Moxifloxacin 400 m	g tablet		1	0	88
7.3.1.8 Other (specify) 1 0 88 7.3.2 [ASK ONLY IF 7.1.1=YES] Which patients are eligible for this regimen (Short standard treatment regimen)? 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB XDR-TB or XDR-TB 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.7 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months Don't know 88 7.4 Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)?	7.3.1.6	Protionamide 250 r	ng tablet		1	0	88
Task ONLY IF 7.1.1=YES Which patients are eligible for this regimen (Short standard treatment regimen)? Task ONLY IF 7.1.1=YES Which patients are eligible for this regimen (Short standard treatment regimen)? Task ONLY IF 7.1.2=YES Which patients are eligible for this regimen (Short standard treatment regimen)? Task ONLY IF 7.1.1=YES Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Task ONLY IF 600 mg tablet Task ONLY IF 7.4.1.2 Task ONLY IF 600 mg tablet Task ONLY IF 7.4.1.2 Task ONLY IF 600 mg tablet Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Task ONLY IF 7.4.1.2 Bedaquiline 600 mg tablet Task ONLY IF 7.4.1.2 Task ONLY IF 7.4.1 Task ONLY IF 7.4.1.2 Task ONLY IF 7.4.1 Task ONLY IF 7.4.1 Task	7.3.1.7	Pyrazinamide 400 n	ng tablet		1	0	88
Which patients are eligible for this regimen (Short standard treatment regimen)? 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB or XDR-TB or XDR-TB or XDR-TB 1 0 88 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months	7.3.1.8	Other (specify)			1	0	88
treatment regimen)? 7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB or XDR-TB 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for 1 0 88 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months Don't know 88 7.4.1 Undividualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)?	7.3.2	[ASK ONLY IF 7.1.1:	=YES]				
7.3.2.1 Newly diagnosed RR-/MDR-TB patients that are confirmed or considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB or XDR-TB 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months Don't know. 88 7.4 Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? Yes No DK DK Bedaquiline 600 mg tablet 1 0 88		Which patients are	eligible for this regimen (Short standar	d	Yes	No	DK
considered or presumed low risk for resistance to FQ and/or SLI, as evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB or XDR-TB 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months		treatment regimen)?				
evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB or XDR-TB 1 0 88 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months B8 7.4 Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 1 0 88	7.3.2.1						
evidenced by: Laboratory evidence of susceptibility to FQ and/or SLI on baseline SL-LPA test. 7.3.2.2 No prior exposure history to core SLDs for more than 1 month 1 0 88 7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB or XDR-TB or XDR-TB 1 0 88 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months					1	0	88
7.3.2.2No prior exposure history to core SLDs for more than 1 month10887.3.2.3No known history of contact with a patient documented to have PreXDR-TB or XDR-TB10887.3.2.4Children under 15 years who are diagnosed with RR-/MDR-TB10887.3.2.5People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens.10887.3.2.6Other (specify)10887.3.3.3[ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20]Months				and/or SLI	_		
7.3.2.3 No known history of contact with a patient documented to have Pre-XDR-TB or XDR-TB 7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Non't know							
XDR-TB or XDR-TB 1					1	0	88
7.3.2.4 Children under 15 years who are diagnosed with RR-/MDR-TB 1 0 88 7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Months Don't know	7.3.2.3		of contact with a patient documented to	o have Pre-	1	0	88
7.3.2.5 People living with HIV and pulmonary DR-TB diagnosis, including those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 1 0 88	7324		years who are diagnosed with RR-/MDR	:-TB	1	0	88
those receiving antiretroviral treatment, with no need for modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 1 0 88							- 00
modifications of DR-TB or ARV regimens. 7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Non't know	7101210				1	0	88
7.3.2.6 Other (specify) 1 0 88 7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 1 0 88		_					
7.3.3 [ASK ONLY IF 7.1.1=YES] What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 7.3.3 [ASK ONLY IF Months	7.3.2.6		3		1	0	00
What is the usual duration of this regimen (Short standard treatment Regimen)? [ENTER 6-20] Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? No DK Pt. 1.2. Bedaquiline 600 mg tablet 1 0 88				ı	1	U	88
standard treatment Regimen)? [ENTER 6-20] 7.4 Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 1 0 88	7.3.3	_	-				
[ENTER 6-20] know			<u> </u>				
7.4 Individualized Longer Regimen (20 month), (20 Bdq-Mfx-Lzd-Cfz-Cs- Dlm-Pto-Z) [ASK ONLY IF 7.1.2=YES] 7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 1 0 88			: Regimen)?				
7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 7.4.1.2 Bedaquiline 600 mg tablet 7.4.1.2 Redaquiline 600 mg tablet 7.4.1.2 Redaquiline 600 mg tablet		[ENTER 6-20]		know			88
7.4.1 Which medications are used in this regimen (i.e., the individualized longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet Yes No DK 1 0 88	7.4	_	ger Regimen (20 month), (20 Bdq-Mfx-	Lzd-Cfz-Cs- [Olm-Pto-Z) [ASK ON	LY IF
longer regimen of 20 months)? 7.4.1.2 Bedaquiline 600 mg tablet 1 0 88	7 <u>4</u> 1	_	are used in this regimen (i.e. the indiv	idualized			
7.4.1.2 Bedaquiline 600 mg tablet 1 0 88	7.7.1			aunzeu	Yes	No	DK
	7.4.1.2				1	0	88
	7.4.1.3				1	0	88

7. DR-TB	Treatment Services [ASK ONLY IF 2.4.3=1 or 3 (facility initiat	es DR-TB tre	eatment)]		
			Yes	No	DK
7.4.1.4	Cycloserine 250 mg capsule		1	0	88
7.4.1.5	Delamanid 50 mg tablet		1	0	88
7.4.1.6	Linezolid 600 mg tablet		1	0	88
7.4.1.7	Moxifloxacin 400 mg tablet		1	0	88
7.4.1.8	Protionamide 250 mg tablet		1	0	88
7.4.1.9	Pyrazinamide 400 mg tablet		1	0	88
7.4.1.10	Other (specify)		1	0	88
7.4.2	[ASK ONLY IF 7.1.2=YES] Which patients are eligible for this regimen (individualized regimen)?	longer	Yes	No	DK
7.4.2.1	Presumed or confirmed PreXDR-/XDR-TB		1	0	88
7.4.2.2	Known contact with patient failing second-line treatment		1	0	88
7.4.2.3	Evidence of pregnancy		1	0	88
7.4.2.4	Disseminated, meningeal or central nervous system TB or a extrapulmonary TB in HIV patients	iny	1	0	88
7.4.2.5	Initial treatment with standardized regimen that needs to be switched to an individualized regimen (due to resistance, described toxicities, failure or standard DR-TB treatment and/or re-treatment interruption for more than eight weeks)	rug	1	0	88
7.4.2.6	Risk of intolerance because of possible serious drug-drug interactions, severe adverse drug reactions to core drugs u regimen	sed in	1	0	88
7.4.2.7	Patients with increased likelihood of acquisition of addition resistance, treatment failure, or death due to co-morbidition seriously sick patients such as patients with low body mass BMI <16.5kg/m2, Advanced HIV/AIDS, etc)	es or other	1	0	88
7.4.2.8	Other (specify)		1	0	88
7.4.3	[ASK ONLY IF 7.1.2=YES] What is the usual duration of this regimen (Individualized longer regimen)? [ENTER 6-36]	Months Don't know	1 1		88
7.9	Ancillary Drugs				
			Yes	No	DK
7.9.1	Does this facility have ancillary drugs for management of si effects?	de	1	0	88
	[ASK ONLY IF 7.9.1=YES] Which ancillary drugs are available?		Yes	No	DK
7.9.1.1	Amitryptylline tablet		1	0	88
7.9.1.2	Bromozepam tablet		1	0	88
7.9.1.3	Calcium gluconate injection		1	0	88
7.9.1.4	Ceftraxone injection		1	0	88
7.9.1.5	Chlorpromazine tablet or injection		1	0	88
7.9.1.6	Cimetidine injection		1	0	88
7.9.1.7	Dextromethorphan syrup		1	0	88
7.9.1.8	Diclofenac tablet or suppository		1	0	88
7.9.1.9	Diphenhydramine tablet or injection		1	0	88

			Yes	No	DK
7.9.1.10	DNS 5% with giving set injection		1	0	88
7.9.1.11	Fluoxetine tablet		1	0	88
7.9.1.12	Haloperidol tablet		1	0	88
7.9.1.13	Indomethacin suppository		1	0	88
7.9.1.14	Insulin lent or regular injection		1	0	88
7.9.1.15	Insulin syringe		1	0	88
7.9.1.16	KCL tablet or injection		1	0	88
7.9.1.17	Levothyroxine tablet		1	0	88
7.9.1.18	Loperamide tablet		1	0	88
7.9.1.19	Magnesium sulfate tablet		1	0	88
7.9.1.20	Metochorpamide tablet or injection		1	0	88
7.9.1.21	Omeperazole tablet		1	0	88
7.9.1.22	Ranitidine tablet or injection		1	0	88
7.9.1.23	Pyridoxine tablet		1	0	88
7.9.1.24	Ringer lactate injection		1	0	88
7.9.1.25	Other (specify)		1	0	88
7.9.2	Does this facility participate in active pharmaco	ovigilance, e.g., a	ctive	0	00
	drug safety monitoring (aDSM)?		1	0	88
7.10	DR-TB Treatment Equipment				
7.10.1	Does this facility have at least one	Yes, observed.			_
	(500) 1: 2				2
	electrocardiogram (ECG) machine?	Yes, not obser			1
	[OBSERVE]	Yes, not obser	ved		1 0
	[OBSERVE]	Yes, not obser	ved		1 0 88
7.10.1.1	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED]	Yes, not obser No Don't know	ved		1 0 88
7.10.1.1	[OBSERVE]	Yes, not obser No Don't know	Yes		1 0 88 1 0
	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working?	Yes, not obser No Don't know	Yes NoDon't know		1 0 88
	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)]	Yes, not obser No Don't know	Yes		1 0 88 1 0
7.10.1.1 7.10.1.2	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on an	Yes, not obser No Don't know verage?	Yes No Don't know		1 0 88 1 0 88
7.10.1.2	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50]	Yes, not obser No Don't know verage?	Yes No Don't know Number		1 0 88 1 0 88
	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on an	Yes, not obsernous not observable not obs	Yes No Don't know Number Don't know		1 0 88 1 0 88
7.10.1.2	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50]	Yes, not obsernous not observable not obse	Yes Don't know Don't know Don't know Number		1 0 88 1 0 88
7.10.1.2 7.10.1.3	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on ar [ENTER 1 - 50] Are there any clinical staff who can interpret EC	Yes, not obser No	Yes No Don't know Number Don't know Yes No		1 0 88 1 0 88 . 88 . 1 0 88
7.10.1.2	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry	Yes, not observed Yes, not observed Yes, not observed	Yes Don't know Don't know Don't know Don't know Yes No Don't know		1 0 88 1 0 88
7.10.1.2 7.10.1.3	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on ar [ENTER 1 - 50] Are there any clinical staff who can interpret EC	Yes, not observed Yes, not observed Yes, not observed Yes, not observed	Yes Don't know Don't know Don't know Don't know Yes No Don't know		1 0 88 1 0 88
7.10.1.2 7.10.1.3	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry	Yes, not observed Yes, not observed Yes, not observed Yes, not observed No	Yes Don't know Don't know Pon't know Don't know Yes No Don't know		1 0 88 1 0 88 . 88 . 1 0 88 2 1 0
7.10.1.2 7.10.1.3 7.10.2	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry equipment? [OBSERVE]	Yes, not observed Yes, observed Yes, not observe	Yes No Don't know Don't know Yes No Don't know Yes Ved		1 0 88 1 0 88
7.10.1.2 7.10.1.3	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry equipment? [OBSERVE]	Yes, not observed Yes, observed Yes, not observe	Yes Don't know Don't know Don't know Yes No Don't know Yes	1 0 88 1 0 88 . 1 0 88 2 1 0 88	
7.10.1.2 7.10.1.3 7.10.2	[OBSERVE] [ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry equipment? [OBSERVE]	Yes, not observed Yes, observed Yes, not observe	Yes Don't know Yes No Don't know Yes No Don't know Yes No Don't know		1 0 88 1 0 88
7.10.1.2 7.10.1.3 7.10.2	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry equipment? [OBSERVE] [ASK ONLY IF 7.10.2=YES, OBSERVED] Is the machine working?	Yes, not observed Yes, observed Yes, not observe	Yes Don't know Yes No Don't know Yes No Don't know Yes No Don't know Yes Don't know		1 0 88 1 0 88
7.10.1.2 7.10.1.3 7.10.2	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry equipment? [OBSERVE] [ASK ONLY IF 7.10.2=YES, OBSERVED] Is the machine working?	Yes, not observed yes, not observed Yes, observed Yes, not observe	Yes Don't know Yes Yes No Don't know Yes Yes No Don't know Yes No Don't know Yes No Don't know		1 0 88 1 0 88 . 1 0 88 2 1 0 88 1 0 88 1
7.10.1.2 7.10.1.3 7.10.2	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry equipment? [OBSERVE] [ASK ONLY IF 7.10.2=YES, OBSERVED] Is the machine working?	Yes, not observed yes, not observed Yes, observed Yes, not observe	Yes Don't know Yes No Don't know Yes No Don't know Yes No Don't know Yes No Don't know		1 0 88 1 0 88 . 1 0 88 . 1 0 88 1 0 88 1 0 88
7.10.1.2	[ASK ONLY IF 7.10.1=YES, OBSERVED] Is the machine working? [ASK ONLY IF 7.10.1=YES (1 or 2)] How many ECGs are performed per week, on a [ENTER 1 - 50] Are there any clinical staff who can interpret EC Does this facility have audiometry equipment? [OBSERVE] [ASK ONLY IF 7.10.2=YES, OBSERVED] Is the machine working?	Yes, not observed yes, not obs	Yes Don't know Yes Yes No Don't know Yes Yes No Don't know Yes No Don't know Yes No Don't know		1 0 88 1 0 88 88 1 0 88 2 1 0 88 1 0 88

7. DR-TB	Treatment Services [ASK ONLY IF 2.4.3=1 or 3 (facility initiates	s DR-TB treatment)]	
7.10.2.3	[ASK ONLY IF 7.10.2=YES (1 or 2)] How many audiometry tests are performed per week, on average? [ENTER 1 - 30]	Number 88	
7.10.2.4	[ASK ONLY IF 7.10.2=YES (1 or 2)] Are there any clinical staff who can interpret audiometry findings?	Yes	
7.11	Pediatric DR-TB Treatment		
7.11.1	Did this facility provide DR-TB treatment for children under age 15 in the last 12 months?	Yes No Don't know	1 0 88
7.11.1.1	[ASK ONLY IF 7.11.1=YES] Does this facility have any pediatric formulations for second-line drugs available?	Yes No Don't know	1 0 88

9 Dodios	ric Services [ASK ONLY IF 2.2.1=YES OR 2.4.2=YES (1 or 2	or 2) /facility c	oos shildran	1	
8.1	[ASK ONLY IF 2.2.1=YES (diagnostic facility sees children)] What methods or processes have you used to diagnose children with presumptive TB in the last 12 months? [LET THE RESPONDENT PROVIDE THEIR ANSWERS UNPROMPTED BEFORE PROMPTING THEM FOR THE REST OF THE ANSWERS]	Yes, unprompted	Yes, prompted	No	DK
8.1.1	Use clinical algorithm to determine if a child has TB	2	1	0	88
8.1.2	By X-ray	2	1	0	88
8.1.3	Use sputum induction to get samples from children for testing	2	1	0	88
8.1.4	Use gastric aspiration to get samples from children for testing	2	1	0	88
8.1.5	Test samples from nasopharyngeal aspirates	2	1	0	88
8.1.6	Test sputum with smear microscopy	2	1	0	88
8.1.7	Test sputum with culture	2	1	0	88
8.1.8	Test sputum with GeneXpert	2	1	0	88
8.1.9	Other (specify)	2	1	0	88
8.2	Children at Risk for TB				
	From your experience, what are the risk factors that may lead a child to contract TB or that would cause you to suspect that a child may have TB? [LET THE RESPONDENT PROVIDE THEIR ANSWERS UNPROMPTED BEFORE PROMPTING THEM FOR THE REST OF THE ANSWERS]	Yes, unprompted	Yes, d prompted	No	DK
8.2.1	Child contact of confirmed TB patient	2	1	0	88
8.2.2	Child living in overcrowded home	2	1	0	88

			Yes,	Yes,	No	DK
			unprompted	prompted		
8.2.3	Malnourished child		2	1	0	88
8.2.4	Child living with HIV/AIDS		2	1	0	88
8.2.5	Child exposed to HIV/AIDS		2	1	0	88
8.2.6	Child with frequent Pneumonia		2	1	0	88
8.2.7	Other (specify)		2	1	0	88
8.3	Pediatric TB Treatment [ASK ONLY IF	2.4.2=YES (1, 2, c	or 3) (treatmer	nt facility se	es childre	n)]
	The next set of questions asks about r children with TB.	medications that a	are used to trea	Yes	No	DK
8.3.1	Does this facility use fixed-dose comb DS-TB?	1	0	88		
8.3.1.1	[ASK ONLY IF 8.3.1=YES]			1	0	88
	Are any of the FDCs available in dispe				· ·	00
8.3.2	Does this facility use loose or single-d	-	for children (fo	r 1	0	88
0001	treating TB disease, not TPT regimen)	<u> </u>				
8.3.2.1	[ASK ONLY IF 8.3.2=YES] Which loose drugs are used?			Yes	No	DK
8.3.2.1.1	Isoniazid 100 mg dispersible tablet			1	0	88
8.3.2.1.2	Ethambutol 100 mg film coated tablet	<u> </u>		1	0	
					-	88
8.3.2.1.3	Other (specify)			1	0	88
8.3.3	[ASK ONLY IF 8.3.2=YES] Does this facility use loose pills that could be cut up or mixed with food?				0	88
8.3.4	Does this facility use the same medica for children?	ations used for ad	ults but cut up	1	0	88
8.3.5	How is the dosage determined for	Fixed in the kit				1
	children?	Weight based				2
		Age based				3
	[SELECT ALL THAT APPLY]	Don't know				88
		Other (specify)				96

9. Healt	th Extension Workers (HEWs) [ASK ONLY IF 2.5 = 1 or 3 (facility works	with HEWs)]				
	In this section, we would like to learn about the links your facility h support to TB patients.	nas with HEWs	that provi	de		
9.1	Services Provided by HEWs					
	What types of services do the HEWs provide?	Yes	No	DK		
9.1.1	Education about TB in the community	1	0	88		
9.1.2	Screening for TB symptoms	1	0	88		
9.1.3	Referral of symptomatic cases for TB diagnosis	1	0	88		
9.1.4	Collection and delivering of specimens to a health center	1	0	88		
9.1.5	[ASK ONLY IF 6.1.5=YES (community-based DOT facility)]	1	0	00		
	Directly observed treatment (DOT)	1	0	88		
9.1.6	Adherence counselling	1	0	88		

9. Health	Extension Workers (HEWs) [ASK ONLY IF 2.5 = 1 or 3 (facility works	with H	EWs)]		
			Yes	No	DK
9.1.7	Trace or locate clients who miss follow-up visits		1	0	88
9.1.8	Contact tracing for confirmed TB patients		1	0	88
9.1.9	Slide fixing for referral		1	0	88
9.1.10	Psychosocial support		1	0	88
9.1.11	HIV testing and counselling		1	0	88
9.1.12	Other (specify)		1	0	88
9.2	Management of HEWs				
			Yes	No	DK
9.2.1	Have HEWs associated with this facility receive formal training in TE (onsite and/or offsite), such as screening, diagnosis, or treatment within the last 24 months?	3	1	0	88
9.2.2	[ASK ONLY IF 9.1.5=YES] Does the facility have an up-to-date list of HEWs who provide DOT?	?	1	0	88
9.2.3	Does the facility keep a record of the performance of the HEWs?		1	0	88
9.2.4	Does the facility TB focal person meet regularly (monthly or quarter with HEWs?	rly)	1	0	88
9.2.5	Do TB staff members from this facility do community level supervis of the HEWs?	ion	1	0	88
9.2.5.1	[ASK ONLY IF 9.2.5=YES] How many supervision visits to the community level were carried out by TB staff from this health facility in the last 3 months? [ENTER 0-20]	Visits Don't	L		88

10. Policio	es, Protocols, and Guidelines					
	Next, I'd like to assess the avail and required protocols, policie services available at the facility documentation, and if so, may	s, and messages on TB r. Do you have the following	Yes, observed	Yes, not observed	Don't have	DK
10.1	General					
10.1.1	Flowcharts or algorithms on TE	owcharts or algorithms on TB screening		1	0	88
10.1.2	National Guideline for TB, TB/F Ethiopia (6th edition)	HIV, DR TB, and Leprosy in	2	1	0	88
10.1.3	[ASK ONLY IF 6.1.4=YES or 6.1. community-based DOT facility A training manual for DOT prov)]	2	1	0	88
10.1.4	TB posters on walls, leaflets, but in local languages for distribution materials about TB		2	1	0	88
10.1.4.1	[IF 10.1.4=YES, OBSERVED, DETERMINE THE AMOUNT OF TB EDUCATIONAL MATERIALS AVAILABLE TO PATIENTS]	Sufficient educational materi (i.e., posters, brochures, or p Limited educational materials or few pamphlets, inadequat	atient pamp s available (i	ohlets) i.e., a single _l	ooster	1 0

The staff member who is best able to answer the questions in the following section is either a <u>lab</u> <u>technician</u> or the <u>TB focal person</u>.

10.2	Diagnostic Facilities [ASK ONLY IF 2.2= 1 (diagnosis facility]				
		Yes, observed	Yes, not observed	Don't have	DK
10.2.1	Flowcharts or algorithms on TB diagnosis	2	1	0	88
10.2.2	[ASK ONLY IF 3.1.2 (b) =YES (facility uses an onsite X-ray)] Guidelines on the use of chest X-ray for TB screening and diagnosis	2	1	0	88
10.2.3	[ASK ONLY IF 3.1.3 (b) =YES (facility does smear microscopy)] Smear microscopy manual or guidelines	2	1	0	88
10.2.4	[ASK ONLY IF 3.1.5 (b)=YES (facility has GeneXpert)] Algorithms for GeneXpert	2	1	0	88
10.3	Treatment Facilities [ASK ONLY IF 2.4=1 or 2 or 3]				
10.3.1	Essential drug or medicines list	2	1	0	88

11. Sta	ff Capacity to Deliver TB Services			
	Did any providers of TB services at this facility receive new or refresher training in the following topics in the last 24 months?	Yes	No	DK
11.1	Screening algorithm for TB	1	0	88
11.2	Screening or diagnosis of TB based on X-rays	1	0	88
11.3	Diagnosis of TB based on clinical symptoms or examination (for adults)	1	0	88
11.4	Diagnosis of TB based on sputum tests using smear microscopy	1	0	88
11.5	Diagnosis of TB based on sputum tests using culture	1	0	88
11.6	Diagnosis of TB using GeneXpert	1	0	88
11.7	Dispensing of drugs for TB treatment	1	0	88
11.8	Management of DS-TB treatment	1	0	88
11.9	Identification of presumptive DR-TB	1	0	88
11.10	Management of DR-TB treatment	1	0	88
11.11	Management of TB/HIV coinfection	1	0	88
11.12	TB infection control	1	0	88
11.13	TB kit reconstitution	1	0	88
11.14	Other training (Specify)	1	0	88

12. Supervision and Feedback Practices

Next, I would like to ask about supervision and feedback from upper levels regarding TB services.

12. Supe	ervision and Feedback Practices					
12.1	Supervisory visit from upper level office	Yes, observed in the facility supervision book	Yes, bu logged i facili supervisio	n the ty	No	DK
12.1	(a) Has a supervisor from Woreda Health office come here on a TB-related supervisory visit within the last 3 months?	2	1		0	88
	(b) Has a supervisor from Zonal/Sub-city Health office come here on a TB-related supervisory visit within the last 3 months?	2	1		0	88
	(c) Has a supervisor from Regional Health office come here on a TB-related supervisory visit within the last 6 months?	2	1		0	88
	(d) Has a supervisor from Federal Health office come here on a TB-related supervisory visit within the last 6 months?	2	1		0	88
12.1.1	[ASK ONLY IF 12.1.(a) =YES] (a) During the last 12 months, how many TB-relat visits has this facility received from Woreda Healt		Visits Don't know			88
	[ENTER 1-12] [ASK ONLY IF 12.1.(b)=YES]		Don t knov	V		88
	(b) During the last 12 months, how many TB-relat visits has this facility received from Zonal/Sub-Cit [ENTER 1-12]		Visits Don't know	v		88
	[ASK ONLY IF 12.1.(c)=YES]					
	(c) During the last 12 months, how many TB-relat visits has this facility received from Regional Heal		Visits			
	[ENTER 1-12]		Don't know	v		88
	[ASK ONLY IF 12.1.(d)=YES] (d) During the last 12 months, how many TB-relativisits has this facility received from Federal Health	•	Visits			
	[ENTER 1-12]		Don't know	v		88
	[ASK THE REST OF THE QUESTIONS IN THIS SECTI 12.1.1(a) -(d) =YES]	ON ONLY IF ANY	1			
12.2	The last time that a supervisor from outside the f do any of the following?	acility visited, dic	d he or she	Yes	No	DK
12.2.1	Assess the TB unit pharmacy (dispensing unit), e. a records, etc.	-		1	0	88
12.2.2	Assess the TB data, e.g., completeness, quality, as registers, treatment cards, quarterly or monthly r	eports, etc.	orting of	1	0	88
12.2.3	Discuss the performance of the facility, based on	TB service data		1	0	88
12.2.4	Complete the supervisory checklist	ione from the aire	icit	1	0	88
12.2.5	Provide a record of written comments or suggest [ASK ONLY IF 12.2.5=YES] The written comments or suggestions from super			1	0	88
	within the last 3–6 months are observed [OBSER\	-				

13. Ava	ailability of Basic Equipment (in TB cl	inic, OPD, o	r anywhere	in the fa	cility) [OB	SERVE]	
	[ASK TO OBSERVE IF THE FOLLOWING BASIC EQUIPMENT AND SUPPLIES USED IN THE PROVISION OF CLIENT SERVICES ARE AVAILABLE AND FUNCTIONAL IN THE FACILITY TODAY]	(a) Have ed	quipment? Yes, not	Don't	DK	(a)=0	ONLY IF DBSERVED unctioning	-
	Equipment	observed	observed	have	DK	Yes	No	DK
13.1	Adult weighing scale	2	1	0	88	1	0	88
13.2	Child weighing scale – 250-gram gradation	2	1	0	88	1	0	88
13.3	Infant weighing scale – 100-gram gradation	2	1	0	88	1	0	88
13.4	Measuring tape-height board or stadiometer	2	1	0	88	1	0	88
13.5	Thermometer	2	1	0	88	1	0	88
13.6	Stethoscope	2	1	0	88	1	0	88
13.7	Blood pressure apparatus (may be digital or manual sphygmomanometer with stethoscope)	2	1	0	88	1	0	88
13.8	Light source (examination light, torch light, etc.)	2	1	0	88	1	0	88
13.9	Intravenous infusion kits	2	1	0	88	1	0	88
13.10	Oxygen concentrators	2	1	0	88	1	0	88
13.11	Oxygen cylinders	2	1	0	88	1	0	88
13.12	Central oxygen supply	2	1	0	88	1	0	88
13.13	Flowmeter for oxygen therapy (with humidification)	2	1	0	88	1	0	88
13.14	Oxygen delivery apparatus (key connecting tubes and mask or nasal prongs)	2	1	0	88	1	0	88
13.15	Pulse oximeter	2	1	0	88	1	0	88

The staff member who is best able to answer the questions in the following section is either a <u>lab</u> <u>technician</u> or the <u>TB focal person</u>.

14.1	Diagnostic Tests and Equipment								
	[ASK TO OBSERVE IF THE FOLLOWING TB TESTS/EQUIPMENT/REAGENT ARE USED IN THIS FACILITLY AND				[ASK (
	ARE AVAILABLE AND FUNCTIONAL IN THE FACILITY		(a) Us		(b)	-	_		F (b)=YES]
	TODAY]			cility?	Obser	1	` '	unction	
		Υ	N	DK	Y	N	Υ	N	DK
	[ASK THE NEXT QUESTIONS ONLY I				y has Sn	near Mi	crosco	py)]	
14.1	Ziehl-Neelsen test for AFB	1	0	88					
4444	[ASK THE NEXT 3 QUESTIONS ONLY			_	1 4				
14.1.1	Carbol fuscin stain	1	0	88	1	0			
14.1.2	Sulphuric acid (20–25% concentration) or acid alcohol	1	0	88	1	0			
14.1.3	Methyl blue stain	1	0	88	1	0			
14.2	Fluorescence microscope (FM) LED	1	0	88	1	0	1	0	88
14.2.1	[ASK ONLY IF 14.2 (a)=YES] Auramine stain for fluorescence microscope	1	0	88	1	0			
	[ASK THE NEXT 3 QUESTIONS ONLY	/ IF 3	1 5 (h)=	VFS (facili	ity has G	SeneXne	rt)]		
14.3	GeneXpert module	3.	1.5 (5)-	l lacin	I				
0	[AT LEAST ONE SHOULD BE FUNCTIONAL]				1	0	1	0	88
14.3.1	At least 1 valid Xpert MTB/RIF cartridge, i.e., not expired				1	0	1	0	88
14.4	[ASK ONLY IF 3.2.1.3=YES OR 3.2.1.4=YES OR 3.2.2.2=YES OR								
	3.2.2.3=YES (facility uses solid or liquid culture)] TB culture or growth medium (e.g., MGIT 960)	1	0	88					
14.5	Biosafety hood or cabinet	1	0	88	1	0	1	0	88
		_					Yes	No	DN
14.5.1	[ASK ONLY IF 14.5 (b)=YES] Is the biosafety hood or cabinet cer	tified	?				1	0	88
14.6	Quality Control/Quality Assurance								
	I would like to ask you about qualit services provided in the laboratory				ssurance	proced	ures fo	or TB di	agnosis

14. TB Labo	oratory Procedures [ASK ONLY IF 2.2.2= 1 or	2.2.2= 3 (1	facility has an onsite lab)]	
14.6.1	[ASK ONLY IF 3.1.3 (b)=YES (facility does	None		0
	smear microscopy)]	Interna	I QC/QA only	1
	For smear microscopy tests, what type of		I QC/QA only	2
	quality control and quality assurance do		ternal and external QC/QA	3
	you use in this facility?		now	88
	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.	1=1, 2, 3]		
14.6.1.1	Do you maintain records of the results	Yes		1
	from the quality control procedures?	No		0
		Don't k	now	88
14.6.1.2	Do you have guidelines and procedures for	Yes		1
	quality control (either internal or external)	No		0
	for the specimens assessed in this facility?	Don't k	now	88
14.6.1.2.1	[ASK ONLY IF 14.6.1.2=YES]	Yes		1
	The quality control guidelines are	No		
	observed. [OBSERVE]	Don't k	now	88
14.6.2	[ASK ONLY IF 3.1.5 (b) =YES (facility has None		0	
	GeneXpert)]	Interna	I QC/QA only	1
	For Xpert tests, what type of quality	Externa	2	
	control and quality assurance do you use		ternal and external QC/QA	3
	in this facility?		now	88
	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.	.2=1, 2, 3]		
14.6.2.1	Do you maintain records of the results from		Yes	1
14.0.2.1	quality control procedures?		No	0
	quanty control processors.		Don't know	88
14.6.2.2	Do you have guidelines and procedures for	guality	Yes	1
	control (either internal or external) for the	900,	No	0
	specimens assessed in this facility?		Don't know	88
14.6.2.2.1	[ASK ONLY IF 14.6.2.2 =YES]		Yes	1
14.0.2.2.1	The quality control guidelines are observed		No	0
	[OBSERVE]		140	0
14.6.3	[ASK ONLY IF 3.1.4 (b) =YES (facility	None		0
	diagnose TB by culture) and 3.2.1.4 or	Internal	QC/QA only	1
	3.2.2.3=YES (uses liquid culture)]	External	QC/QA only	2
	For liquid media tests, what type of	Both inte	ernal and external QC/QA	3
	quality control and quality assurance do	Don't kn	ow	88
	you use in this facility?			
	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6	3=1, 2, 3]		
14.6.3.1	Do you maintain records of the results from	the	Yes	1
	quality control procedures?		No	0
			Don't know	88
14.6.3.2	Do you have guidelines and procedures for	quality	Yes	1
	control (either internal or external) for the		No	0
	specimens assessed in this facility?		Don't know	88
14.6.3.2.1	[ASK ONLY IF 14.6.3.2=YES]		Yes	1
	The quality control guidelines are observed		No	0
	[OBSERVE]			

14. TB Labo	oratory Procedures [ASK ONLY IF 2.2.2= 1 or 2	.2.2= 3 (fac	cility has an onsite lab)]						
14.6.4	[ASK ONLY IF 3.1.4 (b) =YES (facility	None	0						
	diagnose TB by culture and 3.2.1.3 or		QC/QA only 1						
	3.2.2.2 = 1 (YES, uses solid culture)]		QC/QA only						
	For solid media tests, what type of quality		•						
	control and quality assurance do you use		rnal and external QC/QA 3						
	in this facility?	Don't kno	88 88						
	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.4	=1, 2, 3]							
14.6.4.1	Do you maintain records of the results from		Yes 1						
	quality control procedures?		No 0						
44643			Don't know 88	<u> </u>					
14.6.4.2	Do you have guidelines and procedures for q	-	Yes 1						
	control (either internal or external) for the		No						
14.6.4.2.1	specimens assessed in this facility? [ASK ONLY IF 14.6.4.2=YES]	-	Don't know 88 Yes 1	<u> </u>					
14.0.4.2.1	The quality control guidelines are observed		Yes 1 No 0						
	[OBSERVE]		NO						
14.6.5	[ASK ONLY IF 3.2.1.2 = YES (facility uses LPA	None		0					
	for first-line drug susceptibility testing)]	I QC/QA only	1						
	For LPA tests, what type of quality control	· · · · · · · · · · · · · · · · · · ·							
	and quality assurance do you use in this	Both internal and external QC/QA							
	facility?		• •	3					
		Don't k	now	88					
	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.5	5=1, 2, 3]							
14.6.5.1	Do you maintain records of the results from	the quality	Yes	1					
	control procedures?	No	0						
			Don't know						
14.6.5.2	Do you have guidelines and procedures for q	Yes	1						
	control (either internal or external) for the sp	No	0						
	assessed in this facility?		Don't know	88					
14.6.5.2.1	[ASK ONLY IF 14.6.5.2=YES]	_	Yes	1					
	The quality control guidelines are observed [•	0					
14.6.6	[ASK ONLY IF 3.2.2.1 = YES (facility uses		00/04	0					
	LPA for second-line drug susceptibility		QC/QA only	1					
	testing)]		QC/QA only	2					
	For LPA tests, what type of quality control		ernal and external QC/QA	3 88					
	and quality assurance do you use in this	Don't know							
	facility?								
	facility? [ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.6]	 							
14 6 6 1	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.6		Yes	1					
14.6.6.1	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.6] Do you maintain records of the results from the second of the second			1 0					
14.6.6.1	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.6		No	0					
	[ASK THE NEXT 2 QUESTIONS ONLY IF 14.6.6] Do you maintain records of the results from the control procedures?	the quality	No Don't know	0 88					
14.6.6.1	Do you have guidelines and procedures for q	the quality	No Don't know Yes	0					
	Do you have guidelines and procedures for q control (either internal or external) for the sp	the quality	No Don't know Yes No	0 88 1 0					
	Do you have guidelines and procedures for q	the quality	No Don't know Yes	0 88 1					

The staff member who is best able to answer the questions in the following section is either a <u>lab</u> <u>technician</u>, a <u>nurse</u>, or a <u>sputum collector</u>.

15. Mana	agement of Specimens						
15.1	Specimen Collection						
	The next few questions are about specimen collection.						
15.1.1	[DON'T READ THE ANSWER UNTIL THE RESPONDENT HAS HAD A CHANCE TO ANSWER UNPROMPTED] Correct						
	When is sputum collected by patients or when do patients to collect sputum?	you ask th	ne	Incorr	ect	0	
	[Correct answer: Two consecutive sputum samples "on the spot" i.e., at the health facility rather than sending patients home with a specimen cup to collect early morning sputum]				know	88	
15.1.2	Are there Standard Operation Procedures (SOPs) for specimen collection? [OBSERVE]	Yes, observed				2 1 0 88	
15.1.3	Are there approved laboratory request forms? [OBSERVE]	Yes, not No	Yes, observed			2 1 0 88	
15.1.4	, ,	ere there any stockouts of specimen management Yes oplies (e.g., sealable, leakproof sputum containers) in No			know		
15.2	Onsite Laboratory [ASK ONLY IF 2.2.2= 1 or 2.2.2	=3 (facility	has an o	onsite la	ab)]		
	Now, I would like to ask you about the management laboratory.	ent of sput	um samp	oles and	I turnaround time for	the	
			Ye	:S	No	DK	
15.2.1	Do you maintain any sputum containers that are and leakproof at this service site for collecting spu		1		0	88	
15.2.1.1	[ASK ONLY IF 15.2.1=YES] Sputum container is observed [OBSERVE]		1		0		
15.2.3	[ASK ONLY IF 3.1.3 (b)=YES (facility does smear microscopy)] (a) On average, how many working days does it take to receive specimen results for smear microscopy from the laboratory at this facility? 1 day		s ays	1 2 3 4 88			
	(b) On average, how many working days does it take to receive specimen results for GeneXpert from the laboratory at this facility? 2 days			aysys	1 2 3 4 88		

ASK ONLY IF 3.1.4 (b) =YES (facility diagnose TB by culture)	15. Mana	gement of Specimens							
Facility (d) On average, how many working days does it take to receive specimen results for first-line LPAs from the laboratory at this facility?		(c) On average, how many working days does it take to receive specimen results for culture from the laboratory at this facility?				3–5 months >5 months			
Next, I would like to ask you about offsite laboratory procedures.		facility)] (d) On average, how many working of specimen results for first-line LPAs fr	many working days does it take to receive			3–5 months >5 months			
What testing services were offered by the offsite laboratory in the last 12 months?	15.3	Offsite Laboratory [ASK ONLY IF 2.2	.2= 2 or 2.2.2=3 (fac	ility uses of	fsite la	nb)]			
What testing services were offered by the offsite laboratory in the last 12 months?		Next. I would like to ask you about o	ffsite laboratory pro	cedures.					
1		What testing services were offered b			ıst	Yes	No	DK	
ASK THE FOLLOWING 4 QUESTIONS ONLY IF 2.4.3=1 or 3 {facility initiates DR-TB treatment}	15.3.1.1	Smear microscopy				1	0	88	
15.3.1.3 First-line drug susceptibility testing by first-line LPA (other than GeneXpert) 1	15.3.1.2	First-line drug susceptibility testing b	y GeneXpert			1	0	88	
Seminorm Seminorm		ASK THE FOLLOWING 4 QUESTIONS	ONLY IF 2.4.3=1 or	3 (facility in	itiates	DR-TB	treatment)]	ı	
15.3.1.5 Second-line drug susceptibility testing by second-line LPA	15.3.1.3					0	88		
15.3.1.6 Second-line drug susceptibility testing by culture 1 0 88	15.3.1.4	First-line drug susceptibility testing by culture				1	0	88	
15.3.2 Does this facility have the contact details of their offsite laboratory? Yes, not observed 1 1 No 0 Don't know 88 15.3.3 Does the facility maintain records of results of sputum tests conducted offsite? Yes, not observed 2 Yes, not observed 1 No 0 Don't know 88 15.3.4 Is there an up-to-date specimen dispatch list? Yes, observed 2 Yes, not observed 1 No 0 Don't know 88 15.3.4 Is there an up-to-date specimen dispatch list? Yes, observed 1 No 0 Don't know 88 15.3.5 Does the facility have access to a specimen transport service? No Don't know 88 15.3.5.1 [ASK ONLY IF 15.3.5=YES] Lab staff No Don't know 88 15.3.5.1 [ASK ONLY IF 15.3.5=YES] Courier service 2 Implementing partner 3 SELECT ALL THAT APPLY Cold-chain van 4 Woreda staff Don't know 88 Other (specify) 96 15.3.5.2 [ASK ONLY IF 15.3.5=YES] Only TB TB and others 2 TB and others 2	15.3.1.5	Second-line drug susceptibility testing by second-line LPA 1					0	88	
Offsite laboratory? [OBSERVE] Yes, not observed 1 15.3.3 Does the facility maintain records of results of sputum tests conducted offsite? [OBSERVE] Yes, observed 2 15.3.4 Is there an up-to-date specimen dispatch list? [OBSERVE] Yes, observed 2 15.3.4 Is there an up-to-date specimen dispatch list? [OBSERVE] Yes, observed 2 15.3.5.1 Does the facility have access to a specimen transport service? Yes, not observed 1 No Don't know 88 15.3.5.1 Does the facility have access to a specimen transport service? Yes 1 No Don't know 88 15.3.5.1 [ASK ONLY IF 15.3.5=YES] Lab staff 1 What type (s) of service is used? Courier service 2 Implementing partner 3 3 [SELECT ALL THAT APPLY] Cold-chain van 4 Woreda staff 5 5 Don't know 88 0 ther (specify) 96 15.3.5.2 [ASK ONLY IF 15.3.5=YES] Only TB 1 What type of specimens are picked TB and others 2	15.3.1.6	Second-line drug susceptibility testin	g by culture			1	0	88	
15.3.3 Does the facility maintain records of results of sputum tests conducted offsite? Yes, not observed 1 1 1 1 1 1 1 1 1	15.3.2	offsite laboratory?	tails of their	Yes, not ob	serve	d		1 0	
15.3.4 Is there an up-to-date specimen dispatch list? Yes, observed 2 Yes, not observed 1 No 0 Don't know 88 15.3.5 Does the facility have access to a specimen transport service? Yes 1 No 0 Don't know 88 15.3.5.1 [ASK ONLY IF 15.3.5=YES] Lab staff 1 What type (s) of service is used? Courier service 2 Implementing partner 3 [SELECT ALL THAT APPLY] Cold-chain van 4 Woreda staff 5 Don't know 88 Other (specify) 96 15.3.5.2 [ASK ONLY IF 15.3.5=YES] Only TB 1 What type of specimens are picked TB and others 2	15.3.3	Does the facility maintain records of results of sputum tests conducted offsite? [OBSERVE] Yes, observed				1 0			
15.3.5 Does the facility have access to a specimen transport service? Yes 1 15.3.5.1 [ASK ONLY IF 15.3.5=YES] Lab staff 1 What type (s) of service is used? Courier service 2 Implementing partner 3 [SELECT ALL THAT APPLY] Cold-chain van 4 Woreda staff 5 Don't know 88 Other (specify) 96 15.3.5.2 [ASK ONLY IF 15.3.5=YES] Only TB 1 What type of specimens are picked TB and others 2	15.3.4	Is there an up-to-date specimen dispatch list? [OBSERVE] Yes, observes, not on the control of			servedt observed				
15.3.5.1 [ASK ONLY IF 15.3.5=YES] Lab staff	15.3.5	Does the facility have access to a specimen transport service? Yes						1 0	
What type (s) of service is used? Courier service 2 Implementing partner 3 Cold-chain van 4 Woreda staff 5 Don't know 88 Other (specify) 96 15.3.5.2 [ASK ONLY IF 15.3.5=YES] Only TB 1 What type of specimens are picked TB and others 2	15.3.5.1	[ASK ONLY IF 15.3.5=YES]	Lab staff	1					
[SELECT ALL THAT APPLY] Cold-chain van		= =						_	
15.3.5.2 [ASK ONLY IF 15.3.5=YES] Only TB 1 What type of specimens are picked TB and others 2		[SELECT ALL THAT APPLY] Cold-chain van							
15.3.5.2 [ASK ONLY IF 15.3.5=YES] Only TB		Don't know						88	
What type of specimens are picked TB and others									
	15.3.5.2	_	-					_	
L MAC: L LAMIT KIRAW		up?						2 88	

15. Mana	gement of Specimens				
15.3.6	Does the specimen transport service use temperature control (e.g., cold chain van, cooler box, etc.)?	No	Yes No Don't know		
15.3.7.1	On average, how long does it take for a specimen to reach the offsite laboratory?	1 day			1 2 3 4 88
15.3.7.2	On average, how often does specimen transportation to the offsite laboratory occur?	Don't know			1 2 3 4 88
15.3.8.1	[ASK ONLY IF 15.3.1.1= 1 (Smear microscopy is offered It offsite laboratory)] On average, how many working days does it take to rece results for smear microscopy at the facility from the offsi laboratory?	IF 15.3.1.1= 1 (Smear microscopy is offered by the pratory)] e, how many working days does it take to receive the smear microscopy at the facility from the offsite 1 day			1 2 3 4 88
15.3.8.2	[ASK ONLY IF 15.3.1.2= 1 (GeneXpert is offered by the offsite laboratory)] On average, how many working days does it take to receive the results for GeneXpert at the facility from the offsite laboratory? Don't know				1 2 3 4 88
15.3.8.3	[ASK ONLY IF 15.3.1.4 = 1 or 15.3.1.6 = 1 (first-line or second-line DST by culture is offered by the offsite laboratory)] On average, how many working days does it take to receive the results for culture at the facility from the offsite 1–2 months				1 2 3 88
15.3.8.4	On average, how many working days does it take to receive the results for first-line LPA at the facility from the offsite		–3 days -7 days 7 days on't know	1 2 3 88	
15.3.8.5				1 2 3 88	
15.3.9.1 15.3.9.2 15.3.9.3	How are TB test results returned to this facility? Telephone communication Cold-chain van		Yes 1 1 1 1	No 0 0 0	DK 88 88
15.3.9.4 15.3.9.4 15.3.9.6	Courier service (postal service) Lab staff Woreda staff Other (specify) mombar who is best able to answer the questions in		1 1 1	0 0 0	88 88 88

The staff member who is best able to answer the questions in the following section is the $\underline{\sf TB}$ focal person.

15.4	Sputum Investigation – Treatment [ASK ONLY IF 2.4= 1 or 2 or 3 (DS-TB treatment facility)]				
	Now I would like to ask you about sputum investigations ordered during treatment.	Yes	No	DK	
15.4.1	[ASK ONLY IF 6.1.2=YES (facility provides intensive phase treatment)] Does this facility request sputum during the last week of the initial phase of treatment for drug-susceptible TB?	1	0	88	
15.4.2	[ASK ONLY IF 6.1.3=YES (facility provides continuation phase treatment)] Does this facility request sputum in the last month of the continuation phase of treatment for drug-susceptible TB?	1	0	88	
15.4.3	Does this facility request drug susceptibility testing for patients who were previously treated for TB by GeneXpert?	1	0	88	
15.4.4	Does this facility request drug susceptibility testing for patients who fail to convert on treatment by GeneXpert?	1	0	88	
15.4.5	Does this facility request any type of drug susceptibility testing for suspected DR-TB, including GeneXpert?	1	0	88	
15.4.6	[ASK ONLY IF 2.4.3=1 or 2 or 3 (facility provides DR-TB treatment)] Does this facility request monthly follow-up smears and cultures throughout treatment for DR-TB patients on the shorter regimen?	1	0	88	
15.4.7	[ASK ONLY IF 2.4.3=1 or 2 or 3 (facility provides DR-TB treatment)] Does this facility request monthly follow-up smears and cultures until conversion in the intensive phase for DR-TB for patients on the individualized longer regimen?	1	0	88	
15.4.8	[ASK ONLY IF 2.4.3=1 or 2 or 3 (facility provides DR-TB treatment)] Does this facility request at least quarterly smears and cultures until conversion in the continuation phase for DR-TB for patients on the longer regimen?	1	0	88	

The staff member who is best able to answer the questions in the following sections is a <u>pharmacy staff person</u> or the <u>TB focal person</u>.

16. Man	16. Management of Supplies and Commodities						
	[OBSERVE THE PLACE WHERE THE SUPPLIES AND COMMODITIES ARE STORED] Do the storage conditions for supplies and commodities comply with the following standards?	Yes	No	DK			
16.1	Room or store is clean and dust-free	1	0	88			
16.2	Supplies and commodities are stored to prevent water damage	1	0	88			
16.3	Room or store is adequately ventilated	1	0	88			
16.4	Room or store is properly lit	1	0	88			
16.5	Supplies and commodities are stored away from direct sunlight	1	0	88			
16.6	Supplies and commodities are stored without direct contact with walls or floors	1	0	88			
16.8	Usable supplies and commodities are separated from expired and damaged ones.	1	0	88			
16.8	Room or store has a functional thermometer	1	0	88			
16.8.1	[ASK ONLY IF 16.7 = YES] Room or store has proper temperature (30 degrees Celsius or less)	1	0	88			

17. Drug Stock [ASK ONLY IF 2.4 or 2.4.3 =1 or 2 or 3 (DS-TB or DR-TB Treatment Facility)]

[ASK TO GO TO THE MAIN SITE IN THE FACILTY WHERE ROUTINE MEDICINES ARE STORED. FIND THE PERSON MOST KNOWLEDGEABLE ABOUT STORAGE AND MANAGEMENT OF MEDICINES IN THE FACILITY. INTRODUCE YOURSELF, EXPLAIN THE PURPOSE OF THE SURVEY, AND ASK THE FOLLOWING QUESTIONS.]

I would like to know if the following medicines are available today in this facility. If any of the medicines I mention are stored in another location in the facility, please tell me where it is stored so I can go there to verify.

are store	ta in another location in the facility, picase ten int	. WHICH CHE IS SE	orca so rear	i go tilere te	verily.	
	Drugs and medicines available at the facility during the assessment according to NTP guidelines. [CHECK TO SEE IF AT LEAST ONE IS VALID, I.E., NOT EXPIRED/NOT DAMAGED]	Observed, at least one valid	Observed, none valid	No stock observed	Never stocked	DK
17.1.1	Rifampicin/Isoniazid/Pyrazinamide/Ethambutol, 150 /75/400/ 275, film coated tablet	3	2	1	0	88
17.1.2	Rifampicin/Isoniazid, 150/75, film-coated tablet	3	2	1	0	88
17.1.3	Ethambutol, 100 mg, film coated tablet	3	2	1	0	88
17.1.4	Rifampicin/Isoniazid, 75/50 mg, dispersible tablet	3	2	1	0	88
17.1.5	Rifampicin/Isoniazid/Pyrazinamide, 75/50/150 mg, dispersible tablet	3	2	1	0	88
17.1.6	Amoxicillin + Clavulanic acid, 500 mg + 125 mg, tablet	3	2	1	0	88
17.1.7	Ethambutol 400 mg tablet	3	2	1	0	88
17.1.8	Isoniazid 300 mg tablet	3	2	1	0	88
17.1.9	Pyridoxine 100 mg tablet	3	2	1	0	88
17.1.10	Pyridoxine 50 mg tablet	3	2	1	0	88
17.1.11	Pyridoxine 25 mg tablet	3	2	1	0	88
17.1.12	Isoniazid 100 mg dispersible tablet	3	2	1	0	88
17.1.13	Isoniazid 100 mg film uncoated tablet	3	2	1	0	88
	[ASK ONLY IF 2.4.3=1 or 2 or 3 (facility provides	DR-TB treatm	ent)]			
17.1.14	Amikacin 500 mg/2 ml solution for injection	3	2	1	0	88
17.1.15	Bedaquiline 100 mg tablet	3	2	1	0	88
17.1.16	Capreomycin 1000 mg powder for injection	3	2	1	0	88
17.1.17	Clofazimine 100 mg capsule	3	2	1	0	88
17.1.18	Cycloserine 250 mg capsule	3	2	1	0	88
17.1.19	Delamanid 50 mg tablet	3	2	1	0	88
17.1.20	Kanamycin 1000 mg/4 ml solution for injection	3	2	1	0	88
17.1.21	Levofloxacin 250 mg tablet	3	2	1	0	88
17.1.22	Linezolid 600 mg tablet	3	2	1	0	88
17.1.23	Moxifloxacin 400 mg tablet	3	2	1	0	88
17.1.24	Paraaminosalycilic acid 4 g sachet	3	2	1	0	88
17.1.25	Protionamide 250 mg tablet	3	2	1	0	88
17.1.26	Pyrazinamide 400 mg tablet	3	2	1	0	88
		·	· · · · · · · · · · · · · · · · · · ·		· ·	

17. Drug Stock [ASK ONLY IF 2.4 or 2.4.3 =1 or 2 or 3 (DS-TB or DR-TB Treatment Facility)]								
		Observed, at least one valid	Observed, none valid	No sto observ	_	Never tocked	DK	
17.1.27	Levofloxacin 100 mg dispersible tablet	3	2	1		0	88	
17.1.28	Cyclocerine 125 mg capsule	3	2	1		0	88	
17.1.29	Moxifloxacin 100 mg dispersible tablet	3	2	1		0	88	
	[ASK THE NEXT 2 QUESTIONS ONLY IF 2.4 or 2.4.3 =1 or 2 or 3 (DS-TB or DR-TB Treatment Facility)]					No	DK	
17.2	Does the facility maintain a minimum stock level of both first- and second-line anti-TB medication?					0	88	
17.3	Did any anti-TB medicine (first- or second-line) stockouts occur in the last six months?					0	88	
The staff member who is best able to answer the question is the <u>TB focal person</u> .								
17.3.1	[ASK ONLY IF 17.3=YES]							
	Did any patient go without TB treatment because of stockouts within the last six months?				1	0	88	

The staff member who is best able to answer the questions in the following section is either the <u>infection control focal person</u> or the <u>TB focal person</u>.

18. Infection Control						
	I'm going to ask about infection prevention measures and then I'd like to see the supplies used for infection control.	Yes	No	DK		
18.1	General					
18.1.1	Has a staff member been designated as an infection prevention and control focal point with a terms of reference and annual work plan?	1	0	88		
18.1.2	Are patients routinely asked about cough when entering the facility?	1	0	88		
18.1.3	Is cough triage implemented (i.e., patients that are coughing are separated from others and fast-tracked for evaluation)?	1	0	88		
18.1.4	Is there a separate waiting area in the facility to isolate potentially infectious individuals?	1	0	88		
18.1.5	Does a cough monitor or other designated person assist with separation and triage of coughing patients?	1	0	88		
18.1.6	Are surgical masks available for presumptive and confirmed DS-TB/DR-TB patients?	1	0	88		
18.1.7	Is a system in place to screen and evaluate staff for TB disease?	1	0	88		
18.1.7.1	[ASK ONLY IF 18.1.7=YES] Have any staff been diagnosed with active TB disease in the last fiscal year (Hamle 1, 2010 - Sene 30, 2011)?	1	0	88		

18. Infection	on Control						
18.1.7.1.1	[ASK ONLY IF 18.1.7.1=YES] How many full-time TB staff (clinical in the last fiscal year (Hamle 1, 201) [MUST BE 0-1.2.4 (number of full-total)	0-Sene 30, 2011)?	Staff Don't kn	ow .			88
18.1.7.1.2				Staff Don't know			
18.1.8	How many full-time staff (both clinical and non-clinical) working in this facility had active TB disease in the last fiscal year (Hamle 1, 2010-Sene 30, 2011)? How many part-time staff (both clinical and non-clinical) working in this facility had active TB disease in the last fiscal year (Hamle 1, 2010-Sene 30, 2011)? Staff Don't know					88	
	, , , , , , , , , , , , , , , , , , , ,	, .	1 2011 61111		Yes	No	DK
18.1.10	Are TB staff offered an HIV test ann	nually?			1	0	88
18.1.11	Are TB staff offered ART if HIV+?				1	0	88
18.1.12	Where do HIV+TB staff receive ART?	Within the facility Referred out Don't know Other (specify)					1 2 88 96
18.2	Resources in Service Areas [OBSER	VE]					
	[PLEASE CHECK IF THE FOLLOWING FOR INFECTION CONTROL ARE AVA FACILITY WHERE TB PATIENTS ARE ON THE DAY OF ASSESSMENT – AS	AILABLE IN THE RECEIVING SERVICES	Yes, observed		s, not served	Don't have	DK
18.2.1	An updated and approved infection control plan (2011 E.C)	prevention and	2		1	0	88
18.2.2	An updated annual TB infection pre risk assessment result (2011 E.C)	evention and control	2		1	0	88
18.2.3	Supplies for coughing patients (e.g. masks, etc.)	, tissues, surgical	2		1	0	88
18.2.4	A confidential log for all staff with p confirmed TB	oresumptive or	2		1	0	88
18.2.5	Patient waiting areas are either out access to continuous fresh air	doors or indoors with	2		1	0	88
The staff n	nember who is best able to answe	er the questions in the	following	secti	on is th	he lah	

The staff member who is best able to answer the questions in the following section is the <u>lab</u> <u>technician</u>.

18.3 Supplies in Examination Areas

	[PLEASE CHECK IF THE FOLLOWING ITEMS ARE AVAILABLE IN THE CLIENT EXAMINATION AREAS, E.G., TB TESTING AREA, SERVICE PROVISION, AND GENERAL LAB AREAS. FOR ITEMS THAT YOU DO NOT SEE, ASK TO HAVE THEM SHOWN TO YOU]	Yes, observed	Yes, not observed	Don't have	DK
18.3.1	Running water (piped, bucket with tap or pour pitcher)	2	1	0	88
18.3.2	Handwashing soap (may be liquid soap)	2	1	0	88
18.3.3	Alcohol-based hand rub	2	1	0	88
18.3.4	Medical waste receptacle (pedal bin) with lid and plastic bin liners	2	1	0	88
18.3.5	Other waste receptacle	2	1	0	88
18.3.6	Sharps container (i.e., safety box)	2	1	0	88
18.3.7	Disposable latex gloves	2	1	0	88
18.3.8	Disinfectant (e.g., chlorine, alcohol)	2	1	0	88
18.3.9	Single use standard disposable syringes with needles or auto-disable syringes with needles	2	1	0	88
18.3.10	Gowns	2	1	0	88
18.3.11	Eye protection/goggles or face protection	2	1	0	88
18.3.12	Injection safety precaution guidelines for standard precautions	2	1	0	88
18.3.13	Needles destroyer	2	1	0	88
18.3.14	Methylated spirit and glycerin 70:30	2	1	0	88

The staff member who is best able to answer the questions in the following section is the $\underline{\text{lab}}$ $\underline{\text{technician}}$ and $\underline{\text{sputum collector}}$.

18.4	Specimen Collection				
	Are specimens collected in any of the following designated areas?	Yes, observed	Yes, not observed	No	DK
18.4.1	Outside the screening and treatment area	2	1	0	88
18.4.2	Away from other patients	2	1	0	88
18.4.3	In a separate room	2	1	0	88
18.4.4	In a well-ventilated area, e.g., open air or with open windows	2	1	0	88

The staff member who is best able to answer the questions in the following section is the $\underline{\sf TB}$ focal $\underline{\sf person}$.

18.5	N-95 and FFP2 Respirators [ASK TO SEE THEM]				
		Yes, observe	Yes, not observed	No	DK
18.5.1	Are N-95 and/or FFP2 respirators readily available for staff?	2	1	0	88
			Yes	No	DK
18.5.1.1	[ASK ONLY IF 18.5.1=YES (1, 2)] Have staff been trained on the proper fit of the respirators?		1	0	88
18.5.1.2	[ASK ONLY IF 18.5.1=YES (1, 2)] Always		ways		1
			Sometimes		2
	and/or FFP2 respirators?	Nev	er		3

End o	End of Facility Visit							
		(a) Visit Result		(b) Visit End Time				
				[Use the 24-hour clock system, e.g., 14:30]				
003	Visit 1	Completed	1					
		Partially completed	2					
		Records unavailable	3					
		Facility refused	4	Hours Minutes				
		Postponed	5	Hours Williages				
		Other (specify)	96					
004	Visit 2	Completed	1					
	(if	Partially completed	2					
	needed)	Records unavailable	3					
		Facility refused	4	Hours Minutes				
		Postponed	5	nours Williates				
		Other (specify)	96					

Comi	Comments/Observations [RESEARCH ASSISTANT]						
099	Please provide detailed comments about any observations you may have from the facility audit that you think are important for the research team to know (further explanation of any of the answers you recorded, clarifications, etc.).						

ETHIOPIA QUALITY OF TB SERVICES ASSESSMENT: **PROVIDER INTERVIEW**

FILL IN THE NEXT THREE SECTIONS (START OF FACILITY VISIT, FACILITY IDENTIFICATION, AND FACILITY CHARACTERISTICS) BEFORE STARTING THE ACTUAL INTERVIEW WITH A RESPONDENT.

Start	of Facility Visit					
		(a) Visit Date dd/mm/yyyy	(b) Visit Start Time [Use the 24-hour clock system, e.g., 14:30]	(c) Interviewer ID	(d) Interviewer Name	
001	Visit 1	//	Hours Minutes			
002	Visit 2 (if needed)		Hours Minutes			
Facili	ty Identification	1				
			(a) Code	(b) Name		
010	Region					
011	Zone/Sub-city					
012	Woreda					
013	Kebele					
014	Facility					
015	GPS Location					
Facili	ty Characteristi	cs				
020	Does this facil	ity provide TB diagn	ostic services?			1 0
021	Does this facility provide TB treatment services?					1 0
022	[ASK ONLY IF of this facility a	-				1 0
023		ity provide any HIV- esting, care, or treat	related services, such as ment?			1 0
	l					

Partici	pant Consent								
030	Provider number								
Eligibil	Eligibility Screening Questions								
[Appro of TB-r questic couple	Instructions to the interviewer: [Approach one of the clinic staff, who is either health facility in-charges, TB focal person and/or staff in charge of TB-related services, introduce yourself (Hello. My name is) and ask him/her if s/he is willing to answer questions about their experience providing TB care at this facility. If they agree, tell them that you have a couple of preliminary questions. To ensure that the provider meets the criteria for the study, please obtain the following information.]								
031	Have you provided care to TB patients in the last 12 months?	Yes No	1 0						
032	[ASK ONLY IF 031=YES] Have you been working in TB care/services at this facility for more than 3 months?	Yes No [No response]	1 0 99						
them a	[If either of the screening questions is No or No response, the provider is NOT eligible for this study – thank them and find the next available staff member. If the provider is eligible for the study (i.e., both screening questions are YES), it is essential that you gain their informed consent before beginning the interview. Read the service provider consent form to the provider and record their response below.]								
033	[SELECT THE APPROPRIATE RESPONSE BASED ON THE INFORMED CONSENT]	Consented Declined	1 0						
Visit" s	y declined to give consent, (1) thank the provider, (2) record 'Provider refused section at the end of the survey, and (3) approach another provider. ented, continue with the interview.]	' in the "End of Facility	,						

1. E	ducation and Experience		
1.1	Sex	Male	1
	[OBSERVE AND SELECT THE APPROPRIATE RESPONSE.	Female	2
	ASK ONLY IF UNSURE.]	[No response]	99
1.2.	In what year were you born?		
	[YEAR MUST BE 1950-2000. IF UNKNOWN, SELECT 88,	Year	
	or IF NO RESPONSE, SELECT 99.]	Don't know	88
		[No response]	99
1.3	What is the highest level of education you reached?	10 Plus 3/ Diploma (Health Related)	1
		Bachelor's degree (Health Related)	2
		Master's degree (Health Related)	3
		Doctorate (Medical Doctorate)	4
		Doctorate (PHD)	5
		Other non-health diploma (specify)	95
		Other non-health degree (specify)	96
		[No response]	99

1. E	ducation and Experience		
1.4	How would you best describe your current occupational category at this facility? For example, are you a registered nurse or physician?	Druggist	1 2 3 4 5 6 7 8 9 96 99
1.5	[NOT APPLICABLE TO HEWs] Are you a manager or in-charge for any clinical services?	No	1 0 99
1.6	[NOT APPLICABLE TO HEWs] Are you the TB focal or designated or delegated TB focal at this facility?	TB focal person Designated Delegated person No [No response]	1 2 3 0 99
1.7	How many years and months have you been working in this facility? [YEARS MUST BE 0-30. MONTHS MUST BE 0-11.]	Years Months [No response]	99
1.8	Typically, how many hours a week do you usually work at this facility (including duty and weekends)? [MUST BE 1-60]	Hours per week	99
1.9	Approximately, how many clients do you personally see or care for in this facility in a typical week? [MUST BE 1-250]	Number of patients [No response]	999
1.10	How many years and months have you been providing TB related services at this facility? [MUST BE ≤ 1.7]	Years Months [No response]	99
1.11	How many hours a week do you provide TB related services? 1-100 [MUST BE ≤ 1.8]	Hours per week	99
1.12	Approximately, how many TB patients, or their contacts, do you personally see or care for in this facility in a typical week? 1-250 [MUST BE ≤ 1.9]	Number of patients [No response]	999

1. E	ducation and Experience		
1.13	Approximately, how much time do you spend with each new patient during their first visit (Initiation visit)? [MUST BE 1-360]	Minutes [No response]	99
1.14	Approximately, how much time do you spend with each patient during follow-up visit excluding DOT? [MUST BE 1-360]	Minutes [No response]	99

2.	Training				
	ill ask about training you received on specific TB-related services. u received any training, initial or refresher, on [service]?	Yes, within 24	Yes, over 24	No	[NR]
_	ining could be provided as a package/comprehensive or on the topic listed below]	months	months		
2.1	Training on TB/HIV Services				
2.1.1	HIV testing and counselling for TB patients	2	1	0	99
2.1.2	Referral for HIV testing and counselling for TB patients	2	1	0	99
2.1.3	TB preventive treatment - TPT/IPT (INH, 3RH, 3HP)	2	1	0	99
2.1.4	HIV care and treatment services to TB/HIV coinfected patients	2	1	0	99
	[ASK THE NEXT 5 QUESTIONS ONLY IF 2.1.4=YES (1, 2)]		•		
2.1.4.1	ART for TB/HIV coinfected patients	2	1	0	99
2.1.4.2	Identification of TB/HIV drug-drug interactions	2	1	0	99
	[THE NEXT 3 QUESTIONS ARE NOT APPLICABLE TO HEWS]				
2.1.4.3	Identification of immune reconstitution inflammatory syndrome (IRIS)	2	1	0	99
2.1.4.4	CPT prophylaxis for TB/HIV coinfected patients	2	1	0	99
2.1.4.5	Viral load testing for TB/HIV coinfected patients	2	1	0	99
2.2	Training on TB Diagnostic Services [THIS SECTION IS NOT APPLICABLE	LE TO HEWs]			
2.2.1	Diagnosis of TB by clinical symptoms and signs	2	1	0	99
2.2.2	Diagnosis of TB by sputum smear microscopy	2	1	0	99
2.2.3	Diagnosis of TB by X-ray	2	1	0	99
2.2.4	Diagnosis of TB by Xpert MTB/RIF (GeneXpert)	2	1	0	99
2.2.5	Diagnosis of drug-resistant TB	2	1	0	99
2.2.5.1	[ASK ONLY IF 2.2.5=YES (1, 2)] TB culture or growth medium (e.g., MGIT 960)	2	1	0	99
2.2.5.2	[ASK ONLY IF 2.2.5=YES (1, 2)] Line probe assays (LPA)	2	1	0	99
2.2.6	Referral for drug-resistant TB diagnosis	2	1	0	99
2.3	Training on TB Treatment Services				
	[THE NEXT 3 QUESTIONS ARE NOT APPLICABLE TO HEWs]				
2.3.1	Prescription of drugs for TB treatment	2	1	0	99
2.3.2	Treatment of drug-sensitive TB	2	1	0	99

2.	Training				
		Yes, within 24	Yes, over 24	No	[NR]
		months	months		
2.3.3	Treatment of drug-resistant TB	2	1	0	99
2.3.4	Referral for TB treatment	2	1	0	99
2.3.5	Directly observed treatment (DOT)	2	1	0	99
2.3.6	TB treatment follow-up services, e.g., phone calls or home visits to TB patients if they miss an appointment, SMS text reminders to support patients' adherence to medications and treatment, etc.	2	1	0	99
2.3.7	Identification of and referral for patients who fail treatment	2	1	0	99

3. TB 9	Services Provided					
	Now I will ask if you currently provide certain TB-related services. Have you provided [service] in the last 12 months at this facility?				[NR]	
3.1	TB Screening Services					
3.1.1	Screening of TB by clinical symptoms and	signs	1	0	99	
3.2	TB Diagnostic Services [ASK ONLY IF 020= [NOT APPLICABLE TO HEWS]	YES (diagnostic facility)]				
3.2.1	Diagnosis of TB by clinical symptoms and	signs	1	0	99	
3.2.2	Diagnosis of TB by X-ray		1	0	99	
3.2.3	Diagnosis of TB by smear microscopy		1	0	99	
3.2.4	Diagnosis of TB by Xpert MTB/RIF (GeneX	pert)	1	0	99	
3.2.5	What is the most common method you use for diagnosing TB in this facility?	Diagnosis of TB by clinical symptoms and signs Diagnosis of TB by conventional X-ray Diagnosis of TB by digital X-ray Diagnosis of TB by computer assisted digital X-ray (CAD4TB) Diagnosis of TB by smear microscopy Diagnosis of TB by Xpert MTB/RIF (GeneXpert) Other (specify)				
3.2.6	[NOT APPLICABLE TO HEWs] First-line drug susceptibility testing		1	0	99	
	[ASK THE NEXT 5 QUESTIONS ONLY IF 3.2 What methods do you use to detect resist	-	Yes	No	[NR]	
3.2.6.1	Xpert MTB/RIF (GeneXpert) to detect resis		1	0	99	
3.2.6.2	First-line line probe assays (e.g., MTBDRplus)		1	0	99	
3.2.6.3	Solid culture		1	0	99	
3.2.6.4	Liquid culture		1	0	99	
3.2.6.5	Any other method used to detect resistan	ce to first-line drugs? (specify)	1	0	99	

3. TB	Services Provided			
		Yes	No	[NR]
3.2.7	[ASK ONLY IF 3.2.6=NO or NR, 0 or 99]	1	0	99
	Referral for first-line drug susceptibility testing	1	U	33
3.2.8	Second-line drug susceptibility testing	1	0	99
	[ASK THE NEXT 4 QUESTIONS ONLY IF 3.2.8=YES]	Yes	No	[NR]
	What methods do you use to detect resistance to second-line drugs?	163	NO	ניאוין
3.2.8.1	Second line probe assays (e.g., MTBDRsI)	1	0	99
3.2.8.2	Solid culture	1	0	99
3.2.8.3	Liquid culture	1	0	99
3.2.8.4	Any other method used to detect resistance to second-line drugs? (specify)	1	0	99
3.2.9	[ASK ONLY IF 3.2.8=NO or NR or 0 or 99]		•	00
	Referral for second-line drug susceptibility testing	1	0	99
		1		
3.3	TB Treatment Services [ASK ONLY IF 021=YES (treatment facility)]			
2.2.4	[NOT APPLICABLE TO HEWs]	1	0	00
3.3.1	Prescription of drugs for TB treatment	1	0	99
3.3.2	TB treatment and follow-up including DOTs	1	0	99
	[ASK 3.3.2.1 TO 3.3.2.4 ONLY IF 3.3.2 IS YES]			
3.3.2.1	Treatment and follow-up of drug-sensitive TB	1	0	99
3.3.2.2	Referral for drug-sensitive TB treatment	1	0	99
	[THE NEXT 2 QUESTIONS ARE NOT APPLICABLE TO HEWS]	•		
3.3.2.3	Treatment and follow-up of drug-resistant TB	1	0	99
3.3.2.4	Referral for drug-resistant TB treatment	1	0	99
3.3.3	DOT	1	0	99
3.3.4	Reminder phone calls or SMS texts to support patients' adherence to treatment	1	0	99
3.3.5	Patient tracking of those who miss an appointment	1	0	99
	[ASK THE NEXT 2 QUESTIONS ONLY IF 3.3.5=YES]			
3.3.5.1	Follow-up phone calls or SMS texts to TB patients if they miss an appointment	1	0	99
3.3.5.2	Home visits to TB patients if they miss an appointment	1	0	99
3.4	TB/HIV Services [ASK ONLY IF 023=YES (facility provides TB/HIV services)]			
3.4.1	HIV testing and counselling for TB patients onsite	1	0	99
3.4.2	Referral for HIV testing and counselling for TB patients	1	0	99
3.4.3	[NOT APPLICABLE TO HEWs]	1	0	99
	TB preventive therapy (TPT/IPT)	1	U	צפ

3. TB	Services Provided			
	[ASK THE NEXT 3 QUESTIONS ONLY IF 3.4.3=YES] What type of TB preventive therapy (TPT) do you provide?	Yes	No	[NR]
3.4.3.1	INH (6, 9, 12 months or continuous)	1	0	99
3.4.3.2	3HP (Rifapentine and INH)	1	0	99
3.4.3.3	RH	1	0	99
3.4.4	[NOT APPLICABLE TO HEWs] Do you provide CPT, viral load testing or ART to TB/HIV coinfected patients?	1	0	99
	[ASK THE NEXT 3 QUESTIONS ONLY IF 3.4.4=YES]	1	0	99
3.4.4.1	CPT prophylaxis for TB/HIV coinfected patients	1	0	99
3.4.4.2	Viral load testing for TB/HIV coinfected patients	1	0	99
3.4.4.3	ART for TB/HIV coinfected patients	1	0	99
3.4.4.3. 1	[ASK ONLY IF 3.4.4.3=YES] Screening for symptoms of anti-TB and ARV drug-drug interactions	1	0	99

4. TB Cc	ntact Tracing					
4.1	Do you conduct contact tracing for TB patients diagnosed and/or	Yes	1			
	treated in this facility?	No	0			
		[No response]	99			
	[IF 4.1=YES, CONTINUE WITH THE REST OF THIS SECTION; OTHERWISE, SKIP TO THE NEXT SECTION					
	The next set of questions are about TB contact tracing. Take your time to provide as much detail as you can.	answer these question	ns and			
4.2	Which TB patients are prioritized for tracing their contacts?					
	[SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT PROMPT	Γ. INSTEAD, ASK				
	"ANYONE ELSE?"]					
	All TB patients should have their contacts traced		1			
	Bacteriologically-confirmed pulmonary TB patients (PBC)		2			
	Children under fifteen years who are diagnosed with TB		3			
	TB patients with drug resistant TB (DR-TB)		4			
	People living with HIV or other illnesses that compromise the immune sy	stem	5			
	Other (specify)		96			
	[None of the above/no response]		99			

4. TB C	ontact Tracing					
4.3	How do you identify contacts of TB patients? [SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT PROMPT. INSTEAD, ASK "ANY OTHER MEANS?"]					
	TB patients provide a list of their contacts			1		
	TB patients are asked to bring their contacts to the facility for evaluation			2		
	Through Health Extension Workers					
	Community linkage facilitators (e.g., Health development army)			3		
	We visit the households and communities where the patients live follow			4		
	patient			5		
	Other (specify)		•••••	96		
	[None of the above/no response]			99		
1.1				99		
4.4	Which contacts are included in contact investigation? [SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT PROMPT "ANYONE ELSE?"]	. INSTEAD, A	SK			
	Anyone in contact with the patient			1		
	Close friends who spent time with the index case			2		
	Contacts who have HIV			3		
	Symptomatic adult contacts			4		
	Household contacts (includes adults and children)					
	Only the children living in the household					
	All child contacts					
	Neighbors					
	Workplace or school contacts					
	Other (specify)			96		
	[None of the above/no response]			99		
		Yes	No	[NR]		
4.5	Do you provide HIV counselling and testing to contacts?	1	0	99		
	[ASK THE NEXT 5 QUESTIONS ONLY IF 4.5=YES] How do you manage any contacts who are tested for HIV and found to be HIV-positive?	Yes	No	[NR]		
4.5.1	Refer to HIV care and treatment center (onsite or offsite)	1	0	99		
4.5.2	Provide counselling onsite	1	0	99		
4.5.3	[NOT APPLICABLE TO HEWs]	1	0	99		
	Provide TB preventive treatment (TPT)		Ŭ			
4.5.4	Collect sputum samples	1	0	99		
4.5.5	Do you do anything else? (specify)	1	0	99		
4.6.1	[NOT APPLICABLE TO HEWs]					
	Do you provide TB preventive treatment for contacts of bacteriologically-diagnosed pulmonary TB patients (PPOS) on first-line treatment?	1	0	99		
	[ASK THE NEXT 4 QUESTIONS ONLY IF 4.6.1=YES]	Yes	No	[NR]		
	Which contacts receive TB preventive treatment? Anyone else?					
4.6.1.1	Children under 15 years old	1	0	99		

4. TB Co	ntact Tracing			
		Yes	No	[NR]
4.6.1.2	Pregnant women	1	0	99
4.6.1.3	People living with HIV/AIDS identified through contact investigation	1	0	99
4.6.1. 4	Other (specify)	1	0	99
4.6.2	[NOT APPLICABLE TO HEWS]			
	Do you provide TB preventive treatment for contacts of clinically-diagnosed pulmonary TB patients (PNEG) on first-line treatment?	1	0	99
	[ASK THE NEXT 4 QUESTIONS ONLY IF 4.6.2=YES]			
	Which contacts receive TB preventive treatment? Anyone else?	Yes	No	[NR]
4.6.2.1	•	1	0	00
4.6.2.1	Children under 15 years old	1	0	99
4.6.2.2	Pregnant women	1	0	99
4.6.2.3	People living with HIV/AIDS identified through contact investigation	1	0	99
4.6.2.4	Other (specify)	1	0	99
4.7	Do you collect and report routine data on contact investigation?	Yes No [No response]		1 0 99
	[IF 4.7=YES, CONTINUE WITH THE REST OF THIS SECTION; OTHERWISE,	SKIP TO THE I	NEXT SECT	ION]
4.7.1	Which forms or tools do you use to collect and report data on contact investigation? Note: please include any registers, books, or forms that you use that are supplied by implementing partners	Use	Not used	[NR]
4.7.1.1	TB contact screening and TPT/IPT treatment follow-up register	1	0	99
4.7.1.2	TB suspect referral form	1	0	99
4.7.1.3	TB register	1	0	99
4.7.1.4	Other (specify)	1	0	99
4.7.2	What type of information do you collect and report on contact investigation?	Yes	No	[NR]
4.7.2.1	Number of contacts of drug-susceptible TB	1	0	99
4.7.2.2	Number of contacts of drug-resistant TB	1	0	99
4.7.2.3	Number of children contacts with index of drug susceptible pulmonary TB case	1	0	99
4.7.2.4	Number of children contacts with index of pulmonary TB cases screened for TB	1	0	99
4.7.2.8	Number of children contacts with index of pulmonary TB cases screened negative results for TB	1	0	99
4.7.2.9	Other (specify)	1	0	99

5. P	5. Pediatric TB							
5.1	General Knowledge							
	Please respond to the following statements by saying if you agree or disagree with them.	Agree	Disagree	Not sure	[NR]			
5.1.1	A child with TB disease will always have a cough.	1	0	88	99			

5. Po	ediatric TB							
				Agre	ee	Disagree	Not sure	[NR]
1	Children with TB and HIV are at greater risk or of TB than children with TB but without HIV.	f complica	itions	1		0	88	99
	Most pediatric patients with TB disease will sl signs and symptoms of TB disease.	how the ty	/pical	1		0	88	99
1	Children younger than 2 years old are at greamost serious forms of TB, such as TB meninging. TB.			1		0	88	99
5.1.5	Children with latent TB infection are not cont no symptoms, and have normal exams and ch	-		1		0	88	99
1	Children are usually infected with TB by some household.	one in the	eir	1		0	88	99
	Children with TB disease indicate recent transcommunity or household.	smission ir	n the	1		0	88	99
1	Not all people with latent TB infection will dedisease, but young children and those with commune systems are at much greater risk.	-	ed	1		0	88	99
5.2	Recognizing TB in Children							
	Please respond to the following statements by saying if you are not likely, somewhat likely, or likely to suspect TB in a child with the following symptoms.	Very Unlikely	Unlik	ely I	Likely	Very likely	Don't know	[NR]
5.2.1	Fever and cough for 2 weeks and more	1	2		3	4	88	99
	Failure to thrive (such as low weight for age, low energy level, tired, etc.)	1	2		3	4	88	99
5.2.3	A sore throat and fever	1	2		3	4	88	99
	Pneumonia that is unresponsive to antibiotics	1	2		3	4	88	99
	Sudden onset of a fever and nasal congestion	1	2		3	4	88	99
5.2.6	A child with fever and cough whose family member has known TB	1	2		3	4	88	99
5.3	Diagnosis of TB in Children [NOT APPLICABLE	TO HEW	sl					
	Next, I would like to ask how you routinely evaluate a child for TB, either at your facility or by referring the child to another facility. Do you use [method]? Anything else?			⁄es	No	DK	[NR]	
	Clinical signs and symptoms (physical exam)				1	0	88	99
5.3.2	Chest X-ray				1	0	88	99
5.3.3	HIV test				1	0	88	99

5. Pediatric TB						
		Yes	No	DK	[NR]	
5.3.5	Sputum specimen for culture	1	0	88	99	
5.3.6	Sputum specimen for GeneXpert	1	0	88	99	
5.3.7	Gastric aspiration	1	0	88	99	
5.3.8	Other (specify)	1	0	88	99	
	[SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT ELSE?"] None				1	
	Those under the age of 1				2	
	Those over the age of 1				3	
	Those with risk factors for HIV, such as a mother with HIV/AIDS				4	
	Those with signs and symptoms of HIV/AIDS, such as opportunistic infections					
	Other (specify)					
	[ino response]				99	

	Now, I want to ask you a few more questions about the management and care of TB patients as p your work in this facility.	art
L	Establishing Rapport and Building Trust	
	The interpersonal relationship between provider and patient is very important for successful treatment outcome, especially since TB requires taking medications for many months. What are some things you do to establish rapport and build trust with your patients?	
	[SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT PROMPT. INSTEAD ASK "ANYTHING ELSE"]	
	Be consistent in what is done and told to the patient	
	Be flexible in meeting the patient's needs	
	Communicate clearly	
	Have an open mind about the patient's cultural beliefs	
	Listen carefully to the patient	
	Recognize and address the patient's fears about the illness	
	Respectfully suggest to change behaviors that increase the risk of spreading TB infection to	
	others or puts the patients at greater risk of adverse effects due to TB	
	Treat the patient with dignity and respect	
	Provide counselling to the patient to show that you care about them	
	Contact them when they miss treatment to show that you are looking out for them	:
	Conduct home visits (going to clients' houses, learn more about their daily life, etc.)	
	Provide encouragement and interact with patient in a friendly manner	
	Other (specify)	9
	None of the above	9

6. TB	6. TB Case Management					
6.2	Patient Assessment [ASK ONLY IF 020=Y	ES]				
	As part of the initial patient assessment t ask the patient to tell or explain to you?	o determine their unders	standing of	TB, what d	lo you	
	[SELECT ALL THAT THE RESPONDENT ME	NTIONS, BUT DO NOT PI	ROMPT]			
	Patient's previous medical/psychosocial	history				1
	Attitudes/beliefs towards TB					2
	Knowledge of TB					3
	Ability to follow the TB treatment plan					4
	Potential barriers to treatment, e.g., lack of transportation, TB medications will be too					
		expensive, etc.				
	Resources, e.g., family, other social supp					6
	Personal information (professional activity, living situation, contact information, etc.)					
	Personal information (professional activity, living situation, contact information, etc.) Other (specify)					
						99
	Note of the above					
6.3	Counselling To ensure your patients have a good under					
	type of information, please tell me if it is given verbally and/or in writing. [SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT PROMPT. FOR THE TOPIC ASK IF THE INFORMATION IS PROVIDED VERBALLY AND/OR IN WRITING.]					
	[SELECT ALL THAT THE RESPONDENT ME	NTIONS, BUT DO NOT PR	vriting.	d treatmen		
	[SELECT ALL THAT THE RESPONDENT ME	NTIONS, BUT DO NOT PR	vriting. OMPT. FO RITING.]		ICS MENT	ΓIONED,
	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED V Topics	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of	vriting. OMPT. FO RITING.]	R THE TOP	ICS MENT	ΓIONED,
	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TOpics Topics General TB Information	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted	(b) How	R THE TOP LY IF (a)=YE v is informa Written	S] tion prov	rided?
6.3.1	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED V Topics General TB Information Test results/ What the test results mean	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted	(b) How	R THE TOP LY IF (a)=YE v is informa Written	S] tion prov Both	rided? [NR]
6.3.2	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO Topics Topics General TB Information Test results/ What the test results mean What TB is	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted	(b) How	R THE TOP LY IF (a)=YE v is informa Written	S] tion prov	rided?
	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED V Topics General TB Information Test results/ What the test results mean	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted	(b) How	R THE TOP LY IF (a)=YE v is informa Written	S] tion prov Both	rided? [NR]
6.3.2	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO TOPICS General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted	(b) How Verbally	R THE TOP LY IF (a)=YE v is informa Written 2 2	S] tion prov	rided? [NR]
6.3.2 6.3.3	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED OF TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1	(b) How Verbally	R THE TOP LY IF (a)=YE v is informa Written 2 2 2	S] tion prov	rided? [NR] 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1	(b) How Verbally	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2 2	S] tion prov	rided? [NR] 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1	vriting. OMPT. FO RITING.] [ASK ONI (b) How Verbally 1 1 1	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2	Both 3 3 3	rided? [NR] 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1 1 1	vriting. OMPT. FO RITING.] [ASK ONI (b) How Verbally 1 1 1	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2 2 2	Both 3 3 3	rided? [NR] 99 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6 6.3.7	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including the treatment phase the patient is in	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1	vriting. OMPT. FO RITING.] [ASK ONI (b) How Verbally 1 1 1 1 1	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2 2	Both 3 3 3 3	FIONED, rided? [NR] 99 99 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED OF TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including the treatment phase the patient is in Importance of taking medications	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1 1 1	vriting. OMPT. FO RITING.] [ASK ONI (b) How Verbally 1 1 1 1 1	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2 2 2	Both 3 3 3 3	FIONED, rided? [NR] 99 99 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6 6.3.7	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED OF TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including the treatment phase the patient is in Importance of taking medications regularly	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Verbally 1 1 1 1 1 1 1 1	R THE TOP LY IF (a)=YE v is informate Written 2 2 2 2 2 2 2 2 2	Both 3 3 3 3 3 3	FIONED, rided? [NR] 99 99 99 99 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6 6.3.7	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including the treatment phase the patient is in Importance of taking medications regularly How the medications should be taken,	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Verbally 1 1 1 1 1 1 1 1 1	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2 2 2 2	Both 3 3 3 3 3	FIONED, rided? [NR] 99 99 99 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6 6.3.7	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED OF TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including the treatment phase the patient is in Importance of taking medications regularly	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	vriting. COMPT. FO RITING.] [ASK ONI (b) How Verbally 1 1 1 1 1 1 1	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2 2 2 2 2 2	Both 3 3 3 3 3 3	FIONED, rided? [NR] 99 99 99 99 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6 6.3.7 6.3.8 6.3.9	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED TO TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including the treatment phase the patient is in Importance of taking medications regularly How the medications should be taken, e.g. dosage, frequency, etc.	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Verbally 1 1 1 1 1 1 1 1	R THE TOP LY IF (a)=YE v is informate Written 2 2 2 2 2 2 2 2 2	Both 3 3 3 3 3 3	FIONED, rided? [NR] 99 99 99 99 99 99 99
6.3.2 6.3.3 6.3.4 6.3.5 6.3.6 6.3.7 6.3.8 6.3.9	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED OF TOPICS Topics General TB Information Test results/ What the test results mean What TB is How TB is spread (transmission) to others That TB can be cured TB Treatment Information The need for a treatment supporter How long treatment will last Treatment status or progress including the treatment phase the patient is in Importance of taking medications regularly How the medications should be taken, e.g. dosage, frequency, etc. Importance of taking medications for	NTIONS, BUT DO NOT PR VERBALLY AND/OR IN W (a) Do you provide the following pieces of information? Yes, unprompted 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	vriting. COMPT. FO RITING.] [ASK ONI (b) How Verbally 1 1 1 1 1 1 1	R THE TOP LY IF (a)=YE v is informa Written 2 2 2 2 2 2 2 2 2	Both 3 3 3 3 3 3	FIONED, rided? [NR] 99 99 99 99 99 99 99

6. TB (Case Management						
	Topics	(c) Do you provide the following pieces of information?	[ASK ONLY IF (a)=YES] (d) How is information provided		rided?		
		Yes, unprompted	Verbally	Written	Both	[NR]	
6.3.112	What to do if they run out of their medications	1	1	2	3	99	
6.3.13	Possible side effects of TB medication	1	1	2	3	99	
6.3.14	What to do if they experience side effects from the TB medication	1	1	2	3	99	
6.3.15	Nutrition	1	1	2	3	99	
6.3.16	Good practices (no smoking or drinking alcohol, good hygiene, infection control and prevention, such as staying outside or opening windows inside, etc.)	1	1	2	3	99	
6.3.17	What to do when a patient misses their treatment	1	1	2	3	99	
6.3.18	Other (specify)	1	1	2	3	99	
6.3.19	None of the above	1					
6.4	TB/HIV Information						
	What type of information do you discuss	with patients concerning	TB/HIV? Fo	r each typ	e of infor	mation.	
	please tell me if it is given verbally and/or		,			,	
	[SELECT ALL THAT THE RESPONDENT ME ASK IF THE INFORMATION IS PROVIDED			R THE TOPI	CS MEN	ΓIONED,	
		(a) Provide	(a) Provide [ASK ONLY IF (a)=YES]				
		information?	(b) How	is informat	ion provi	ded?	
	Topics	Yes, unprompted	Verbally	Written	Both	[NR]	
6.4.1	General information about TB/HIV coinfection	1	1	2	3	99	
6.4.2	HIV transmission/prevention	1	1	2	3	99	
6.4.3	Advise TB patients to get tested for HIV	1	1	2	3	99	
6.4.4	HIV care and treatment services to TB/HI' coinfected patients	V 1	1	2	3	99	
6.4.5	TB/HIV drug-drug interactions	1	1	2	3	99	
6.4.6	What to do if they experience TB/HIV dru drug interactions		1	2	3	99	
6.4.7	Signs and symptoms of immune	1	1	2	3	99	
6.4.8	reconstitution inflammatory syndrome (II What to do if signs and symptoms of immune reconstitution inflammatory syndrome (IRIS) become evident	1	1	2	3	99	
6.4.9	Treatment adherence for TB and for HIV	1	1	2	3	99	
6.4.10	TB is curable while HIV is not, and treatm should be continued	ent 1	1	2	3	99	
6.4.11		<u> </u>	l .	 			
0.4.11	Other (specify)	1	1	2	3	99	
6.4.12	Other (specify) None of the above	99	1	2	3	99	

6. TB Case Management				
6.5	[ASK ONLY IF 021=YES (treatment facility)]			
	What do you do when a patient misses their treatment (either by yourself or through HEWs or community volunteers)?			
	[SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT PROMPT. INSTEAD ASK "ANYTHING ELSE?"]			
	Advise them to return for treatment	1		
	Counsel on adherence and continue treatment from where they stopped	2		
	Counsel and repeat lab investigation	3		
	Follow-up and track by contacting their school or workplace	4		
	Follow-up and track by home visit	5		
	Follow-up and track by phone	6		
	Follow-up and track by SMS	7		
	Record missed day and extend treatment	8		
	Other (specify)	96		
	None of the above	99		

7. Infection Prevention and Control					
	Now I would like to ask you some questions about your knowledge and practices to prevent transmission of TB among health care workers and patients within the facility.				
7.1	Training				
7.1.1	Have you ever received any training on TB infection control?	Yes No [No response]			1 0 99
7.1.1.1	[ASK ONLY IF 7.1.1=YES] Within the last 24 months				1 2 99
7.2	Knowledge				
	What would you do to prevent transmission care workers and patients within the facility	-	Yes	No	[NR]
7.2.1	Should doors and windows be left open who presumed or confirmed to have TB is in the	enever a patient	1	0	99
7.2.2	Can fans (ventilators) be used in TB wards to transmission of TB?	o reduce the	1	0	99
7.2.3	Should presumed or confirmed TB patients be separated from other patients?				99
7.2.4	Should health care providers minimize the time TB patients spend in the health facility?				99
7.2.5	Can surgical masks protect health care providers from inhaling the TB bacteria?			99	
7.2.6	Can the use of respiratory protection, such a respirators, by health care providers protect the TB bacteria?	•	1	0	99

7.3	Practices			
	What do you do whenever you are with presumed or confirmed TB patients and/or working in the TB wards to prevent transmission of TB?	Yes	No	[NR]
7.3.1	Do you use a mask/respirator whenever treating TB presumptive or confirmed patients	1	0	99
7.3.2	Do you give priority to coughing patients, i.e., attend to patients who are coughing first	1	0	99
7.3.3	Do you educate TB patients on cough etiquette, i.e., covering their mouth with hand, tissue, or elbow while coughing or sneezing, not spitting on the floor, etc.	1	0	99
7.3.4	Do you keep all windows open?	1	0	99
7.3.5	Are you aware of the sitting arrangement with the patient, i.e., patient not coughing in front of the health worker with the wind blowing towards the health worker?	1	0	99
7.3.6	Do you turn on fans to exhaust air outside the room, or blow air in the direction away from others while treating TB presumptive or confirmed cases		0	99
7.3.7	Do you request for TB diagnostic testing if the patient is symptomatic	1	0	99
7.3.8	Do you always screen all family members of confirmed TB patients for TB symptoms	1	0	99
7.3.9	DO you discuss with family members or those living with your TB patients, basic information and skills to protect household members and contacts from infection	1	0	99
7.3.10	Other (specify)	1	0	99

8. TE	Stigma						
	I am going to read to you some statements and I would like you to tell me to what extent you agree or disagree, ranging from 1-strongly disagree to 4-strongly agree. You can provide your answer as a number between 1 and 4. When I ask you these questions, I want you to think about the colleagues that you work with at this facility. [SD=STRONGLY DISAGREE; D=DISAGREE; A=AGREE; SA=STRONGLY AGREE]	SD	D	Neither agree nor disagree	А	SA	[NR]
8.1	Attitudes toward healthcare workers						
8.1.1	Some health workers in this facility who are suspected of having TB are stigmatized.	1	2	3	4	5	99
8.1.2	Some health workers in this facility avoid contact with coworkers whom they think may have TB.	1	2	3	4	5	99

8. TB	Stigma						
		SD	D	Neither agree nor disagree	Α	SA	[NR]
8.1.3	Some health workers in this facility would not want to eat or drink with a coworker whom they think has TB.	1	2	3	4	5	99
8.1.4	Some health workers in this facility are stigmatized when others find out that they have gone for TB screening.	1	2	3	4	5	99
8.1.5	Some health workers in this facility feel uncomfortable working near coworkers who have TB.	1	2	3	4	5	99
8.2	Attitudes toward TB patients						
8.2.1	Some health workers stay away from TB patients.	1	2	3	4	5	99
8.2.2	Some health workers feel getting TB is a person's own fault.	1	2	3	4	5	99
8.2.3	Some health workers feel angry towards TB patients.	1	2	3	4	5	99
8.2.4	Some health workers think it would be good for TB patients to be isolated during the intensive phase of treatment.	1	2	3	4	5	99

9. Sup	portive Supervision [ASK ONLY IF 1.4 = 2 (HEW)]				
Now I would like to ask you some questions about supervision that you have personally receive					
9.1	Has anyone from this health facility ever come for a	Yes	1		
	supervisory and monitoring visit to check your work on	No	0		
	TB with in the last 3 months?	[No response]	99		
9.1.1	[ASK ONLY IF 9.1=YES]	Within the last week	1		
		Within the last month	2		
	When was the last time someone from this health came	More than a month ago	3		
	here on a TB supervisory visit?	[No response]	99		
9.1.1.1	[ASK ONLY IF 9.1=YES]				
	During the last 12 months, how many times have you been supervised or monitored on TB by someone from	Number of visits			
	this health center? [ENTER 1-20]	[No response]	99		
9.2	Has anyone from Woreda office ever come for a	Yes	1		
	supervisory and monitoring visit to check your work on	No	0		
	TB with in the last 3 months?	[No response]	99		
9.2.1	[ASK ONLY IF 9.2=YES]	Within the last week	1		
	When was the last time someone from Woreda office	Within the last month	2		
	came here on a TB supervisory visit?	More than a month ago	3		
		[No response]	99		

9. Supp	9. Supportive Supervision [ASK ONLY IF 1.4 = 2 (HEW)]					
9.2.1.1	[ASK ONLY IF 9.2=YES]					
	During the last 12 months, how many times have you	Number of visits				
	been supervised or monitored on TB by someone from					
	Woreda office?	[No response]	99			
	[ENTER 1-20]					
9.3	The last time you were personally supervised on TB, what did your supervisor do during the					
	visit?					
	[SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO	O NOT PROMPT]				
	Assess the pharmacy, e.g., drug stockout, expiry, records,	etc	1			
	Assess patient and logistics data, e.g., completeness, qua	lity, and/or timely reporting	2			
	Discuss the performance of the facility based on the TB ser	vice data	3			
	Complete a supervisory checklist		4			
	Other (specify)		96			
9.4	The last time you were personally supervised, did your	Yes,	1			
	supervisor give you a record of written comments or	No	0			
	suggestions?	[No response]	99			
	[ASK TO SEE IT]					

entives and Improvements			
In addition to your official remuneration (salary) what	None		
the work you do related to TR within the last 12	Time off/vacation	1	
	Uniforms, vests, caps, etc	2	
	Discount medicine, free medical care	3	
THAT APPLY]	Training	4	
	Food assistance (E.g. Milk)	5	
	Top ups/Allowances	6	
	Other (specify)	96	
	[No response]	99	
•		done	
1)			
2)			
3)			
	other benefits and incentives have you received for the work you do related to TB within the last 12 months? [READ THE OPTIONS BELOW "NONE" AND SELECT ALL THAT APPLY] As a TB service provider or health worker, what are the to improve your ability to provide high quality TB care to 1) 2)	In addition to your official remuneration (salary) what other benefits and incentives have you received for the work you do related to TB within the last 12 months? [READ THE OPTIONS BELOW "NONE" AND SELECT ALL THAT APPLY] That apply As a TB service provider or health worker, what are the three most important things that could be to improve your ability to provide high quality TB care to your patients? None	

End o	End of Facility Visit						
		(a) Visit Result		(b) Visit End Time [Use the 24-hour clock system, e.g. 14:30]			
003	Visit 1	Completed	1 2 3 4 5 96	Hours Minutes			
004	Visit 2 (if needed)	Completed Partially completed Provider unavailable Provider refused Other (specify)	1 2 3 4 96	Hours Minutes			

THANK YOUR RESPONDENT AND MOVE TO THE NEXT DATA COLLECTION POINT IF DIFFERENT FROM CURRENT LOCATION. BE SURE TO COMPLETE THE LAST ITEM IN THE QUESTIONNAIRE (BELOW).

Comr	ments/Observations
099	[RESEARCH ASSISTANT: Please provide detailed comments or observations you may have about this interview (issues with questions, challenges in determining which response to select, etc.)]

ETHIOPIA QUALITY OF TB SERVICES ASSESSMENT: PATIENT INTERVIEW

Start	Start of Facility Visit						
		(a) Visit Date dd/mm/yyyy	(b) Visit Start Time [Use the 24-hour clock system, e.g., 14:30]	(c) Interviewer ID	(d) Interviewer Name		
001	Visit 1		Hours Minutes				
002	Visit 2 (if needed)	//	Hours Minutes				

Facility	Facility Identification				
		(a) Code	(b) Name		
010	Region				
011	Zone				
012	Woreda/District				
013	Kebele				
014	Facility				
015	GPS Location				

[MAKE SURE YOU HAVE AN INKPAD OR INK PEN AVAILABLE BEFORE STARTING THE CONSENT-OBTAINING PROCESS.]

Partio	cipant Consent		
020	Patient number		
Eligib	ility Screening Questions		
Instru	uctions to the interviewer:		
-	n a patient has finished his/her consultation with the		
-	and ask him/her if s/he is willing to answer questions		is
	ty. Tell the respondent that the information given by h	-	
patie	mation will be used for the survey purpose only in a m nt.1	lanner that no one would be able to identify an	ıy
021	[If they declined to give consent, (1) thank the	Consented	1
	patient, (2) fill in the patient refusal form, (3)	Declined	0
	record 'Patient refused' in the "End of Facility Visit"		
	section at the end of the survey, and (4) wait for		
	another patient.		
fif al-	If consented, continue with the interview.]		
-	ey agree, tell them that you have a few preliminary qu ia for the study, please obtain the following informati	·	
022	[Are they at least 15 years old? Ask if you're not	Yes	
	sure.]	No	
023	[ASK ONLY IF 022=YES]	No, they do not have TB	
0_0	Have you been diagnosed with TB or are you being	Yes, drug susceptible TB	
	treated for TB at this facility? If so, what type of TB	Yes, drug resistant TB	
	do you have, i.e., drug susceptible or drug resistant	Yes, extra-pulmonary TB	1 3
	(DS-TB, DR-TB, MDR-TB, etc.)?]	Yes, unknown TB type	
		Don't know if they have TB	88
		[No response]	99
	[ASK 024 and 025 ONLY IF 023=YES (1-3)]	[No response]	
024	[If 023=1 (drug susceptible)] Have you been	T.,	1
024	receiving TB treatment at this facility for at least 2	No	
	weeks?	[No response]	99
025	[If 023=2 or 3 (drug resistant/unknown)] Have you	[No response]	1
025	been receiving TB treatment at this facility for at	Yes	
	least 4 weeks?	No	99
		[No response]	
-	y of the screening questions are No, Don't know, or No		
study	thank them and wait for the next available patient.		
If the	patient is eligible for the study (i.e., all questions are	YES), it is essential that you gain their informed	d
conse	ent before beginning the interview. Read the patient conse below.]		
026	[SELECT THE APPROPRIATE RESPONSE BASED ON	Consented	1
	THE INFORMED CONSENT]	Declined	(

1. Pati	ent Characteristics				
1.1	Sex		Male	1	
	[OBSERVE AND SELI	ECT THE APPROPRIATE	Female	2	
	RESPONSE. ASK ON		[No response]	99	
1.2.1			[No response]	- 33	
1.2.1	In what year were y		V		
	[YEAR MUST BE 192	22-1998]	Year		
			Don't know	88	
			[No response]	99	
1.2.2	How old were you o	n your last birthday?			
	[YEARS MUST BE 15	-90. COMPARE AND	Years		
	CORRECT 1.2.1 AND	1.2.2 IF THEY ARE	Don't know	98	
	INCONSISTENT BY N	MORE THAN 3 YEARS]	[No response]	99	
1.3	What is the	No formal education		0	
highest level of First Cycle Primary (Grade 1-4)				1	
	education you		ade 5-8)	2	
	have completed?	-	ew curriculum 9-12 old curriculum)	3	
	'		2 new)	4	
				5	
		Diploma or 10+3		6	
		1 st degree		7	
		2 nd degree and above		8	
1.4	What is your marita	I status now?	Never married	1	
			Currently living with a partner (unmarried)	2	
			Married	3	
			Separated	4	
			Divorced	5	
			Widowed	6	
1 [Da varelina in an ent		[No response]	99	
1.5	Do you live in an urb	oan or rural area?	Urban	1	
			Rural	2	
			[No response]	99	
1.6	What is your employ	yment status?	Employed full-time	1	
			Employed part-time	2	
			Self-employed	3	
			Unemployed	4	
			Retired	5	
			Student	6	
			Housewife/husband	7	
			Dependent	8	
			· ·		
			[No response]	99	

1.7						
	income?		601 – 1,650 Birr	2		
			1,651 – 3,200 Birr	3		
			3,201 – 5,250 Birr	4		
			5,251 – 7,800 Birr	5		
			7,801 – 10,900 Birr	6		
			Over 10,900 Birr	7		
			[No response]	99		
1.8	Is this health facility close enough	h for you to get	Yes	1		
1.0	here easily?	irror you to get	No	0		
	,,		[No response]	99		
1.9	What type of transportation do y	ou use most	Bicycle	1		
	often to get to this facility?		Bus	2		
			Personal Car	3		
			Horse/Mule/Donkey			
			Motorcycle			
			Taxi/Bajaj/Horse Cart (Gari)	5 6		
			Walking	7		
			Other (specify)	9699		
1.10	On average, how long does it tak	e vou to get to	[NO response]	9099		
1.10	this facility from your home?	e you to get to				
			Hours Minutes			
	[HOURS MUST BE 0-48; MINUTE	S MUST BE 0-	Don't know	88		
	59]		[No response]	99		
4.44	Davis and also	W		1		
1.11	Do you smoke?	Yes				
		No[No response]				
1.11.1	[ASK ONLY IF 1.11=YES]	Yes				
1.11.1	Has a healthcare worker at this	No				
	facility talked with you about	[No response]				
	quitting smoking?	[99		

2. Cas	scade of Care		
	Now, I would like to ask about the TB care that	you have received.	
2.1	How long after you first started having	Within 1 week	1
	symptoms, such as coughing, did you go to	1-2 weeks	2
	any health facility?	More than two weeks	3
		Don't know	88
		[No response]	99
2.2	Where did you get tested for the first time	At this facility	1
	for TB?	At a different public facility	2
		At a different private facility	3
		Don't know	88
		[No response]	99
2.3	How long after you were tested were you	Within the same day	1
	told you had TB?	Within two days	2
		Within one week	3
		1-2 weeks	4
		More than two weeks	5
		Don't know	88
		[No response]	99
2.4	How long after you were told you had TB did	Within the same day	1
	you start treatment?	Within two days	2
		Within one week	3
		1-2 weeks	4
		More than two weeks	5
		Don't know	88
		[No response]	99
2.5	How long have you been on treatment?	Less than 3 months	1
		3-6 months	2
		7-9 months	3
		10-24 months	4
		More than 2 years	5
		Don't know	88
		[No response]	99
2.6	What phase of treatment are you in now?	Intensive	1
		Continuation	2
		Don't know	88
		Other (specify)	96
		[No response]	99

3. Avai	lability of TB Services					
	Now I would like to ask you about your experience	with this facility in	Yes	No	[NR]	
	general.					
3.1	Were you physically examined by a healthcare work	ker at this facility	1	0	99	
	during your first visit for TB?		-		33	
3.2	Do you always talk to the same healthcare provider	(s) every time you	1	0	99	
	visit this facility?		_			
3.3	Do you have difficulties in getting TB care in this fac	ility because of a	1	0	99	
	language barrier?					
3.4	Have you ever been turned away from receiving TB care during official			0	99	
	working hours at this facility?	T., .				
3.4.1	[ASK ONLY IF 3.4=YES]	No drugs			1	
	Why were you turned away?	I came late			2	
		I forgot my card			3	
		No healthcare prov			4 96	
	Other (specify) [No response]				99	
3.5	Do you collect TB medicines at this facility?	1	0	99		
3.5	· · · · · · · · · · · · · · · · · · ·))	
2 - 4	[ASK THE NEXT 3 QUESTIONS ONLY IF 3.5=YES]		1 4	1 .	1 00	
3.5.1	Are the medicines always available?		1	0	99	
3.5.2	Are you told how to take the medicines each time y		1	0	99	
3.5.3	Have you been given written instructions in local la	nguage on how to	1	0	99	
	take your medicines?		_	· ·	33	
3.6	Are the clinic hours convenient for you?		1	0	99	
3.6.1	[ASK ONLY IF 3.6=NO]					
	Why is that?					
			Yes	No	[NR]	
3.7	Are the waiting time(s) before talking to healthcare	providers at this	4	_	- 00	
	facility generally acceptable to you?		1	0	99	
3.8	During today's visit, about how long did you wait					
	to talk to any provider? (please add up the total					
	time)	Hours	 Minut	 		
	[HOURS MUST BE 0-12; MINUTES MUST BE 0-59]	Don't know			88	
		[No response]				
2.5		+			99	
3.9	Did you spend time at more than one unit during		Yes		1 2	
	your visit today?	No	No			
		[No response]			99	
3.9.1	[ASK ONLY IF 3.9=YES]	OPD/Triage	OPD/Triage			
	Where did you spend the longest time?				2	
		Pharmacy			3 4	
		Other (specify)			96	
		[No response]			99	

3.10	During today's visit, how long did you spend with your providers, e.g. healthcare provider, lab, pharmacist, etc.? If you saw more than one provider, please add up the total time. [HOURS MUST BE 0-8; MINUTES MUST BE 0-59]		Hours Minutes Don't know [No response]			88 99
				Yes	No	[NR]
3.11	Have you ever gone to another health facility	y to rece	eive TB care?	1	0	99
3.11.1	[ASK ONLY IF 3.11=YES]	Chan	ge of address			1
	Why did you go to another health facility?	I was	referred			2
		Looki	ng for a second opinion	on		3
		There was no provider at this facility			4	
	Other (specify)				96	
	Don't know				88	
		[No re	esponse]			99

4. T	B Contact Investigation				
4.1	[DO NOT ASK PATIENTS WITH EXTRA-PULMONARY TB (023 =3)] When you were first diagnosed with TB, did you receive information or counselling about the need to have the people with whom you have been in close contact checked or tested for TB? Your close contacts could include your family members, friends, schoolmates, or coworkers that you spend time with. [IF 4.1=YES, CONTINUE WITH THIS SECTION; OTHERWISE, SKIP TO	Yes No Don't know [No response]			1 0 88 99
4.2	Who counselled you about how to identify your close contacts and the need to have them checked for TB? [SELECT ALL THAT THE RESPONDENT MENTIONS, BUT DO NOT PROMPT] Healthcare worker at this facility (doctor, nurse, clinical officer)				1 2 3 4 96 99
4.3	Please tell me more about how your contacts were first identified.	Yes	No	DK	[NR]
4.3.1	Were you visited at home by someone involved with your care? (e.g., HEWs, community volunteers, etc.)	1	0	88	99
4.3.2	ASK ONLY IF 1.6 = 1, 2, 3 or 6 Were you visited at school or work by someone involved with your care? (e.g., HEWs, community volunteers, etc.)	1	0	88	99
4.3.3	Were you visited at other places you frequent by someone involved with your care? (e.g., HEWs, community volunteers, etc.)	1	0	88	99

4. TB	4. TB Contact Investigation							
				Yes	No	DK	[NR]	
4.3.4	Were you visited by a healthcare worker fro (excluding HEWs)	m this facility?		1	0	88	99	
4.4	Were you asked to bring your contacts to th	e facility?		1	0	88	99	
4.5		I would like to know more about the types of contacts you were				5.,	[21.5]	
	asked about.	•		Yes	No	DK	[NR]	
4.5.1	Do you have any child contacts (below 15 ye	ears)?		1	0	88	99	
4.5.2	Were you asked about all contacts living in y including children?	our house,		1	0	88	99	
4.5.3	Were you asked about contacts you know fr or school?	om your workpl	ace	1	0	88	99	
4.6	Were your contacts asked about whether the of TB?	ey had sympton	ns	1	0	88	99	
4.7	Were you asked to bring your contacts to a health care facility for TB testing?			1	0	88	99	
4.8	Did your contacts receive any tests to check if they had the disease?			1	0	88	99	
	[ASK ONLY IF 4.8=YES] What kinds of tests did your contacts receive?			Yes	No	DK	[NR]	
4.8.1	Sputum examination			1	0	88	99	
4.8.2	Chest X-ray			1	0	88	99	
4.8.3	Other (specify)			1	0	88	99	
4.9	Were any of your adult contacts diagnosed	with TB?		1	0	88	99	
4.9.1	[ASK ONLY IF 4.9=YES]			4		0.0	00	
	Did they start taking treatment for it?			1	0	88	99	
4.9.2	[ASK ONLY IF 4.9=NO, DK, or NR] Were any of your adult contacts told they sh treatment that will prevent them from getti			1	0	88	99	
4.10	[ASK ONLY IF 4.5.1=YES (have child contact Were any of your child contacts diagnosed was a second or secon			1	0	88	99	
4.10.1	[ASK ONLY IF 4.10=YES] Did they start taking treatment for it?			1	0	88	99	
4.10.2	[ASK ONLY IF 4.10=NO, DK, or NR] Were any of your child contacts told they sh treatment that will prevent them from getti			1	0	88	99	
	Please respond to the following statements about contact investigation by saying if you agree or disagree.	Agree	agr	either ee nor sagree	С	Disagree	[NR]	
4.11	I understood the information I received about identifying my contacts.	3		2 1		99		
4.12	I understood the information I received about advising my contacts to get tested for TB.	3		2		1	99	
4.13	I understood why it was necessary to identify my contacts.	3		2		1	99	

4. TI	4. TB Contact Investigation								
		Agree	Neither agree nor disagree	Disagree	[NR]				
4.14	I received support on how to identify my contacts and where to bring them for services.	3	2	1	99				
4.15	I understood the kinds of tests that my contacts received.	3	2	1	99				
4.16	My contacts were treated well by the healthcare/outreach worker.	3	2	1	99				

5. TB Practices								
	Next, I would like to as	k you about health care	practices related to your TB.					
5.1	Who currently supervi	•	Health worker at this facility					
5.2	[ASK ONLY if 5.1= 1,2,3 On average, how many your treatment support your medicines? [ENTER 0-7]	days per week does	Days [No response]					
5.3	Have you ever stopped medicines for a month reason? (Add the num were stopped during t	or more for any ber of days medicines	Yes					
5.3.1	[ASK ONLY IF 5.3=YES] Why did you stop taking your medicine? [SELECT ALL THAT APPLY]	Medicines were not at Pharmacy was too far Could not afford to but No time to get medicit Was travelling	o stop	1 2 3 4 5 6 7 8 9 96				

6. TB Knowledge											
	Now I would like to ask about your knowledge and awareness of TB. [ASK THE LEADING QUESTION FIRST AND SELECT "UNPROMPTED" FOR ALL RESPONSES FROM THAT RESPONDENT WITHOUT NEEDING A PROMPT. THEN START PROMPTING EACH ITEM THAT WAS MISSED AND ANSWER ACCORDINGLY.]										
6.1	TB Symptoms										
	There are various symptoms an individual with TB would experience to know if s/he has the disease.										
	Can you tell me what symptoms a person with TB will have?	Yes, Unprompted	Yes, Prompted	No	DK	[NR]					
6.1.1	Chronic cough (more than 2 weeks)	2	1	0	88	99					
6.1.2	Coughing up mucus or phlegm	2	1	0	88	99					
6.1.3	Blood-streaked mucus or sputum	2	1	0	88	99					
6.1.4	Unexplained weight loss	2	1	0	88	99					
6.1.5	Fever and/or chills	2	1	0	88	99					
6.1.6	Night sweats	2	1	0	88	99					
6.1.7	Persistent shortness of breath	2	1	0	88	99					
6.1.8	Tiredness/fatigue	2	1	0	88	99					
6.1.9	Pain in the chest or back	2	1	0	88	99					
6.1.10	Other (specify)	2	1	0	88	99					
			I								
6.2	TB Causes and Transmission										
	What do you think causes TB or spreads it from	Yes,	Yes,	No	DK	[NR]					
	one person to another?	Unprompted	Prompted	NO	DK	[INK]					
6.2.1	Germs/bacteria	2	1	0	88	99					
6.2.2	Infected person coughing or sneezing	2	1	0	88	99					
6.2.3	Crowded living conditions	2	1	0	88	99					
6.2.4	Blood transfusions	2	1	0	88	99					
6.2.5	Sharing utensils	2	1	0	88	99					
6.2.6	Touching a person with TB	2	1	0	88	99					
6.2.7	Through food	2	1	0	88	99					
6.2.8	Mosquito bites	2	1	0	88	99					
6.2.9	Sexual contact	2	1	0	88	99					
6.2.10	Smoking	2	1	0	88	99					
6.2.11	Other (specify)	2	1	0	88	99					
		I	I	1		1					
6.3	TB Risk Factors										
	What do you think makes a person more at risk of getting TB?	Yes, Unprompted	Yes, Prompted	No	DK	[NR]					
6.3.1	Smoking	2	1	0	88	99					
6.3.2	Alcohol drinking	2	1	0	88	99					
6.3.3	Fatigue	2	1	0	88	99					

6. TB Kr	nowledge					
		Yes, Unprompted	Yes, Prompted	No	DK	[NR]
6.3.4	Malnutrition	2	1	0	88	99
6.3.5	Unhygienic practices	2	1	0	88	99
6.3.6	Poor ventilation	2	1	0	88	99
6.3.7	Pollution	2	1	0	88	99
6.3.8	Being HIV infected	2	1	0	88	99
6.3.9	Contact with or living with someone who has TB	2	1	0	88	99
6.3.10	Inherited	2	1	0	88	99
6.3.11	Having diabetes	2	1	0	88	99
6.3.12	Poverty	2	1	0	88	99
6.3.13	Overcrowding	2	1	0	88	99
6.3.14	Other (specify)	2	1	0	88	99
6.4	Drug Side Effects					
	What are the possible side effects patients may experience from using or taking medicines for TB?	Yes, Unprompted	Yes, Prompted	No	DK	[NR]
6.4.1	Nausea	2	1	0	88	99
6.4.2	Vomiting	2	1	0	88	99
6.4.3	Heart burn	2	1	0	88	99
6.4.4	Loss of appetite	2	1	0	88	99
6.4.5	Discolored urine or tears	2	1	0	88	99
6.4.6	Fever	2	1	0	88	99
6.4.7	Yellowish eyes	2	1	0	88	99
6.4.8	Problems with eyesight	2	1	0	88	99
6.4.9	Joint pain	2	1	0	88	99
6.4.10	Rash/Itchiness	2	1	0	88	99
6.4.11	Tingling, burning, or numbness of the hands and feet	2	1	0	88	99
6.4.12	Abdominal pain	2	1	0	88	99
6.4.13	Tinnitus (noise or ringing in the ears)	2	1	0	88	99
6.4.14	Fatigue	2	1	0	88	99
6.4.15	Insomnia	2	1	0	88	99
6.4.16	Balance issues (loss of balance)	2	1	0	88	99
6.4.17	Hearing loss	2	1	0	88	99
6.4.18	Mental disorders (psychosis, depression, anxiety)	2	1	0	88	99
6.4.19	Diarrhea	2	1	0	88	99
6.4.20	Other (specify)	-2	-1	0	88	99

6. TB I	Knowledge		
6.5	Can TB be cured?	Yes	1
		No	0
		Don't know	88
		[No response]	99
6.6	[ASK ONLY IF 023=1 (DS-TB)]		
	What is the usual time or typical period for treating drug susceptible TB?	Months	
	[MUST BE 0-12.		
	ENTER '0' IF THEIR ANSWER IS <1 MONTH.	Don't know	88
	ENTER '12' IF THEIR ANSWER IS >12 MONTHS.]	[No response]	99
6.7	[ASK ONLY IF 023=2 (DR-TB)] What is the usual time or typical period for treating drug resistant TB?	Months	
	[MUST BE 0-30.		
	ENTER '0' IF THEIR ANSWER IS <1 MONTH.		
	ENTER '30' IF THEIR ANSWER IS >30 MONTHS.]	Don't know	88
		[No response]	99

7. Stig	7. Stigma/Discrimination									
77 30.15	Next, I would like to ask you to rate the following statements about your experience with TB. I am going to read to you some statements and I would like you to tell me to what extent you agree or disagree, ranging from 1-strongly disagree to 5-strongly agree.									
7.1	Facility-Level Discrimination									
	First, I would like to know how you are treated by others at this facility. Strongly disagree Disagre									
7.1.1	Overall, I feel welcome in this health facility.	1	2	3	4	5	99			
7.1.2	Healthcare providers here turn their face away when speaking with me.	1	2	3	4	5	99			
7.1.3	Overall, healthcare providers here treat me with respect.	1	2	3	4	5	99			
7.1.4	Healthcare providers within this facility show discriminatory attitudes toward me because of my disease.	1	2	3	4	5	99			
7.1.5	Overall, the healthcare providers are friendly to me.	1	2	3	4	5	99			
7.1.6	Overall, the healthcare providers treat me the same way I am treated when I receive care for other illnesses.	1	2	3	4	5	99			
7.1.7	Healthcare workers have avoided touching me.	1	2	3	4	5	99			

7. Stign	ma/Discrimination								
		Strongly disagree	Disagree	agr	ither ee or igree	Agr	ee	Strongly agree	[NR]
7.1.8	Overall, I feel distressed, intimidated, or offended when interacting with healthcare providers at this facility.	1	2		3	4	ļ	5	99
7.2	Community-Level Stigma/Discrim	nination							
7.2.1	Have you disclosed your illness to	your famil	y?	No	espons	1 0 99			
7.2.2	Have you disclosed your illness to your friends?			Yes No					1
	[ASK THE NEXT 7 QUESTIONS ON	I Y IF 7.2.1=	YFS OR	NO FE	esponse	e 			99
	7.2.2=YES] Now, I would like to know what si experienced due to having TB. Ag to tell me to what extent you agree the following statements using the before, where 1 is strongly disagreagree.	tuations yo ain, I would ee or disagr e same sca	ou have I like you ee with le as	SD	D	N	Α	SA	[NR]
7.2.3	I felt hurt when I saw how people have TB.	I felt hurt when I saw how people reacted to learning I			2	3	4	5	99
7.2.4	I stopped going to social events, religious services, or community events because of negative reactions to my disease.		1	2	3	4	5	99	
7.2.5	People do not want to eat or drin have TB.	k with me b	ecause I	1	2	3	4	5	99
7.2.6	I keep a distance from others to a from TB.	void spread	ding germs	1	2	3	4	5	99
	[ASK THE NEXT 2 QUESTIONS ON	LY IF 7.2.1=	YES]						
7.2.7	Family members keep a distance have TB.	from me be	ecause I	1	2	3	4	5	99
7.2.8	Family members feel guilt in the chave TB.	community	because I	1	2	3	4	5	99
7.2.9	[ONLY ASK IF 7.2.2=YES] I lost friends when I told them I ha	ave TB.		1	2	3	4	5	99
7.3	Patients' Stigmatizing Emotions								
	I want to understand the types of as someone with TB. As before, I a you some statements and I want y extent to which you agree or disag where 1 is strongly disagree and 5	am going to you to tell n gree with th	read ne the nem,	SD	D	N	А	SA	[NR]
7.3.1	I feel that I need to hide the fact t	hat I have T	ъ.	1	2	3	4	5	99

7. Stign	na/Discrimination							
		SD	D	N	А	SA	[NR]	
7.3.2	I worry people who know I have TB will tell others.	1	2	3	4	5	99	
7.3.3	I am very careful whom I tell that I have TB.	1	2	3	4	5	99	
7.3.4	I worry that in this community most people with TB are denied involvement in social events, religious services, or community events when others learn that they have TB.	1	2	3	4	5	99	
7.3.5	I worry that in this community people believe a person who has TB is dirty.	1	2	3	4	5	99	
7.3.6	It is difficult to tell people about my disease.	1	2	3	4	5	99	
7.3.7	I feel guilty that I have TB.	1	2	3	4	5	99	
7.3.8	I feel ashamed that I have TB.	1	2	3	4	5	99	
7.3.9	I sometimes feel worthless because I have TB.	1	2	3	4	5	99	
7.3.10	Having TB makes me feel like I am a bad person.	1	2	3	4	5	99	
7.3.11	I feel I am not as good as others because I have TB.	1	2	3	4	5	99	
7.3.12	I feel I look disgusting because I have TB.	1	2	3	4	5	99	
7.4	Have you ever felt stigmatized or discriminated against because you have TB?		Yes					
			No					
			Don't know					
			[No response]					
7.5	Have you seen or heard of others being stigmatized	Yes	1					
	or discriminated against because of their TB status?	No	0					
	status:	Don't	88					
		[No re	sponse	e]			99	
7.6	What would you like to see changed in TB services, laws, and policies to address TB-related stigma and discrimination (e.g., in the hospital/clinic, community, family, workplace)?							

8. Commu	unication of TB Information				
	[ASK THE LEADING QUESTION FIRST AND SELECT "UI THAT RESPONDENT WITHOUT NEEDING A PROMPT." WAS MISSED AND ANSWER ACCORDINGLY.]				
	During your visits to this health facility, what information about TB and its treatment were shared with you by the health workers?	Yes, Unprompted	Yes, Prompted	No	DK
8.1	How TB is spread to others	2	1	0	99
8.2	Cough hygiene, i.e., how to reduce the risk of making others sick by covering your mouth when you cough	2	1	0	99
8.3	That TB can be cured	2	1	0	99
8.4	How long your treatment will last	2	1	0	99
8.5	Danger signs of TB getting worse	2	1	0	99
8.6	The importance of taking the medicines regularly	2	1	0	99
8.7	Side effects of the medicines	2	1	0	99
8.8	What to do if you have side effects from the medicine	2	1	0	99
8.9	The need for sputum tests at given points during your treatment	2	1	0	99
8.10	The importance of taking the medicines through the end of treatment	2	1	0	99
8.11	When to come back for the next care visit for TB	2	1	0	99
8.12	Healthy behaviors to follow (e.g., no alcohol drinking, good hygiene)	2	1	0	99
8.13	Do you have materials (e.g., pamphlets) from the health facility to remind you of the treatment information provided by the provider Yes No [NR] or other facility staff?				
8.14	Do you have educational materials on your disease?		1	0	99
	[ASK THE NEXT 3 QUESTIONS ONLY IF 8.14=YES]		•		
8.14.1	Do you understand the educational materials?		1	0	99
8.14.2	Do you think the educational materials are appropriate for your health situation?				99
8.14.3	Do you think the educational materials are helpful to	you?	1	0	99

9. Pati	9. Patient – Provider Interaction						
	Next, I would like to ask you about your face- to-face meetings with healthcare providers at this facility.	Always	Sometimes	Never	DK	[NR]	
9.1	During your visits to this facility, do the healthcare providers usually explain things in a way you can understand?	2	1	0	88	99	
9.2	During your visits to this facility, do the healthcare providers listen to your opinion and ideas on the best way to follow your treatment?	2	1	0	88	99	

9. Pati	ient – Provider Interaction					
	Next, I would like to ask you about your face- to-face meetings with healthcare providers at this facility.	Always	Sometimes	Never	DK	[NR]
9.3	Do the healthcare providers at this facility discuss your status or progress with you at every scheduled appointment?	2	1	0	88	99
9.4	During your visits to this facility, do you think the healthcare providers give you a chance to ask questions about anything that concerns you?	2	1	0	88	99
9.5	During your visits to this facility, do you usually have enough time to discuss your health needs with the healthcare providers?	2	1	0	88	99
9.6	During your visits to this facility, do the healthcare providers tell you how TB can affect your everyday life?	2	1	0	88	99
9.7	Do the healthcare providers at this facility address your worries about your disease seriously when you visit the facility?	2	1	0	88	99
9.8	During your visits to this facility, do the healthcare providers listen carefully to you?	2	1	0	88	99
9.9	During your visits to this facility, do the healthcare providers explain how to cope with your problems?	2	1	0	88	99
9.10	During your visits to this facility, do you worry that other patients can hear your conversation with your healthcare providers?	2	1	0	88	99
9.11	During your visits to this facility, do you think you have enough privacy during the examination?	2	1	0	88	99

10. TB,	10. TB/HIV Services						
	Next, I would like to ask you about the link between TB and HIV.	Yes	No	DK	[NR]		
10.1	Has any healthcare provider in this facility told you about the link between TB and HIV?	1	0	88	99		
10.2	Has any healthcare provider in this facility told you how to prevent HIV infection (for yourself)?	1	0	88	99		
10.3	After being told you had TB, were you told to take an HIV test?	1	0	88	99		
10.4	Has any healthcare provider in this facility told you where to get HIV treatment if you might need it?	1	0	88	99		
10.5	Has any healthcare provider in this facility told you that you can get treatment for HIV and TB at the same time if you might need this?	1	0	88	99		
10.6	Are you taking treatment for HIV?	1	0	88	99		
	ASK THE NEXT 2 QUESTIONS ONLY IF 10.6=YES]		•				

10. TB/	10. TB/HIV Services						
	Next, I would like to ask you about the link between TB and HIV.	Yes	No	DK	[NR]		
10.6.1	Has any healthcare provider in this facility told you about conditions in which the HIV treatment can make the symptoms of your disease worse?	1	0	88	99		
10.6.2	Has any healthcare provider in this facility told you what to do if your symptoms get worse after starting HIV treatment?	1	0	88	99		

11. Supp	ort							
	I would like to ask you about any support you receive from this facility.							
11.1	People with TB sometimes a other medical conditions, su diabetes, HIV infection, or of illnesses. Do you have any of medical conditions?	nditions, such as ection, or other Don't know					1 0 88 99	
11.1.1	[ASK ONLY IF 11.1=YES] Who has discussed your other medical conditions with you?	Only healt Only healt Both healt	No one					0 1 2 3 99
11.1.2	[ASK ONLY IF 11.1=YES] Do you feel your other medical needs have been met? None have been met				 	0 1 2 3 99		
11.2	To support its patients, this services to help you complet Which, if any, of the following have you received from this	reatment.	Yes	No	DK	[]	IR]	
11.2.1	Free TB medicines			1	0	88	ç	99
11.2.2	Home based treatment			1	0	88	9	99
11.2.3	Nutritional support/food bas	sket		1	0	88	ç	99
11.2.4	Rehabilitative services			1	0	88	9	99
11.2.5	Transport assistance			1	0	88	9	99
11.2.6	Small group TB health educa	tion session	1	1	0	88	ç	99
11.2.7	One-on-one counselling (fac (doctor, health officer, and/o		y medical staff	1	0	88	ç	99
11.2.8	One-on-one counselling (face to face) by health extension worker (HEW)				88	g	99	
11.2.9	One-on-one peer counselling lay counsellor or a cured TB	• ,	ce) by either a	1	0	88	g	99
11.2.10	Meeting with a psychologist			1	0	88	ç	99
11.2.11	Other services (specify)			1	0	88	g	99

11. Supp	ort				
11.3	Which of the following services do you think would help you the most in continuing and completing your treatment, regardless of whether it is currently offered by this facility?	Yes	No	DK	[NR]
11.3.1	Free TB medicines	1	0	88	99
11.3.2	Home based treatment	1	0	88	99
11.3.3	Nutritional support/food basket	1	0	88	99
11.3.4	Rehabilitative services	1	0	88	99
11.3.5	Transport assistance	1	0	88	99
11.3.6	Small group TB health education session	1	0	88	99
11.3.7	One-on-one counselling (face to face) by medical staff (doctor, health officer, and/or nurse)	1	0	88	99
11.3.8	One-on-one counselling (face to face) by health extension worker (HEWs)	1	0	88	99
11.3.9	One-on-one peer counselling (face to face) by either a lay counsellor or a cured TB patient	1	0	88	99
11.3.10	Meeting with a psychologist	1	0	88	99
11.3.11	Other services (specify)	1	0	88	99

12. Affordability								
	Next, I would like to ask you about the costs of the care for TB.							
12.1	Next, I want to ask if you have					[ASK	ONLY IF (a)=	:YES]
	received certain tests at this	a) Ha	ve you	had [test]?		b) Did y	you have to	pay for it?
	facility, and if so, I will ask if you have to pay for them.	Yes	No	DK	[NR]	Yes	No	[NR]
12.1.1	Sputum tests	1	0	88	99	1	0	99
12.1.2	Blood tests	1	0	88	99	1	0	99
12.1.3	X-rays	1	0	88	99	1	0	99
						Yes	No	[NR]
12.2	Do you have to pay to see a healthcare provider at this facility for routine TB visits?							
12.3	Do you incur any other costs for TB, including informal payments? 1 0 99							99
12.4	Have you ever been unable to come (Transportation, medical care)?	to the h	nealth f	acility becau	use of cost	1	0	99

13. Infr	13. Infrastructure						
	Next, I would like to ask you about physical features of this facility. Please answer the questions about this facility only. Do not include any other facilities in your answer.	Always	Sometimes	Never	DK	[NR]	
13.1	During your visits to this facility, do you find the clinic area to be clean?	2	1	0	88	99	
13.2	Are there enough comfortable places to sit in this facility?	2	1	0	88	99	

13. Infr	13. Infrastructure						
		Always	Sometimes	Never	DK	[NR]	
13.3	During your visits to this facility, is drinkable water usually available?	2	1	0	88	99	
13.4	During your visits to this facility, is a toilet available for use?	2	1	0	88	99	
	[ASK THE NEXT TWO QUESTIONS ONLY IF 12.3= 2 or 1	(Always o	r Sometimes)]			
13.4.1	During your visits to this facility, are the toilets usually clean?	2	1	0	88	99	
13.4.2	During your visits to this facility, are the toilets always available to use (unlocked or keys are available)?	2	1	0	88	99	

14. O	14. Overall Satisfaction						
14.1	Overall, how satisfied are you with the TB care	Very dissatisfied	1				
	you have received at this facility so far?	Dissatisfied	2				
		Neither satisfied nor dissatisfied	3				
		Satisfied	4				
		Very satisfied	5				
		[No response]	99				
14.2	Is there anything you would like to see changed a receive for TB?	t this facility to improve the quality of care that	you				

End o	f Facility Visit			
		(a) Visit Result		(b) Visit End Time [Use the 24-hour clock system, e.g. 14:30]
003	Visit 1	Partially completed	1 2 3 4 5 96	Hours Minutes
004	Visit 2 (if needed)	Completed Partially completed Patient unavailable Patient refused Other (specify)	1 2 3 4 96	Hours Minutes

THANK YOUR RESPONDENT AND MOVE TO THE NEXT AVAILABLE PATIENT.

Comm	Comments/Observations [RESEARCH ASSISTANT]			
099	Please provide detailed comments or observations you may have about this questionnaire (issues with questions, challenges in determining which response to select, etc.).			

ETHIOPIA QUALITY OF TB SERVICES ASSESSMENT: REGISTER REVIEW

Start	Start of Facility Visit					
		(a) Visit Date dd/mm/yyyy	(b) Visit Start Time [Use the 24-hour clock system, e.g. 14:30]	(c) Interviewer ID	(d) Interviewer Name	
001	Visit 1		Hours Minutes			
002	Visit 2 (if needed)		Hours Minutes			
	•	•		•	•	

Facility Identification					
05	Is this a replacement facility or facility with a different name listed than what was provided by the NTP?			Yes No	1 0
		(a) Code	(b) Name		
010	Region				
011	Zone/Sub-city				
012	Woreda				
013	Kebele				
014	Facility				
015	GPS location				

Facility Information					
Data (Collection Tools				
	Are the following registers used at this facility to record TB data? Check if they are available to review. Also ask if there are any other	Both electronic	Yes	Paper	No
224	registers that record TB data.	and paper	Electronic only	only	
021a	Presumptive TB register	3	2	1	0
021b	Presumptive TB register (HEWs)	3	2	1	0
021c	Presumptive TB Register (Other type)	3	2	1	0
022	TB Microscopy Registration book	3	2	1	0
023	GeneXpert Registration Book	3	2	1	0
024	TB Culture and DST Register	3	2	1	0
025	Unit TB Register	3	2	1	0
026.1	ART register	3	2	1	0
026.2	PMTCT Register	3	2	1	0
027	DR-TB treatment register	3	2	1	0
028	(Outpatient department) OPD register	3	2	1	0
029	TB Contact Screening Register	3	2	1	0
031	IPT logbook	3	2	1	0
032	Other (specify)	3	2	1	0
			_	_	
TB Ser	vices Provided [ANSWERS MUST MATCH WHAT IS	IN THE FACILITY AL	JDIT1		
					T 2
033	Does this facility perform smear microscopy either so, is it done onsite or are specimens/slides sent to		nd if Yes, onsite Yes, sent or		2
	(note: regardless of whether smear microscopy is				0
	follow-up)				
034	Does this facility perform GeneXpert tests, and if s	o, are they done on	site Yes, onsite		2
	or are specimens sent to another facility?		Yes, sent o	ut	1
			No		0
	Are the following services available at this facility?)		Yes	No
035	Drug-susceptible (DS)-TB treatment management			1	0
036	HIV-related services			1	0
037	DR-TB treatment management			1	0
038	Does this facility initiate treatment for drug-resista			1	0
039	TB preventive treatment (TPT) for people living wi			1	0
040	TPT to child contacts (under 5 years of age) of con-	firmed TB patients	1	1	0
041	[VALID ONLY IF 040= NO]	,	No guidelin		1
	What is the reason for not providing TPT to child contacts (under 5 years Not trained				2
	of age) of confirmed TB patients?		No drugs		3
	Don't know				88
	[SELECT ALL THAT APPLY]		Other (spec	city)	00
					96

[FOR ALL COUNTS, PLEASE ENTER 0 FOR NONE AND SELECT 999 WHEN YOU ARE UNABLE TO DETERMINE THE COUNT. AT THE END OF THE SURVEY, THERE IS AN OPPORTUNITY FOR YOU TO DESCRIBE ANY ISSUES YOU HAD IN DETERMINING THE COUNTS.]

1. S	creening and Diagnosis (use the OPD Register or P	Presumptive TB Register)		
1.0	LOCATE RECORDS FROM DECEMBER 30, 2017 – JUNE 27, 2018 (TAHASASS 21, 2010 – SENE 20, 2010)			
	Which register(s) will be used to determine the TB screening and diagnosis counts? [SELECT ALL THAT APPLY]	Presumptive TB register (Act Logo)	1 EWs)	
1.1	TB Screening and Diagnosis Totals			
1.1.1	Number of patients with presumptive TB [ENTER 0 FOR NONE]		Indeterminate: 999	
1.1.2	(OPD Register column 16) Number of patients with presumptive TB who had any type of diagnostic test done (e.g., smear, GeneXpert MTB/RIF, chest X /ray, clinical assessment, etc.) [MUST BE ≤ 1.1.1; ENTER 0 FOR NONE] (OPD Register column 17)		Indeterminate: 999	
1.1.3	Number of patients with presumptive TB with clir [MUST BE ≤ 1.1.2; ENTER 0 FOR NONE] (OPD Register column 17)	nical diagnosis test results	Indeterminate: 999	
1.1.4	Number of patients with presumptive TB who recomicroscopy, or GeneXpert MTB/RIF (GeneXpert) to [MUST BE ≤ 1.1.2; ENTER 0 FOR NONE] (OPD Register column 17)		Indeterminate: 999	
1.1.5	Number of patients with presumptive TB with bac [MUST BE ≤ 1.1.4; ENTER 0 FOR NONE] (OPD Register column 17 and 18)	cteriological test results	Indeterminate: 999	
1.1.6	Number of patients with presumptive TB with porresults [MUST BE ≤ 1.1.5; ENTER 0 FOR NONE] (OPD Register column 17 and 18)	sitive bacteriological test	Indeterminate: 999	
1.1.7	Number of patients with presumptive TB with po [MUST BE ≤ 1.1.3; ENTER 0 FOR NONE]	sitive clinical diagnosis		
	(OPD Register column 17, 18 and 21)		Indeterminate: 999	

1. S	creening and Diagnosis (use the OPD Register or Presumptive TB Register)	
1.2	Smear Microscopy [VALID ONLY IF 033=YES (1 or 2)]	
1.2.1	Number of patients with presumptive TB who received a smear microscopy test [MUST BE ≤ 1.1.4; ENTER 0 FOR NONE] (OPD Register column 16 and 17)	Indeterminate: 999
1.2.2	Number of patients with presumptive TB with smear microscopy test results [MUST BE ≤ 1.2.1; ENTER 0 FOR NONE] (OPD Register column 18)	Indeterminate: 999
1.2.3	Number of patients with presumptive TB with positive smear microscopy test results [MUST BE ≤ 1.2.2; ENTER 0 FOR NONE] (OPD Register column 18)	Indeterminate: 999
	,	L
1.3	GeneXpert [VALID ONLY IF 034=YES (1 or 2)]	
1.3.1	Number of patients with presumptive TB who received a GeneXpert test [MUST BE ≤ 1.1.4; ENTER 0 FOR NONE] (OPD Register 16 and 17)	Indeterminate: 999
1.3.2	Number of patients with presumptive TB with GeneXpert test results [MUST BE ≤ 1.3.1; ENTER 0 FOR NONE] (OPD Register column 18)	Indeterminate: 999
1.3.3	Number of patients with presumptive TB with GeneXpert test results positive for TB [MUST BE ≤ 1.3.2 ; ENTER 0 FOR NONE] (OPD Register column 18)	Indeterminate: 999

	2. TB Laboratory Registers (use TB Microscopy Register and Laboratory Register for GeneXpert) [VALID ONLY IF 033 OR 034=YES (ONSITE)]				
2.0	LOCATE RECORDS FROM DECEMBER 30, 2017 – JUNE 27, 2018 (TAHASASS 21, 2010 – SENE 20, 2010)				
	Which register(s) will be used to Presumptive TB register)				
	determine the TB laboratory counts?	Presumptive TB register (HEWs)	2		
		Presumptive TB Register (Other type)	3		
	[SELECT ALL THAT APPLY]	TB Microscopy Registration book	4		
		GeneXpert Registration Book	5		
		Unit TB Register	6		
		DR-TB treatment register	7		
		OPD Register	8		
		Other (specify)	96		
2.1	Smear Microscopy [VALID ONLY IF 033=Y	res (onsite)]			

	boratory Registers (use TB Microscopy Register and Laboratory Register for G D ONLY IF 033 OR 034=YES (ONSITE)]	eneXpert)
2.1.1	Number of diagnostic smears submitted to the laboratory	
	[ENTER 0 FOR NONE]	
	[TB Microscopy Register column "Reason for examination" (SN 15)]	Indeterminate: 999
2.1.2	Number of diagnostic smear results recorded in the laboratory	
	[MUST BE ≤ 2.1.1; ENTER 0 FOR NONE]	
	[TB Microscopy Register column "Reason for examination" (SN 15) and "Examination Results" (SN 16)]	Indeterminate: 999
2.1.3	Number of diagnostic smear results received from the laboratory within 48 hours of submission.	
	[MUST BE ≤ 2.1.2; ENTER 0 FOR NONE]	
	[TB Microscopy Register column "Reason for examination" (SN 15), "Examination Results" (SN 16) "Date Specimen Received" (SN 3) and "Date Reported" (SN 4)]	Indeterminate: 999
2.1.4	Number of diagnostic smear-positive TB results	
	[MUST BE ≤ 2.1.2; ENTER 0 FOR NONE]	
	[TB Microscopy Register column "Reason for Examination" (SN 15) and "Examination Results" (SN 16)]	Indeterminate: 999
2.1.5	Number of smear conversion tests submitted to the laboratory	
	[ENTER 0 FOR NONE]	
	[TD Microscopy Pogistor column "Posson for Evamination" (SN 1EV)	Indeterminate: 999
2.1.6.1	[TB Microscopy Register column "Reason for Examination" (SN 15)] Number of smear conversion test with results recorded	
2.1.0.1	[MUST BE ≤ 2.1.5; ENTER 0 FOR NONE]	
	[MOST DE 1 21213 / ENTER OF OR NORE]	
	[TB Microscopy Register column "Reason for examination" (SN 15),	Indeterminate: 999
	"Examination Results" (SN 16) and "Date Reported" (SN 4)]	
2.1.6.2	Number of smear conversion test results recorded (only count follow-up	
	smears at 2 months, i.e., the end of the intensive phase)	
	[MUST BE ≤ 2.1.6a; ENTER 0 FOR NONE]	
		Indeterminate: 999
	[TB Microscopy Register column "Reason for examination" (SN 15),	
247	"Examination Results" (SN 16) and "Date Reported" (SN 4)]	
2.1.7	Number of smear conversion test results reported by the laboratory within 48 hours of submission	
	[MUST BE ≤ 2.1.6a; ENTER 0 FOR NONE]	
	[MOST DE 2.2.00 , ENTEROTOR NONE]	
	[TB Microscopy Register column "Reason for examination" (SN 15),	Indeterminate: 999
	"Examination Results" (SN 16) "Date Specimen Received" (SN 3) and "Date	
	Reported" (SN 4)]	
2.1.8	Number of negative smear conversion test results recorded in the	
	laboratory	
	[MUST BE ≤ 2.1.6; ENTER 0 FOR NONE]	
	[TD 14:	Indeterminate: 999
	[TB Microscopy Register column "Reason for examination" (SN 15) and "Examination Results" (SN 16)]	
	Lyammation results (214 10)]	

	2. TB Laboratory Registers (use TB Microscopy Register and Laboratory Register for GeneXpert) [VALID ONLY IF 033 OR 034=YES (ONSITE)]			
2.2	GeneXpert [VALID ONLY IF 034=YES (ONSITE)]			
2.2.1	Number of GeneXpert samples submitted to laboratory [ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Specimen type" (SN 5) and "Reason for Examination" (SN 17)]	Indeterminate: 999		
2.2.2	Number of GeneXpert test results recorded in the laboratory [MUST BE ≤ 2.3.1; ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Specimen type" (SN 5), "Reason for Examination" (SN 17) and "Result of Xpert" (SN 18)]	Indeterminate: 999		
2.2.3	Number of GeneXpert test results reported by the laboratory within 24 hours of submission [MUST BE ≤ 2.3.2; ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Sputum collection date" (SN 3), "Date reported" (SN 4), "Specimen type" (SN 5), "Reason for Examination" (SN 17) and "Result of Xpert" (SN 18)]	Indeterminate: 999		
2.2.4	Number of GeneXpert tests with positive result for TB [MUST BE ≤ 2.3.2; ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Specimen type" (SN 5) "Reason for Examination" (SN 17), and "Result of Xpert" (SN 18)]	Indeterminate: 999		
2.2.5	Number of GeneXpert tests with positive result for resistance to rifampicin (RR) [MUST BE ≤ 2.3.4; ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Specimen type" (SN 5) "Reason for Examination" (SN 17), and "Result of Xpert" (SN 18)]	Indeterminate: 999		
2.2.6	Number of GeneXpert tests with negative result (N=MTB not detected) [MUST BE ≤ 2.3.2; ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Specimen type" (SN 5) "Reason for Examination" (SN 17), and "Result of Xpert" (SN 18)]	Indeterminate: 999		
2.2.7	Number of GeneXpert tests with error result (E) [MUST BE ≤ 2.3.2; ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Specimen type" (SN 5) "Reason for Examination" (SN 17), and "Result of Xpert" (SN 18)]	Indeterminate: 999		
2.2.8	Number of GeneXpert tests with MTB detected, rifampicin resistance indeterminate (TI) [MUST BE ≤ 2.2.2; ENTER 0 FOR NONE] [Laboratory Register for GeneXpert column "Specimen type" (SN 5) "Reason for Examination" (SN 17), and "Result of Xpert" (SN 18)]	Indeterminate: 999		

	2. TB Laboratory Registers (use TB Microscopy Register and Laboratory Register for GeneXpert) [VALID ONLY IF 033 OR 034=YES (ONSITE)]			
2.2.9	Number of GeneXpert tests with invalid result (I)			
	[MUST BE ≤ 2.3.2; ENTER 0 FOR NONE]			
	[Laboratory Register for GeneXpert column "Specimen type" (SN 5) "Reason for Examination" (SN 17), and "Result of Xpert" (SN 18)]	Indeterminate: 999		
2.2.10	Number of GeneXpert tests with no result (NR)			
	[MUST BE ≤ 2.3.2; ENTER 0 FOR NONE]			
	[Laboratory Register for GeneXpert column "Specimen type" (SN 5) "Reason	Indeterminate: 999		
	for Examination" (SN 17), and "Result of Xpert" (SN 18)]			

[THE (COUNTS IN EACH SECTION REPRESI	Register) [VALID ONLY IF 035=YES] ENT A COHORT OF PATIENTS THAT <u>STARTED</u> TREAT IF WHETHER THE OUTCOME IS AFTER THE END DAT		ГНЕ
3.0	LOCATE RECORDS FROM DECEMBE	BER 30, 2017 – JUNE 27, 2018 (TAHASASS 21, 2010	– SENE 20, 2010))
	Which register(s) will be used to determine the DS-TB treatment counts? [SELECT ALL THAT APPLY]	Unit TB Register		1 2 96
3.1	DS-TB Treatment			
3.1.1	Number of new patients who star [ENTER 0 FOR NONE] (Unit TB Register column 11 (P+, F	ted treatment (new patient cohort number)	Indeterminate:]
3.1.2	, , ,	·	999	
3.1.2	[MUST BE ≤ 3.1.1; ENTER 0 FOR NONE] Indetermin		Indeterminate:] :
3.1.3		nd/or positive GeneXpert pulmonary TB cases		
	registered for treatment [MUST BE ≤ 3.1.1; ENTER 0 FOR NONE]		Indeterminate:] :
	(Unit TB Register column 11 (P+) a	and 16)	999	
3.1.4		confirmed TB cases registered that were smear- ve phase of treatment NONE]	Indeterminate: 999]
			•	
3.2	TB/HIV (Unit TB Register) [VALID (May also need to use the ART re			

	TB Treatment Outcomes (Unit TB Register) [VALID ONLY IF 035=YES]	MENT DUDING THE
	COUNTS IN EACH SECTION REPRESENT A COHORT OF PATIENTS THAT <u>STARTED</u> TREATI PERIOD SPECIFIED, REGARDLESS OF WHETHER THE OUTCOME IS AFTER THE END DAT	
3.2.1	Number of registered DS-TB patients who had their HIV status documented in the	-,
3.2.1	TB register (new and relapse)	
	[ENTER 0 FOR NONE]	
	Note: do not include patients transferred-in	Indeterminate:
	Note: do not include patients transferred-in	999
	(Unit TB Register columns 11 and 51)	333
3.2.2	Number of registered HIV-positive DS-TB patients (new and relapse)	
5.2.2	[MUST BE ≤ 3.2.1; ENTER 0 FOR NONE]	
	Note: do not include patients transferred-in	
		Indeterminate:
	(Unit TB Register columns 11 and 51)	999
3.2.3	Number of HIV-positive DS-TB patients (new and relapse) receiving CPT	
	(cotrimoxazole preventive therapy) during TB treatment per NTLP guidelines	
	[MUST BE ≤ 3.2.2; ENTER 0 FOR NONE]	
	Note: do not include patients transferred-in	Indeterminate:
	·	999
	(Unit TB Register columns 11 and 52)	
3.2.4	Number of HIV-positive DS-TB patients (new and relapse) referred to ART care	
	during TB treatment	
	[MUST BE ≤ 3.2.2; ENTER 0 FOR NONE]	
	Note: do not include patients transferred-in	Indeterminate:
		999
	(Unit TB Register columns 11 and 53)	
3.2.5	Number of HIV-positive DS-TB patients (new and relapse) who started on or	
	continuing ART, during TB treatment	
	[MUST BE ≤ 3.2.4; ENTER 0 FOR NONE]	
	Note: do not include patients transferred-in	Indeterminate:
	(Unit TD Desigter religions 11 and 54)	999
	(Unit TB Register columns 11 and 54)	
3.3	New Cases	
	QUESTIONS 3.3.1 THROUGH 3.3.7 ARE ALL MUTUALLY EXCLUSIVE (THERE SHOULD B	E NO DOUBLE-
	COUNTING OF CLIENTS ACROSS THESE CATEGORIES)	
3.3.1	Number of new TB patients who were classified as cured at the end of their	
	treatment period	
	[MUST BE ≤ 3.1.1; ENTER 0 FOR NONE]	
	(1) (1) TD D (1) (1)	Indeterminate:
2 2 2	(Unit TB Register column 11 and 80)	999
3.3.2	Number of new TB patients who were recorded as completing treatment at the end	
	of their treatment period	
	[MUST BE ≤ 3.1.1; ENTER 0 FOR NONE]	Indeterminate:
	(Unit TB Register column 11 and 80)	999
3.3.3	Number of new TB patients who were classified as failing treatment at the end of	555
ر.ي.ي	their treatment period	
	[MUST BE ≤ 3.1.1; ENTER 0 FOR NONE]	
	[Indeterminate:
	(Unit TB Register column 11 and 80)	999

3. DS-TB Treatment Outcomes (Unit TB Register) [VALID ONLY IF 035=YES] [THE COUNTS IN EACH SECTION REPRESENT A COHORT OF PATIENTS THAT <u>STARTED</u> TREATMENT DURING THE TIME PERIOD SPECIFIED, REGARDLESS OF WHETHER THE OUTCOME IS AFTER THE END DATE]			
3.3.4		•	
3.3.4	Number of new TB patients who died for any reason before starting treatment or		
	during treatment		
	[MUST BE ≤ 3.1.1; ENTER 0 FOR NONE]		
		Indeterminate:	
	(Unit TB Register column 11 and 80)	999	
3.3.5	Number of new TB patients whose treatment was interrupted for 2 or more		
	consecutive months (i.e., lost to follow-up)		
	[MUST BE ≤ 3.1.1; ENTER 0 FOR NONE]		
		Indeterminate:	
	(Unit TB Register column 11 and 80)	999	
3.3.6	Number of new TB patients for whom no treatment outcome is assigned – includes		
	"transferred out" to another treatment unit and unknown treatment outcomes		
	(i.e., not evaluated)		
	[MUST BE ≤ 3.1.1; ENTER 0 FOR NONE]	Indeterminate:	
	[MOST DE 23.1.1 , ENTER OT OR NONE]	999	
	(Unit TB Register column 11 and 80)	555	
3.3.7	Number of new TB patients that were moved to the DR-TB Register		
3.3.7	[MUST BE ≤ 3.1.1]		
	[MO31 BE 2 3.1.1]		
	(Hait TD Desister release 44 and 60)	Indeterminate:	
	(Unit TB Register column 11 and 80)	999	
3.3.8	Add the counts from 3.3.1 to 3.3.7 and enter here. Compare to the 3.1.1 count.		
	They should be equal. If not, determine the cause of the discrepancy and fix. If it		
	cannot be fixed, describe why not:		
		Indeterminate:	
		999	
3.4	Retreatment Cases		
3.4.1	Number of retreatment TB patients (includes relapse, treatment after failure,		
	treatment after lost to follow up, or other previously treated patients without a		
	documented outcome) who initiated a retreatment regimen		
	[ENTER 0 FOR NONE]	Indeterminate:	
		999	
	(Unit TB Register column 11 and 80)	333	
	QUESTIONS 3.4.2 THROUGH 3.4.8 ARE ALL MUTUALLY EXCLUSIVE (THERE SHOUL	D RE NO DOUBLE	
	COUNTING OF CLIENTS ACROSS THESE CATEGORIES)	D BE NO DOOBLE-	
3.4.2	Number of retreatment TB patients who were smear-negative in the last month of		
	treatment and on at least one previous occasion (i.e., cured)		
	[MUST BE ≤ 3.4.1; ENTER 0 FOR NONE]		
	•	Indeterminate:	
	(Unit TB Register column 11 and 80)	999	

3. DS-TB Treatment Outcomes (Unit TB Register) [VALID ONLY IF 035=YES] [THE COUNTS IN EACH SECTION REPRESENT A COHORT OF PATIENTS THAT <u>STARTED</u> TREATMENT DURING THE TIME PERIOD SPECIFIED, REGARDLESS OF WHETHER THE OUTCOME IS AFTER THE END DATE]			
3.4.3	Number of retreatment TB patients who were recorded as completing treatment by the end of their treatment period [MUST BE ≤ 3.4.1; ENTER 0 FOR NONE] (Unit TB Register column 11 and 80)	Indeterminate:	
3.4.4	Number of retreatment TB patients whose sputum smear or culture is positive at month 5 or later during treatment (i.e., treatment failed) [MUST BE ≤ 3.4.1; ENTER 0 FOR NONE] (Unit TB Register column 11 and 80)	Indeterminate: 999	
3.4.5	Number of retreatment TB patients who died for any reason before starting treatment or during treatment [MUST BE ≤ 3.4.1; ENTER 0 FOR NONE] (Unit TB Register column 11 and 80)	Indeterminate: 999	
3.4.6	Number of retreatment TB patients whose treatment was interrupted for 2 or more consecutive months (i.e., lost to follow-up) [MUST BE ≤ 3.4.1; ENTER 0 FOR NONE] (Unit TB Register column 11 and 80)	Indeterminate:	
3.4.7	Number of retreatment TB patients for whom no treatment outcome is assigned – includes "transferred out" to another treatment unit and unknown treatment outcomes (i.e., not evaluated) [MUST BE ≤ 3.4.1; ENTER 0 FOR NONE] (Unit TB Register column 11 and 80)	Indeterminate: 999	
3.4.8	Number of retreatment TB patients that were moved to the DR-TB Register [MUST BE ≤ 3.1.1] (Unit TB Register column 11 and 80)	Indeterminate:	
3.4.9	Add the counts from 3.4.2 to 3.4.8 and enter here. Compare to the 3.4.1 count. They should be equal. If not, determine the cause of the discrepancy and fix. If it cannot be fixed, describe why not:	Indeterminate: 999	

4.	4. DR-TB Diagnosis (Unit TB Register) [VALID ONLY IF 035 =YES]					
4.0	LOCATE RECORDS FROM JUNE 28, 2016 – MAY 28, 2017 (SENE 21, 2008 – GINBOT 20, 2009)					
	Which register(s) will be used to determine the DR-	Unit TB register				
	TB laboratory counts?	TB Culture and DST Laboratory Register	2			
		DR-TB treatment register				
	[SELECT ALL THAT APPLY]	Other (specify)	96			

4.	DR-TB Diagnosis (Unit TB Register) [VALID ONLY IF 035 =YES]	
4.1	DR-TB Screening and Diagnosis	
4.1.1	Number of bacteriologically-confirmed TB cases who received DST (GeneXpert, Culture, LPA) at baseline (time of registration to TB treatment) [ENTER 0 FOR NONE] (Unit TB Register (Column 8)	Indeterminate: 999
4.1.2	Number of bacteriologically-confirmed TB cases with DST results (GeneXpert, Culture, LPA) [MUST BE ≤ 4.1.1; ENTER 0 FOR NONE] (Unit TB Register (Column 8 and 9)	Indeterminate: 999
4.1.3	Number of bacteriologically-confirmed TB cases with DST (GeneXpert, Culture, LPA) results that are positive for rifampicin resistance (RR) at time of registration for treatment [MUST BE ≤ 4.1.2; ENTER 0 FOR NONE] (Unit TB Register (Column 8 and 9)	Indeterminate: 999

5.	DR-TB Tests and Treatment Outcomes			
5.0	LOCATE RECORDS FROM JUNE 28, 2016 – MAY 28, 2017 (SENE 21, 2008 – GINBOT 20, 2009)			
	Which register(s) will be used to determine the DR-TB treatment counts?	Unit TB Register TB Culture and DST Laboratory Registe TB Microscopy Registration book	er	1 2 3
	[SELECT ALL THAT APPLY]	GeneXpert Registration Book DR-TB treatment register Other (specify)		4 5 96
5.0	Additional DR Tests			
	[ASK THE NEXT 3 QUESTIONS ONLY IF 0	38=YES]		
5.0.1	Number of bacteriologically-confirmed RR-TB cases with DST (culture, LPA) results for H=Isoniazid (MDR) [ENTER 0 FOR NONE] (DR-TB Treatment Register column 7, 24, and 12-23)		999	
5.0.2	Number of bacteriologically-confirmed RR-TB cases with DST (culture, LPA) results for resistant to fluoroquinolones (OFX) [ENTER 0 FOR NONE] [DR-TB Treatment Register column 7, 24, and 12-23)		999	
5.0.3	Number of bacteriologically-confirmed RR-TB cases with DST (culture, LPA) results for resistant to second-line injectable drugs [ENTER 0 FOR NONE] [DR-TB Treatment Register column 7, 24, and 12-23)		999	

5.0.4	Number of bacteriologically-confirmed RR-TB cases with DST (culture, LPA) results for resistant to any fluoroquinolones and to at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance (XDR) [ENTER 0 FOR NONE] (DR-TB Treatment Register column 7, 24, and 12-23)	ndeterminate: 999	
	(b) 15 Treatment register column 7, 24, and 12 23)		
5.1	DR-TB Treatment Outcomes (use the DR-Treatment Register) [THE COUNTS REPRESENT A COHORT OF PATIENTS THAT <u>STARTED</u> TREATMENT DURING THE TIME PERIOD SPECIFIED, REGARDLESS OF WHETHER THE OUTCOME IS AFTER THE END DATE]		
5.1.1	Number of DR-TB cases who started second-line treatment [ENTER 0 FOR NONE] (DR-TB Treatment Register column 2)	Indeterminate:	
	QUESTIONS 5.1.2 THROUGH 5.1.8 ARE ALL MUTUALLY EXCLUSIVE (THERE SHOUL COUNTING OF CLIENTS ACROSS THESE CATEGORIES)	D BE NO DOUBLE-	
5.1.2	Number of DR-TB cases who were cured [MUST BE ≤ 5.1.1; ENTER 0 FOR NONE] (DR-TB Treatment Register column 38)	Indeterminate:	
5.1.3	Number of DR-TB cases who completed treatment by the end of the treatment period [MUST BE ≤ 5.1.1; ENTER 0 FOR NONE]	Indeterminate:	
5.1.4	(DR-TB Treatment Register column 38) Number of DR-TB cases with treatment failure documented at the end of their treatment period [MUST BE ≤ 5.1.1; ENTER 0 FOR NONE] (DR-TB Treatment Register column 38)	999 Indeterminate: 999	
5.1.5	Number of DR-TB cases who died for any reason before starting treatment or during treatment [MUST BE ≤ 5.1.1; ENTER 0 FOR NONE] (DR-TB Treatment Register column 38)	Indeterminate: 999	
5.1.6	Number of DR-TB cases whose treatment was interrupted for 2 or more consecutive months (i.e., lost to follow-up) [MUST BE ≤ 5.1.1; ENTER 0 FOR NONE] (DR-TB Treatment Register column 38)	Indeterminate: 999	
5.1.7	Number of DR-TB cases for whom no treatment outcome is assigned, includes "transferred out" to another treatment unit, those still taking treatment for DR-TB and those with unknown treatment outcomes (i.e., not evaluated) [MUST BE ≤ 5.1.1; ENTER 0 FOR NONE]	Indeterminate: 999	
	(DR-TB Treatment Register column 38)		

5.1.8	Number of DR-TB cases who moved to pre/XDR [MUST BE ≤ 5.1.1; ENTER 0 FOR NONE]	
	(DR-TB Treatment Register column 38)	Indeterminate: 999
5.1.9	Add the counts from 5.1.2 to 5.1.8 and enter here. Compare to the 5.1.1 count. They should be equal. If not, determine the cause of the discrepancy and fix. If it cannot be fixed, describe why not:	Indeterminate: 999

6. TB Preventive Therapy (TPT) (use TB Contact Screening Register, ART & PMTCT Register [VALID ONLY IF				
		THE SITE TO PLHIV AND/OR CHILD CONTACTS OF CO	NFIRMED TB	
PATIE	NTS]			
6.0	LOCATE RECORDS FROM DECEME	BER 30, 2017 – JUNE 27, 2018 (TAHASASS 21, 2010 – 9	SENE 20, 2010)	
	Which register(s) will be used to	Unit TB Register	1	
	determine the TPT for child	ART register	2	
	contacts counts?	DR-TB treatment register	3	
		TB Contact Screening Register	4	
	[SELECT ALL THAT APPLY]	IPT Logbook	5	
		Other (specify)	96	
6.1	TPT for Child Contacts (children u	nder 5 years of age) [VALID ONLY IF 040 = YES]		
0.1	[THIS REGISTER IS IN THE TB CLIN	IC FOR ALL HIV-NEGATIVE CHILDREN]		
6.1.1	Number of child contacts (under 5	5) initiated on TPT		
	[ENTER 0 FOR NONE]			
			Indeterminate:	
	(Child Contact Register column 5 and 20)		999	
	QUESTIONS 6.1.2 THROUGH 6.1.8	ARE ALL MUTUALLY EXCLUSIVE (THERE SHOULD BE	NO DOUBLE-	
	COUNTING OF CLIENTS ACROSS THESE CATEGORIES)			
6.1.2	' ' '			
	[MUST BE ≤ 6.1.1; ENTER 0 FOR NONE]			
			Indeterminate:	
	(Child Contact Register column 5,	20, 27)	999	
6.1.3	Number of child contacts (under 5	5) on TPT who interrupted TPT due to loss to follow-		
	up			
	[MUST BE ≤ 6.1.1; ENTER 0 FOR NONE]			
	Indetermin			
	(Child Contact Register column 5, 14, 21) 999			
6.1.4	Number of child contacts (under 5	5) on TPT who died while taking TPT		
	[MUST BE \leq 6.1.1; ENTER 0 FOR I	NONE]		
			Indeterminate:	
	(Child Contact Register column 5, 20, 27) 999			

	R 040 =YES] [TPT IS PROVIDED AT TI	ontact Screening Register, ART & PMTCT Register [\ HE SITE TO PLHIV AND/OR CHILD CONTACTS OF CO	
6.1.5	Number of child contacts (under 5) active TB while taking TPT [MUST BE ≤ 6.1.1; ENTER 0 FOR NO	on TPT who interrupted TPT due to developing ONE]	Indeterminate:
	(Child Contact Register column 5, 2	0, 27)	999
6.1.6	Number of child contacts under 5 y adverse events [MUST BE ≤ 6.1.1; ENTER 0 FOR NO	ears of age who discontinued TPT because of	Indeterminate:
647	(Child Contact Register column 5, 2		999
6.1.7	Number of child contacts (under 5) [MUST BE ≤ 6.1.1; ENTER 0 FOR NO		Indeterminate:
	(Child Contact Register column 5, 2	0, 27)	999
6.1.8	Number of child contacts (under 5) [MUST BE ≤ 6.1.1; ENTER 0 FOR NO		Indeterminate:
	(Child Contact Register column 5, 2	0, 27)	999
6.1.9		and enter here. Compare to the 6.1.1 count. They the cause of the discrepancy and fix. If it cannot be	Indeterminate:
			999
6.2	TPT for Poople Living with HIV/AID	S (PLHIV) [VALID ONLY IF 039=YES]	
6.2.0			
0.2.0	Which register(s) will be used to	R 30, 2017 – JUNE 27, 2018 (TAHASASS 21, 2010 – : Unit TB Register	SENE 20, 2010)
	determine the TPT for PLHIV	ART register	2
	counts?	DR-TB treatment register	3
	[SELECT ALL THAT APPLY]	IPT Logbook PMTCT Register Other (specify)	5 96
6.2.1	Number of PLHIV initiated on TPT [ENTER 0 FOR NONE]		Indeterminate:
	(ART Register column 19)		999
	COUNTING OF CLIENTS ACROSS TH	•	BE NO DOUBLE-
6.2.2	Number of PLHIV on TPT who comp [MUST BE ≤ 6.2.1; ENTER 0 FOR NO		
	(ART Register column 19-24)		Indeterminate: 999

039 O	6. TB Preventive Therapy (TPT) (use TB Contact Screening Register, ART & PMTCT Register [VALID ONLY IF 039 OR 040 =YES] [TPT IS PROVIDED AT THE SITE TO PLHIV AND/OR CHILD CONTACTS OF CONFIRMED TB PATIENTS]			
6.2.3	Number of PLHIV on TPT who interrupted TPT due to developing active TB while taking TPT [MUST BE ≤ 6.2.1; ENTER 0 FOR NONE] (ART Register column 18 and 19-24)	Indeterminate:		
6.2.4	Number of PLHIV on TPT who interrupted TPT due to loss to follow-up [MUST BE ≤ 6.2.1; ENTER 0 FOR NONE] (ART Register column 19-24)	Indeterminate: 999		
6.2.5	Number of PLHIV on TPT who died while taking TPT [MUST BE ≤ 6.2.1; ENTER 0 FOR NONE] (ART Register column 19-24 and 37-56)	Indeterminate: 999		
6.2.6	Number of PLHIV on TPT who discontinued TPT because of adverse events [MUST BE ≤ 6.21; ENTER 0 FOR NONE] (ART Register column 19-24 and 37-46)	Indeterminate: 999		
6.2.7	Number of PLHIV on TPT with unknown outcome [MUST BE ≤ 6.2.1; ENTER 0 FOR NONE] (ART Register column 19-24 and 37-56)	Indeterminate: 999		
6.2.8	Add the counts from 6.2.2 to 6.2.7 and enter here. Compare to the 6.2.1 count. They should be equal. If not, determine the cause of the discrepancy and fix. If it cannot be fixed, describe why not:	Indeterminate: 999		

End of Facility Visit				
		(a) Visit Result		(b) Visit End Time [Use the 24-hour clock system, e.g. 14:30]
003	Visit 1	Completed Partially completed Records unavailable Facility refused Postponed Other (specify)	1 2 3 4 5 96	Hours Minutes

End o	End of Facility Visit			
		(a) Visit Result		(b) Visit End Time [Use the 24-hour clock system, e.g. 14:30]
004	Visit 2 (if needed)	Completed	1 2 3 4 5 96	Hours Minutes

Comments/Observations						
099	Please provide comments or observations you may have about the quality of the record keeping (e.g., what was easy, what was challenging, if you were unable to determine some of the counts explain why, etc.)					

MEASURE Evaluation
University of North Carolina at Chapel Hill
123 West Franklin Street, Suite 330
Chapel Hill, NC 27516 USA
Phone: +1 919-445-9350
measure@unc.edu
www.measureevaluation.org

This publication was produced with the support of the United States Agency for International Development (USAID) under the terms of the MEASURE Evaluation cooperative agreement AID-OAA-I-14-00004. MEASURE Evaluation is implemented by the Carolina Population Center, University of North Carolina at Chapel Hill in partnership with ICF International; John Snow, Inc.; Management Sciences for Health; Palladium; and Tulane University. Views expressed are not necessarily those of USAID or the United States government. TL-20-87

ISBN: 978-1-64232-245-3





